Menu
  • Home
  • About Us
    • About 340B Report
    • Who We Are
    • Testimonials
    • Sample Issue
    • Subscribe
    • Contact
    • Subscriber FAQ
  • Sponsor/Advertise
    • Our Sponsors
    • Why Sponsor?
  • Podcast
    • Inside 340B Report Podcast
    • 340B 360°
  • Resources
    • Document Center
    • Special Reports
    • Webinars
    • Article Archives
  • 340B Leaders
    • Industry Insights
    • Spotlights
      • 340B Industry Leaders
      • 340B Provider Leaders
      • Our Sponsors
    • Expert Directory
    • Expert Tips
  • Events
  • 340B Trackers
    • Contract Pharmacy Restrictions Tracker
    • State Contract Pharmacy Bills & Laws
    • State Provider Reporting Bills & Laws
    • State PBM Reimbursement Laws
    • Drugmaker State Exemptions Tracker
    • Congressional 340B Bill Tracker
  • Subscribe
  • Sign in
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Post Type Selectors
340B Report

340B Report

Article Archives

December 13, 2022 Drew Mckenna Views

Drew Mckenna

Site Sidebar

Link to 340B Report podcasts Inside 340B Report and 340B 360

Link to spotlight on Mike Fish, Pillr Health

Categories

  • 340B Report Sponsors
  • Breaking
  • Closer Look
  • Contract Pharmacy Protection Bills
  • Covered Entity Reporting Requirement Bills
  • Exclusive
  • Expert Tips
  • Federal
  • General
  • Industry Leader Spotlight
  • Judicial
  • Legislative
  • News Alert
  • Non-Governmental
  • Other Industry
  • PBMs and Payers
  • Pharma Industry
  • Provider Leader Spotlight
  • Providers
  • Regulatory
  • Research/Reports
  • Special Reports
  • Sponsored Content
  • Sponsors
  • State
  • State 340B PBM Legislation
  • Trade Association

Recent Posts

  • 340B Providers, Drug Industry Raise Concerns Over HRSA’s 340B Rebate Model Pilot Proposal 
  • HRSA Proposes 340B Rebate Model Pilot for Narrow Set of Drugs Under Strict Conditions
  • Who Are the Federal Judges Deciding the High-Stakes Drugmaker 340B Rebate Appeals?
  • Key Takeaways from the 2025 340B Summer Conference
  • 340B Health Survey: Most Hospitals Would Struggle to Stay Open, Maintain Care Levels Under 340B Rebate Model

Article Archives

  • ►2025 (423)
    • ► July (60)
      • 340B Providers, Drug Industry Raise Concerns Over HRSA’s 340B Rebate Model Pilot Proposal 
      • HRSA Proposes 340B Rebate Model Pilot for Narrow Set of Drugs Under Strict Conditions
      • Who Are the Federal Judges Deciding the High-Stakes Drugmaker 340B Rebate Appeals?
      • Key Takeaways from the 2025 340B Summer Conference
      • 340B Health Survey: Most Hospitals Would Struggle to Stay Open, Maintain Care Levels Under 340B Rebate Model
      • Dark Money Group’s Survey Claims GOP Primary Voters Oppose State Contract Pharmacy Access Laws
      • Safeguard Your 340B Program and Increase Compliance Through Automated, 100% Audit Workflows
      • Patient Groups Back Drugmakers in 340B Rebate Appeal, Without Disclosing Drug Industry Funding or Missed Compliance Deadline
      • Alkermes, Novartis Exempt Additional States from 340B Contract Pharmacy Restrictions
      • Merck, Eisai, Vertex to Refund 340B Covered Entities for Overcharges
      • Record Turnout for Fourth Annual ‘Defend 340B’ March on Capitol Hill
      • Budget Reconciliation's Effects Could Shape Efforts to Reform 340B, Policy Experts Say at 340B Coalition Conference
      • Separating AI Hype from Real Value in 340B Program Management
      • Analysis: How Medicaid Cuts in ‘Big Beautiful Bill’ Could Push Certain Hospitals Out of 340B and the Importance of Planning Ahead
      • State Contract Pharmacy Lawsuit Roundup: Updates in Colorado, Nebraska
      • Matsui, Welch Reintroduce 340B PATIENTS Act in Congress During 340B Coalition Summer Conference
      • OPA Director Touches on 340B Rebate Litigation and Other Key Matters at 340B Coalition Conference
      • 340B PATIENTS Act Reintroduction Expected Soon, Hospital Trade Group Challenges Drug Industry Criticisms
      • Safeguarding Your 340B Program
      • Federal Court Consolidates Drugmaker 340B Rebate Appeals, Denies Hospital Group’s Cross-Appeal Request
      • GSK Exempts New States from 340B Contract Pharmacy Restrictions, Teva Issues New Update on Restricted Drugs
      • Lilly, Indivior, Kedrion to Refund 340B Covered Entities for Overcharges, Others Announce NDC Changes
      • For the First Time, CMS Proposes Claims-Based Methods to Identify 340B Drugs Billed to Medicare Part D
      • Advocates Warn New CMS Proposed Rule Could Hurt 340B Program, Be ‘First Step Towards Payment Cuts’
      • Rethinking 340B: Where Compliance Ends and Strategy Begins
      • California Senators Abruptly Pull 340B Bill from Hearing; Massachusetts Lawmakers Debate Drug Pricing Measures
      • Column: In Memory of My First Mentor
      • CMS Proposes Accelerated OPPS Cuts to Offset 340B Remedy Payments and Medicare Drug Survey That Could Lead to Significant Part B Cuts
      • Federal Judge Dismisses AbbVie’s Challenge to Missouri’s 340B Contract Pharmacy Access Law for Lack of Standing
      • Carter Introduces PBM Reform Bill That Includes 340B ‘Spread Pricing’ Reporting
      • Verity Solutions Presents: 340B Outlook from Capitol Hill and the States
      • Griffith, Harshbarger Officially Take Over as E&C Health Subcommittee’s GOP Leaders
      • Drugmakers File New Appeal Briefs in Push to Overturn 340B Rebate Ruling
      • PhRMA Sues Hawaii Over New 340B Contract Pharmacy Access Law
      • Organon, AbbVie Exempt New States From 340B Contract Pharmacy Restrictions
      • Mike Fish, Senior Vice President of Client Success, Pillr Health
      • In High-Stakes Meetings, 340B Stakeholders Push to Sway HHS’ Rebate Guidance Ahead of Release
      • Supreme Court Allows HHS Reorganization and Layoffs to Continue, Effect on 340B Oversight Unclear
      • Part 3 of a 4-Part Series: Is In-House Pharmacy Capture the Overlooked Strategy to Growing Your 340B Program?
      • Griffith Named U.S. House E&C Committee’s Health Subcommittee Chair, 340B Critic Harshbarger Elevated to Vice Chair
      • New Oregon Law Lets Health Centers Report 340B Claims Through Clearinghouse Instead of PBMs
      • Five Drugmakers Exempt New States from 340B Contract Pharmacy Restrictions
      • State Contract Pharmacy Lawsuit Roundup: Updates in Tennessee and Utah
      • Providers Slam Newly Enacted GOP Budget Law Over Deep Medicaid Cuts
      • California Senate Amends 340B Contract Pharmacy Access Bill to Add Provider Reporting, Audit Requirements
      • Is Your 340B Partner a Good Fit? Look for These Signs
      • New York Assembly Honors Longtime 340B Advocate Mark Malahosky on Retirement
      • Providers Condemn Reconciliation Bill’s Medicaid Cuts, Urge Lawmakers to Reject Ahead of Final House Vote
      • Rep. Buddy Carter to Step Down as House E&C Health Subcommittee Chair
      • Two Drugmakers Sue Oklahoma Over New 340B Contract Pharmacy Access Law
      • PhRMA Sues Vermont Over New 340B Contract Pharmacy Access Law
      • Kentucky Launches Voluntary 340B Claims Program Enabling Providers to Carve in Medicaid MCO
      • State Contract Pharmacy Lawsuit Roundup: Updates in Utah and Tennessee
      • J&J Appeals 340B Rebate Ruling, Hospitals Laud Federal Judge’s Rejection of Drugmaker Lawsuit
      • Ohio Becomes Ninth State to Enact 340B Provider Reporting Law
      • Federal Judge Denies AbbVie’s Bid to Block Tennessee 340B Contract Pharmacy Access Law’s Enforcement
      • HRSA Reinstates Eight Sagebrush Sites into 340B Program, But Judge Rules Earlier Terminations Were Lawful
      • Alkermes, Biogen Exempt New States from 340B Contract Pharmacy Restrictions
      • Drug Industry Takes Aim at 340B Program’s Growth in Pair of Op-Eds
      • Column: Setting the Record Straight on 340B Growth
    • ► June (57)
      • Rhode Island Gov. Signs 340B Contract Pharmacy Access, Provider Reporting Bills into Law
      • Federal Judge Dismisses J&J’s Lawsuit, Rules HHS Must Preapprove 340B Rebate Models
      • HRSA Issues New Health Center 340B Requirements for Insulin, EpiPens Following Trump’s April Executive Order
      • Drugmakers Urge Appeals Court to Toss Hospital Group’s Cross-Appeal in 340B Rebate Case
      • Don’t Miss a Claim: How to Monitor Disqualified Claims in Your 340B Program
      • RFK Jr. Touts HHS Budget Plan, PBM Reform & Drug Pricing Efforts; Rep. Harshbarger Suggests 340B Contract Changes
      • Four Drugmakers Announce New State Exemptions from 340B Contract Pharmacy Restrictions
      • Lauren Navas, Chief Marketing Officer, Ravin Consultants
      • Maine Enacts 340B Contract Pharmacy Access Law with Added Hospital Reporting Requirements
      • Rhode Island Passes Contract Pharmacy Access, Reporting Legislation, Sends to Governor
      • Drugmakers, Hospital Group Appeal Dueling Aspects of 340B Rebate Ruling
      • The Compliance Arms Race: Can Smaller Covered Entities Keep Up?
      • Q+A: Kalderos CEO Angie Franks Talks Truzo, 340B Program Transparency
      • Trump’s ‘Most Favored Nation’ Order Could Lower 340B Ceiling Prices, but Key Details Remain Unclear
      • NACHC Raises Concerns About 340B Rebates, Various Stakeholders Meet with Trump Administration on Rebate Guidance
      • AHA Report: 340B Hospitals Face More Federal Oversight, Fare Better in Audits; HRSA Releases Latest Drugmaker Audit
      • A Neutral Clearinghouse: An Area of Potential Collaboration Between Covered Entities, Manufacturers and Payers
      • D.C. Federal District Court Dismisses Hospital Lawsuits Over J&J’s Controversial 340B Audit Requests
      • Recap of Recent Webinar: Key Issues and What to Expect Next on 340B in Washington, D.C.
      • Rhode Island House Passes 340B Contract Pharmacy Access, Reporting Bill; Senate to Vote Today
      • State Contract Pharmacy Lawsuit Roundup: Updates in Utah and South Dakota
      • Maine Passes 340B Contract Pharmacy Access Bill with Added Hospital Reporting Requirements, Sends to Governor
      • Why a Health Insurance Crisis Led Vermont Lawmakers to Add Hospital Price Caps to a 340B Contract Pharmacy Access Law
      • Explore a Forward-Deployed Inventory Model for High-Cost Drugs
      • Oregon Providers Applaud Passage of 340B Contract Pharmacy Access Law
      • Major North Carolina Health System Sues Aetna, Humana for Alleged 340B Underpayment
      • AbbVie is 1st Drugmaker to Challenge Colorado’s New 340B Contract Pharmacy Access & Reporting Law
      • AstraZeneca Sues to Block Nebraska’s Contract Pharmacy Access Law
      • Expert Tip from SpendMend
      • Vermont, Oregon Enact 340B Contract Pharmacy Access Laws; Vermont Measure Includes Controversial Hospital Price Caps
      • Federal Appellate Court Fast-Tracks Drugmakers’ Appeal of 340B Rebate Ruling
      • CMS Offers New Details on Medicare Drug Price Negotiations, 340B Advocates Raise Concerns About Impact on Program
      • Leading 340B and Pharmacy Solutions Firm Maxor Rebrands as ‘VytlOne’
      • J&J, Lilly and GSK to Refund 340B Covered Entities for Overcharges
      • Expert Tip from The Craneware Group
      • How Oklahoma Lawmakers Defied Their Governor and Fought Dark Money to Enact a 340B Contract Pharmacy Access Law
      • Cassidy Staffer, ASAP 340B Head Call for 340B Program Reforms, Comment on Proposed Shift to CMS
      • Third Straight HRSA Audit Finds Drugmaker 340B Overcharges in 2025
      • Sandoz to Stop Notifying CEs of 340B Contract Pharmacy Changes, Joins Liquidia in Adding Restrictions to New Drugs; Novartis Updates Restrictions
      • Drug-Industry Funded Study Finds Utilization Drives 340B Program Growth, Not Rising Drug Prices
      • In Emergency Motion, Novartis and BMS Urge Appellate Court to Fast-Track Their Appeals of 340B Rebate Ruling
      • Premier Asks Court to Reject HRSA’s Defense of 340B Hospital Drug Purchasing Restrictions Policy, Requests Oral Arguments
      • Keeping the Lifeline Strong: Why 340B Matters More Than Ever for Safety-Net Hospitals and Other Providers
      • Hospital Group-Funded Working Paper Calls for Increased 340B Visibility Among Economists 
      • Amgen Exempts Tennessee Providers From 340B Contract Pharmacy Restrictions Despite New Law’s Carve Out
      • Indiana’s New Budget Law Sparks Alarm Over Last-Minute Provisions Targeting 340B Medicaid Reimbursement
      • State Contract Pharmacy Lawsuit Roundup: Drugmakers File Briefs in 5th Circuit Appeals Case, Updates in Utah and Nebraska
      • Holly Bones, Senior Director, 340B Manufacturer & Supply Chain Relations, Cencora
      • Expert Tip from CompassRx
      • SpecGx to Offer Covered Entities Refunds for a Record 30-Plus Years of 340B Overcharges
      • Oregon Sends 340B Contract Pharmacy Access Bill to Governor; Illinois Falls Short but Advances PBM Reform
      • EMR Change Ahead: 340B Readiness Starts Now!
      • 340B Stakeholders Offer Mixed Views on Trump’s Plan to Move Drug Pricing Program to CMS
      • AbbVie Sues Hawaii Over New 340B Contract Pharmacy Access Law
      • Christopher Hotchkiss, Cofounder, CaptureRx
      • HHS Submits 340B Rebate Guidance for Review, But Publication Timeline Remains Unclear
      • Colorado, Hawaii Enact Combined Contract Pharmacy Access and Provider Reporting Laws; Illinois 340B Bill Passes Senate
    • ► May (79)
      • Trump’s Full 2026 Budget Request Would Shift 340B Program from HRSA to CMS, Maintain Current OPA Funding
      • Vermont Passes 340B Contract Pharmacy Access Bill with Controversial Hospital Price Caps, Sends to Governor
      • Oklahoma Lawmakers Override Governor’s Veto, Enact 340B Contract Pharmacy Access Law
      • First 340B Administrative Dispute Resolution Panel Decision Sides with Drug Industry
      • Stretching Scarce Federal Resources: How Conway Medical Center Is Redefining 340B’s Impact
      • Katie Miller, Key Player in Anti-340B ‘Dark Money’ Campaign, Leaves White House Adviser Role
      • Cassidy Says 340B ‘Was Never Meant to be Part of an Earnings Call’
      • Two Drugmakers Appeal Federal District Judge’s 340B Rebate Ruling in Favor of HHS
      • BI Asks Tennessee Contract Pharmacies to Report Claims Data Ahead of New State Law, BMS Updates Contract Pharmacy Restrictions
      • State Contract Pharmacy Lawsuit Roundup: Health Center Group Motion Denied in 5th Circuit; Drug Industry Makes Motion in Federal Court in South Dakota 
      • Novo Nordisk, Merck, GSK to Refund 340B Covered Entities for Overcharges
      • Column: Battlefront Shifts from Contract Pharmacies to Rebates
      • Expert Tip from CaptureRx
      • Oregon Senate Narrowly Passes 340B Contract Pharmacy Access Bill
      • HRSA Defends 340B Hospital Drug Purchasing Restrictions Policy, Asks Federal Court to Reject Premier’s Challenge
      • House GOP Lawmaker Spartz Introduces Bill That 340B Provider Advocates Say Would Drive Them Out of the Program and Potentially Force Closures
      • Don’t Overlook the Importance of an HIN on Your Wholesale Accounts
      • Vermont House Modifies 340B Contract Pharmacy Access and Hospital Reporting Bill, Hospital Advocates Voice Concerns About Changes
      • Oregon, Illinois State Senators Push for Amendments to 340B Contract Pharmacy Access Bills
      • Drug Industry Files New Lawsuits to Block 340B Contract Pharmacy Access Laws in Tennessee, Utah
      • Sponsors of Oklahoma’s 340B Contract Pharmacy Access Bill Call for Veto Override, Slam ‘Big Pharma’ and Dark Money
      • Amid Federal Court Setbacks, Drugmakers Turn to State Courts to Try to Block 340B Contract Pharmacy Access Laws
      • Webinar —Behind the Headlines: A 340B Insider Briefing with Ted Slafsky
      • 340B Provider-Drugmaker Lobbying Group Adds Hospital, Drugmaker: Key Thune Staffer Departs for Private Sector
      • Genentech Tightens Contract Pharmacy Restrictions to Require Hospital Claims Data, Targets 340B Drug Redistribution; 340B Lawyer Pushes Back
      • State Contract Pharmacy Lawsuit Roundup: Key Briefs in 8th Circuit, Utah, South Dakota; Motion Filed in 5th Circuit
      • Red Chip Enterprises
      • RFK Jr. Tells Senate Panel 340B Program ‘Controversial’ But Important to Rural Hospitals; HHS Releases MFN Targets for Drugmakers
      • Providers Applaud Federal Judge’s 340B Rebate Ruling as Drugmakers Mull Next Steps
      • Federal Judges Allows 340B Hospital Advocacy Group to Intervene in J&J Rebate Lawsuit
      • California Assembly Passes 340B Contract Pharmacy Protections for Grantees, Sends Bills to Senate
      • Drug Industry-Backed AIDS Group Targets 340B in New Ad Campaign
      • Viatris, Amgen, GSK Announce 340B Refunds; Amgen Issues NDC Change
      • Oklahoma Governor Vetoes 340B Contract Pharmacy Access Bill Despite Near-Unanimous Legislative Support
      • Vermont Senate Passes Combined 340B Contract Pharmacy Access and Hospital Reporting Bill
      • Federal Judge Upholds HHS’ Right to Pre-Approve 340B Rebates, Tosses Four of Five Drugmaker Lawsuits
      • Mixed Responses So Far to RFK Jr.’s Comments on 340B Program from 340B Provider Groups
      • AHA Urges RFK Jr. to Reject 340B Rebate Models as HHS Prepares Guidance
      • House E&C Committee Advances Reconciliation Budget’s Health Provisions Along Party Lines after 24-Plus Hours of Contentious Debate
      • As Deadline Looms, Dark Money Groups Pressure Oklahoma Governor to Veto Popular 340B Contract Pharmacy Access Bill
      • Ohio Becomes 29th State to Introduce 340B Contract Pharmacy Access Bill in 2025
      • Hospital, Pharmacist Advocates File Brief Backing Nebraska’s New 340B Contract Pharmacy Access Law Against AbbVie Challenge 
      • AbbVie Sues Tennessee Over 340B Contract Pharmacy Law with New Legal Arguments, Reveals Plans to Exempt Providers in Dakotas
      • AbbVie, Sobi, Organon Exempt More States from 340B Contract Pharmacy Restrictions
      • Drug Industry-Funded White Paper Ties 340B to Rising Commercial Insurance Premiums; Provider Advocates Criticize Study
      • Chelsea Reddoch, Director of Product - 340B Recovery, R1
      • Expert Tip from Apexus
      • HHS Secretary RFK Jr. Weighs in on 340B Program Publicly for 1st Time
      • Rhode Island Senate Passes 340B Contract Pharmacy Access Bill, Vermont Vote Expected Today
      • House E&C Committee to Take Up Budget Reconciliation Bill’s Proposed PBM Accountability, Spread Pricing Provisions
      • Key House Republican and Vocal 340B Critic Launches 2026 U.S. Senate Bid
      • New England Lawmakers Advance 340B Contract Pharmacy Access Bills in Three States
      • Trump Signs Executive Order to Impose ‘Most-Favored Nation’ Drug Pricing Model, Unlike April EO, 340B Implications Unclear
      • Oklahoma Senate Passes 340B Contract Pharmacy Access Bill, Sends to Governor
      • In Novel Approach, Vertex to Automatically Exempt States from 340B Contract Pharmacy Restrictions as New Laws Take Effect and Apply Exemptions Liberally; Other Companies Exempt Additional States 
      • Drugmakers Press Federal Judge to Quickly Rule on 340B Rebates, Argue HHS’ Plan for Guidance ‘Commits to Nothing’
      • Navigating the Complexities of Specialty Medication Claims Processing
      • In Win for Hospitals, Stricter 340B Bill Dies in Colorado One Day After Legislature Passes Provider-Backed Alternative
      • Drug Industry Advocates Say 340B Providers Would be Unintended Beneficiaries in Effort to Kill Trump Proposed Medicaid Pricing Proposal
      • Contract Pharmacy Lawsuit Roundup: Key Briefs Filed in Nebraska, South Dakota and 5th Circuit
      • Powers Law Firm
      • Indiana Enacts 340B Hospital Reporting Law as Colorado Lawmakers Send Combined Contract Pharmacy Access-Provider Reporting Bill to Governor
      • 340B Antitrust Lawsuit Against Insulin Drugmakers Could Have New Life After Federal Appeals Court Hearing 
      • Tennessee Enacts Law to Block Future Drugmaker 340B Restrictions Placed After July 2025
      • Colorado Lawmakers Advance Dueling 340B Contract Pharmacy Access Bills with Different Hospital Restrictions
      • Amgen Exempts More States from 340B Contract Pharmacy Restrictions
      • Hospital Group Warns that Medicare Drug Price Negotiation Payment Process Undermines 340B
      • Hawley, Welch Unveil Bipartisan Senate Bill to Lower Prescription Drug Prices
      • Expert Tip from Bluesight
      • HHS to Issue Guidance on 340B Rebates, IRA Interaction Within 30 Days
      • Trump’s FY 2026 Budget Blueprint Includes $33 Billion in HHS Cuts, No Details on 340B Plans
      • Hawaii Legislature Passes Amended 340B Contract Pharmacy Access Bill with Limited Reporting Requirements
      • National HIV Group Voices Concerns Over Sen. Cassidy’s 340B Probe Findings, Reform Recommendations 
      • Should We Prepare for a 340B Rebate Model?
      • Supreme Court Backs HHS in Dispute Over DSH Calculation, 340B Providers Condemn Decision Which Could Impact Eligibility for Some Hospitals
      • Sumitomo Exempts Four More States From 340B Contract Pharmacy Restrictions, GSK Exempts Nebraska, Utah
      • State 340B Contract Pharmacy Lawsuit Roundup: New Filings in Utah
      • Pillr Health
      • Expert Tip from Cervey
    • ► April (61)
      • Federal Judge Grills Both Sides in Key Hearing on 340B Rebate Dispute
      • Federal Judge Holds High-Stakes Hearings Today on Five Drug Industry 340B Rebate Lawsuits
      • HRSA Audits Find Two Drugmakers Overcharged for 340B Drugs, Driving Calls for More Drug Industry Oversight 
      • Former 340B Health, Evernorth Executives Join Walgreens 
      • California, Texas, Oklahoma Advance 340B Contract Pharmacy Access Bills with Key Amendments
      • Takeda Tightens 340B Contract Pharmacy Restrictions, Biogen Exempts Nebraska From Its Restrictions Policy
      • Stakeholders React to HELP Committee Chair Cassidy’s 340B Probe Findings, Reform Recommendations
      • Senate HELP Committee Chair Cassidy Calls for Federal 340B Reforms, Releases Findings of Yearslong Congressional Probe
      • 340B Lobbying Remained Strong in Early 2025, Filings Show
      • Indiana Legislature Passes Sweeping 340B Hospital Reporting Bill, Sends to Gov. Braun
      • State Contract Pharmacy Lawsuit Roundup: Appellate Court Briefings on 340B Laws in West Virginia, Louisiana
      • As Trump Pharmaceutical Tariffs Loom, Drug Industry Pledges Investment in U.S. Manufacturing, Warns of Disruptions 
      • RxParadigm
      • Health System CEOs Meet with RFK Jr. and Encourage Him to Preserve and Strengthen 340B at HHS Roundtable 
      • HHS Continues to Oppose Unapproved Drugmaker 340B Rebate Models in New Legal Filings
      • Minnesota Finalizes Expanded 340B Provider Reporting Requirements, Extends Submission Deadline to May 30
      • PhRMA Sues Utah Over New 340B Contract Pharmacy Access Law
      • Column: A Powerful Statement from the Heartland
      • Leaked HHS Budget Document Details Plans to Move 340B Program to CMS
      • Tennessee Legislature Approves Scaled-Back Bill Barring Future Drugmaker 340B Restrictions Placed After July 2025
      • Hospitals, Health Centers Criticize Trump’s Executive Order Over Controversial 340B Rule, Possible Medicare Payment Cuts
      • Tariffs on Pharmaceuticals Could Worsen Drug Shortages, Cause Disarray in 340B Prices, Advocates Say
      • Webinar—Neutral 340B Clearinghouse: Now Live
      • GAO Report Finds HHS Must Do More to Address Drug Shortages, Doesn’t Mention 340B as a Factor
      • Merck Exempts Three More States from 340B Restrictions, Novartis Sues Utah Over Contract Pharmacy Access Law
      • State Contract Pharmacy Lawsuit Roundup: 5th Circuit Appeals in Louisiana, 4th Circuit Appeal in West Virginia 
      • Marcus Hill, Manager, Implementations, VHUB at Verity Solutions
      • Expert Tip from Ravin Consultants
      • Trump Revives Controversial 340B Rule for Insulin, EpiPens in Sweeping Health Care Executive Order
      • Oregon, Oklahoma Advance 340B Contract Pharmacy Access Bills
      • AbbVie Sues Three More States Over Newly Enacted 340B Contract Pharmacy Access Laws
      • HHS Briefs House E&C Committee Staff on Restructuring, Senate HELP Postpones Kennedy Hearing
      • SK Life Science Announces 340B Refunds for Epilepsy Treatment
      • New Mexico Enacts Law Prohibiting Drugmaker 340B Contract Pharmacy Restrictions on Health Centers
      • HRSA Allows One Sagebrush Site to Remain in 340B, but Other Sites’ Eligibility Still in Dispute
      • Part 2 of a 4-Part Series: A Look Into 340B’s Changing Landscape and Whether AI Can Be the Solution
      • Drugmakers Ask Court to Rule in Favor of 340B Rebate Model, Reject Hospitals’ Arguments; Kalderos Opposes 340B Health’s Amicus Brief
      • J&J Adds Unbranded Version of Stelara to 340B Contract Pharmacy Restrictions
      • Greg Wilson, Director of Compliance, SpendMend
      • Nebraska Becomes 12th State to Enact 340B Contract Pharmacy Access Law
      • HHS Layoffs, Restructuring Don’t Appear to Have Affected 340B Yet, But Sources Say Program Could Move to CMS
      • First Drugmaker Sues Utah’s New 340B Contract Pharmacy Access Law
      • Lawmakers in Indiana, Minnesota, Arkansas Introduce or Advance Provider Reporting Bills, 340B Restrictions
      • Closed Pennsylvania Hospital Revives 340B Antitrust Lawsuit Against CVS’ TPA Wellpartner
      • Federal Judge Dismisses Two Drugmaker Challenges to Minnesota’s Contract Pharmacy Access Law, Citing Lack of Enforcement Power
      • North Dakota Becomes 11th State to Enact 340B Contract Pharmacy Access Law
      • Senate Confirms ‘Dr. Oz’ as CMS Administrator on Party-Line Vote
      • AstraZeneca Lifts 340B Contract Pharmacy Restrictions in Arkansas Following State Order
      • Nebraska Legislature Easily Passes Contract Pharmacy Access Bill, Sends it to Governor
      • Effective Contract Pharmacy Strategies in an Ever-Changing Landscape
      • Mississippi’s 340B Contract Pharmacy Access Law Faces Scrutiny in Federal Appeals Court Hearing
      • Senate HELP Committee Asks RFK Jr. to Testify on HHS Reorganization Amid Mass Layoffs Including Up to One Third of HRSA Workforce
      • Drugmakers, Kalderos Again Urge Federal Court to Support 340B Rebate Model; 340B Health, Hospitals Look to File Brief 
      • State Contract Pharmacy Lawsuit Roundup: 4th Circuit Appeals in West Virginia, Maryland
      • Danielle Sylvas, 340B Network Development Manager, Cervey
      • Arkansas Orders AstraZeneca to Restore 340B Drug Access at Contract Pharmacies
      • Idaho Becomes Fourth State to Enact 340B Provider Reporting Law
      • Genesis Health Care Launches Campaign Targeting NACHC’s ASAP 340B Partnership With PhRMA
      • In Apparent About-Face, HRSA Confirms Sagebrush’s 340B Eligibility During Federal Court Hearing
      • Trump Administration Creates New Agency Overseeing HRSA Amid Major HHS Staffing Cuts
      • U.S. Rep. Dusty Johnson: ‘No 340B Savings for Transgender Care Act’ Responds to Drug Industry’s Lies, Clarifies Savings’ Use 
    • ► March (55)
      • Utah Becomes Tenth State to Enact 340B Contract Pharmacy Access Law After Governor Declines to Act on Bill
      • Second Sight Solutions’ Parent Company Targeted in Cyber Attack, Firm Says 340B Platforms Do Not Appear to Have Been Affected
      • Idaho Sends 340B Provider Reporting Bill to Governor; Oklahoma House Passes Contract Pharmacy Access Legislation
      • Setting the Record Straight
      • Virginia Governor Signs Bill Protecting 340B Hospitals from PBM Discrimination
      • Colorado Senate Passes Competing 340B Bills with Varying Contract Pharmacy Protections, Reporting Measures, Hospitals Restrictions
      • New North Carolina Bill Would Prohibit Most Hospitals from Generating 340B Savings, Add Reporting Requirements for All Covered Entities
      • Trump-Aligned Think Tank Proposes Lowering U.S. Drug Prices Through IRA and Other Policies, Doesn’t Weigh In on 340B Program
      • Abel Haile, Senior Director, Health System Strategy & Commercial Analytics, Maxor National Pharmacy Services
      • North Dakota Senate Easily Passes 340B Contract Pharmacy Access Bill, Sending It to Governor
      • Senate Committee Confirms Dr. Oz as CMS Administrator in Party-Line Vote, Sends Nomination to Full Chamber
      • Dr. Oz’s Ties to Company that Partners With 340B Hospitals Draws Scrutiny, Senate Panel Prepares Vote on CMS Administrator Nomination
      • Idaho’s 340B Provider Reporting Bill Nears Passage, While Legislators in New York, Minnesota Introduce New 340B Legislation
      • Merck is First to Exempt South Dakota from 340B Contract Pharmacy Restrictions but Reinstates in Kansas, Novartis Exempts Missouri 
      • Column: Heroes in the 340B Contract Pharmacy War
      • U.S. Senate Bipartisan 340B Working Group Announces New Members, New Mexico Sends Contract Pharmacy Access Bill to Gov.
      • Kansas Senate Approves New 340B Contract Pharmacy Access Bill Amid Challenges with Existing Law
      • 340B Contract Pharmacy Access Bills Advance in Nebraska, New Mexico, Kansas, Connecticut and Colorado, But Legislation Dies in Kentucky
      • 340B Advocate Slams Federal ‘No 340B Savings for Transgender Care Act’ Proposal
      • How to Maximize Partner Support for Referral Capture During a HRSA Audit
      • Trump’s HHS Continues to Oppose Unilateral Drugmaker 340B Rebates in Kalderos Lawsuit
      • Drugmakers Agree to Take Part in Second Round of IRA’s Medicare Drug Price Talks
      • Justin Rolling, CaptureRx
      • Vermont House Passes Contract Pharmacy Access Bill, While U.S. House Republican Introduces ‘No 340B Savings for Transgender Care Act’
      • Trump Administration Opposes Unilateral Drugmaker 340B Rebates in First Legal Filing on Issue
      • 340B Program Garners National Headlines Over Dark Money Ads, Employer Pharmacy Benefit Plans 
      • Maine, Mass. Introduce 340B Contract Pharmacy Access Bills; Mass. Also Introduces Separate Provider Reporting Legislation
      • CMS Nominee ‘Dr. Oz’ Grilled Over Potential Medicaid Cuts and Position on Medicare Negotiations at Confirmation Hearing 
      • Sumitomo, J&J Announce 340B Refunds to Covered Entities
      • New Mexico House Passes 340B Contract Pharmacy Protections for Health Centers, Sending Bill to Senate
      • State Contract Pharmacy Bill Updates: Anti-340B Ads Anger Okla. Lawmakers; Key Changes to N.M. Legislation; and Bill Killed in N.H.
      • Federal Judge Dismisses Antitrust Class Action Lawsuit Against CVS Over 340B TPA Policy
      • Navigating Uncertainty: Reflections from the 340B Coalition Winter Conference 
      • Senate Confirmation Hearing for Dr. Oz, Trump’s Pick to Lead CMS, Set for Tomorrow
      • Pfizer, Teva Each Add New Drug to 340B Contract Pharmacy Restrictions for Hospitals
      • Fireside Chat: Strategies for Measuring Success & Ensuring Compliance in Your 340B Program
      • South Dakota Becomes First State to Enact 340B Contract Pharmacy Access Law in 2025
      • 340B Misinformation Makes Up Small Part of 340B Conversations Online, But Garners Outsized Attention, Analysis Finds
      • Recap of Recent Webinar: A Closer Look at Battles Over State 340B Contract Pharmacy Access Bills and Laws
      • Idaho House Unanimously Passes 340B Provider Reporting Bill as Lawmakers Also Introduce Contract Pharmacy Access Bill
      • Federal Judge Allows Hospital Group to Join Government in Legal Battle Over Drugmaker 340B Rebate Models
      • Hospital Advocates File Amicus Briefs in Federal Court Cases on Drugmaker 340B Rebate Models, Maryland’s Contract Pharmacy Law
      • Michigan Senate Easily Passes Bill with 340B Contract Pharmacy Protections, Reporting Requirements for Providers and Manufacturers
      • Utah, South Dakota Legislatures Pass 340B Contract Pharmacy Access Bills in Landslide Votes, Sending to State Governors
      • Dark Money Group Labels Five GOP State Lawmakers As ‘Trump Underminers,’ But Efforts Appear to be Backfiring
      • State Lawmakers Push for 340B Provider Reporting Requirements, Restrictions or Investigations in Indiana, West Virginia, Illinois
      • AstraZeneca Adds Three Specialty Cancer Drugs to 340B Contract Pharmacy Restrictions
      • Florida Lawmaker Clarifies His Medicaid Reimbursement Bill Won’t Impact 340B Savings for Providers
      • In Four Major Votes, Utah, South Dakota, Hawaii and Nebraska Each Advance 340B Contract Pharmacy Access Bills
      • Utah House Unanimously Passes 340B Contract Pharmacy Access Bill, But Senate Pushes for Changes
      • Key Votes on 340B Contract Pharmacy Access Bills in Utah, New Mexico, Michigan; Bill Introductions in Kansas and Florida
      • Florida Providers Concerned New State Medicaid Reimbursement Bill Could Significantly Restrict 340B Savings
      • AbbVie Adds 340B Restrictions to Cancer, Parkinson's Treatment Drugs
      • Eli Lilly, Eisai, GSK and Merck Announce 340B Refunds, Other Drugmakers Report NDC Changes
      • Expert Tip from SunRx
    • ► February (58)
      • Federal Judge Partially Dismisses Two More Drug Industry Challenges to Missouri’s 340B Contract Pharmacy Access Law
      • Texas, Iowa Introduce 340B Contract Pharmacy Access Bills While Utah, Hawaii and Tennessee Advance Similar Bills
      • Congress Unlikely to Focus on 340B In the Near Term, But Key Bills Could Resurface Soon, Conference Speakers Predict
      • On Demand Webinar—What's Next for Covered Entities? Navigating 340B Challenges and the Future of Patient Care
      • House Passes Budget Resolution Despite Concerns Over Medicaid Cuts
      • Sixth Hospital Sues HRSA Over J&J’s Controversial 340B Audit Requests
      • Expert Tip from Apexus
      • Dark-Money 340B Attacks, Rebate Model Among Key Concerns at 340B Coalition Winter Conference
      • Federal Judge Denies Novartis’ Bid to Block Missouri’s 340B Contract Pharmacy Access Law
      • California, Michigan Introduce 340B Contract Pharmacy Access Bills; New Hampshire 340B Bill Faces Setback
      • House Prepares Budget Vote Amid Concerns Over Likely Medicaid Cuts
      • Pillr Health: A New Era of Innovation in 340B and Beyond
      • Sagebrush Withdraws Lawsuit Against HRSA, Aims to Work with Agency on 340B Reinstatement Outside Court
      • GSK is Fourth Drugmaker to Reinstate Contract Pharmacy Restrictions in Kansas
      • Two State Legislative Chambers Overwhelmingly Pass 340B Contract Pharmacy Access Bills
      • Vermont Introduces 17th 340B Contract Pharmacy Access Bill of 2025; North and South Dakota Advance Similar Bills
      • Kentucky Lawmaker Introduces 340B Hospital Reporting Bill After Senate Passes Contract Pharmacy Protections
      • Health Centers Host 340B Recertification Event In Lieu of HRSA’s Canceled Webinar
      • E&C Health Subcommittee to Hold Hearing on PBM Practices, Trump Backs GOP House Budget Plan With Health Spending Cuts
      • Former Kalderos VP Formally Launches Technology Company for 340B Covered Entities
      • Drug Industry-Funded Study Finds 340B Contract Pharmacy Bills Costly to Employer Health Plans and States; Critics Slam Its Methodology and Funding Source
      • State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Mississippi
      • Conservative Groups Ramp up Misleading Attacks on 340B Over Gender-Affirming Care
      • Virginia Legislature Passes Bill to Expand Protections from PBMs to Hospitals; Lawmakers in Utah, Mississippi Weigh Separate 340B Bills
      • Part 1 of a 4-Part Series: What is AI? An Overview, Its Role in 340B, and How You Should Start Thinking About It
      • UPDATED: North Carolina GOP Lawmaker Lauds NYC Health System After Asking for Financial, 340B Program Info Following Super Bowl Ad
      • California Hospital Granted Retroactive 340B Eligibility, Drops Lawsuit Against HRSA
      • Column: Efforts to Derail 340B Contract Pharmacy Protections Hit New Low
      • Kentucky Senate Overwhelming Passes 340B Contract Pharmacy Bill; Federal Judge Partially Dismisses Novartis’ Case Against Missouri Law
      • Nebraska Advances Contract Pharmacy Bill Despite Anti-340B Dark Money Campaign; Rhode Island Introduces Similar Bill
      • Vermont is Sixth State to Introduce 340B Provider Reporting Bill in 2025
      • Senate Confirms RFK Jr. as HHS Secretary on 52-48 Vote Largely Along Party Lines
      • Congressional GOP Leaders Consider Budget Proposals That Call for Deep Health Spending Cuts
      • Study Finds 340B Providers Prescribe More Often Without Increasing Survival Rate of Breast Cancer; Hospital Advocate Challenges Conclusion
      • Sam Yeghiazaryan, Senior Supervisor, Verity Solutions
      • Engels Again Takes the Helm at Key 340B Agency
      • Kentucky Advances Contract Pharmacy Access Bill As Dark Money Group Runs Billboards Outside State Capitols Claiming ‘340B is Subsidizing Gender Transitions for Kids’
      • Indiana Senate Passes Sweeping 340B Provider Reporting Bill As House Advances Separate Bill to Restrict 340B Hospital Use
      • Illinois, Tennessee, New Hampshire Join Growing List of States to Introduce Contract Pharmacy Access Bills in 2025
      • Alkermes to Become Third Drugmaker to Reinstitute Contract Pharmacy Restrictions in West Virginia and Kansas, Providers Condemn Move
      • Hospital Group, Hospitals Look to Join Lawsuits Challenging 340B Rebate Proposals; J&J Seeks Expedited Court Action
      • Vertex Adds Pain Medication to 340B Contract Pharmacy Restrictions
      • Senate HELP Chair Cassidy Signals 340B Legislation Plans, ‘G6’ Senator Promises SUSTAIN Act Update Soon at NACHC Conference
      • HHS Communications Freeze Disrupts OPA, HRSA 340B Audits
      • 340B Outlook from Capitol Hill and the States
      • Drugmakers Push Court to Quickly Strike Down HRSA's Opposition to 340B Rebates
      • Idaho is Fifth State to Introduce 340B Provider Reporting Bill in 2025, Contract Pharmacy Access Bill Expected Soon
      • Providers Condemn Sanofi's Move to Reinstate Contract Pharmacy Restrictions in Kansas
      • State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Missouri and Mississippi
      • Kristen Gurley, General Counsel, Avita Care Solutions
      • Dark Money Group Gave Anti-340B PAC Nearly $5M in 2024, Influential PR Firm Raked in Over $300,000
      • Senate Committee Confirms RFK Jr.’s HHS Secretary Nomination by 14-13 Vote with Cassidy’s Support
      • The Future of 340B in a Value-Based Care Era: Can It Survive and Thrive?
      • Judge Denies STD Clinic’s Bid to Temporarily Regain 340B Eligibility as Fourth Drugmaker Sues
      • Two Big Mergers and Acquisitions in the 340B Service Industry Announced
      • South Dakota Introduces 340B Contract Pharmacy Access Bill; Hawaii Advances Legislation; and Three States Push 340B-PBM Bills
      • Connecticut Bill Would Make Medicaid Reimbursement Contingent on 340B Reporting Requirements
      • Hospital Group Moves to Join Federal Case to Fight J&J’s Contested 340B Rebate Proposal
    • ► January (53)
      • HELP Committee Questions RFK Jr. on Drug Pricing, Medicare and Medicaid but Not 340B 
      • ‘Deceit and Lies’: State Providers Slam Dark Money Ad Targeting 340B Contract Pharmacy Access Bills
      • Georgia is 11th State to Introduce 340B Contract Pharmacy Access Bill in 2025
      • RFK Jr. Backs PBM, Drug Pricing Reform at Senate Confirmation Hearing, 340B Not Discussed but Could Come Up Today
      • Trump Administration Signals Support for IRA Drug Price Negotiations
      • White House Rescinds Funding Freeze, But Concern Among Health Centers Remain 
      • Anti-340B Ads Return: Dark Money Group Targets GOP-Led States Considering Contract Pharmacy Access Bills
      • GOP Eyes 340B Commercial Pay Rate Cut, Advocates Slam Reconciliation Proposal
      • 5 Questions to Assess the Effectiveness of Your 340B Pharmacy Program and Position it to Optimize Outcomes
      • PhRMA-backed Conservative Think Tank Suggests DOGE Should Prioritize 340B Reform to Cut Government Costs
      • HRSA Pushes to Dismiss Health Systems’ Lawsuits Over J&J 340B Audits Amid Uncertainty Under New Trump Admin
      • Dr. Oz, Trump’s Pick to Lead CMS, Linked to Senior Role in Company that Partners With 340B Hospitals
      • Senate Sets Confirmation Hearings for RFK Jr.’s HHS Secretary Nomination, HHS Freezes Communications
      • Compliance with Inflation Reduction ACT (IRA) and Associated Maximum Fair Price (MFP) Rules for 340B Covered Entities
      • STD Clinic Sues HRSA Over 340B Sites Terminations, Claims Agency Actions Will Force Clinic to Close
      • California Hospital Sues HRSA Over 340B Removal, Seeks Retroactive Eligibility
      • New Colorado Bill Would Prohibit 340B Contract Pharmacy Restrictions, Add Hospital Reporting Rules
      • Indiana Governor Orders Investigation into 340B Hospital Off-Site Clinics as State Legislators Introduce Bill to Significantly Narrow Program Scope
      • Connecticut Lawmaker Introduces 340B Cost Reporting Bill, Providers Warn of ‘Unnecessary Burden’
      • State Contract Pharmacy Lawsuit Weekly Roundup: Updates in West Virginia, Missouri
      • NYT Investigation Highlights Federal Law’s Unintended Harm to 340B Providers
      • Four More States Introduce 340B Contract Pharmacy Access Bills in 2025
      • Sanofi Reinstates Contract Pharmacy Restrictions in Kansas, West Virginia Following State Legal Developments
      • Cassidy, Sanders Call for Passing Drug Pricing Bills as Key 340B Committee Holds First Meeting; Kennedy Confirmation Stalls
      • Federal 340B Lobbying Activity Held Steady in Q4 of 2024, Filings Show
      • Just Before Departing, Biden Admin Announces Next 15 Drugs for Medicare Negotiations Amid IRA Uncertainty and 340B Questions
      • CPS
      • Novartis is Fifth Drugmaker to Sue HRSA to Implement Controversial 340B Rebate Model
      • NYT Investigative Article Sparks Both Scrutiny and Support for 340B Prime Vendor Apexus
      • Nebraska, New York Reintroduce 340B Contract Pharmacy Access Bills in 2025
      • House E&C Convenes Under New Leadership, Senate HELP Committee to Meet Next Week
      • BMS Allows Additional Contract Pharmacy Designation for Cancer Drug; Vertex Adds Cystic Fibrosis Drug to Restrictions
      • 340B Program Had No Impact on Prostate Cancer Care, Study Suggests
      • House E&C Health Leader Floats Major 340B Reform; Billions in Cuts to 340B Hospitals Under Consideration, Hospital Group Warns
      • Katie Miller, Key Player in Anti-340B ‘Dark Money’ Campaign Helping RFK Jr.’s HHS Secretary Bid
      • Top 10: Visante's Insights for the Biggest Issues in Health System Pharmacy in 2025
      • HRSA Terminates 20 ‘Ineligible’ 340B Sites from STD Clinic; Clinic Rejects Allegations and Vows to Fight Back
      • New Mexico is Third State to Introduce 340B Contract Pharmacy Access Bill in 2025
      • New Missouri Bill Would Significantly Restrict Uses of 340B Savings, Add Provider Reporting Requirements
      • Column: In the Senate, Keep an Eye on Two Powerful Lawmakers with Very Different Views on 340B
      • Expert Tip from Maxor
      • Kentucky, Utah Introduce First Contract Pharmacy Access Bills of 2025
      • State Contract Pharmacy Lawsuit Weekly Roundup: Appeals in Mississippi and Maryland; Update in Missouri
      • Webinar—Resolving 340B Noncompliance: From Reversals to Refunds
      • Cassidy Officially Takes Helm of Senate Committee that Oversees 340B Policy
      • High-Profile Dems, Including AOC, Win Spots on Key House Panel That Oversees 340B
      • Heron, Dr. Reddy’s, Organon, CooperSurgical Issue NDC Changes 
      • Optimizing Your 340B Program: Ensuring Accurate Capture and Identifying Data Gaps
      • Trump Selects Key Player in Anti-340B ‘Dark Money’ Campaign to Join New Department of Government Efficiency
      • Staff, Members for Key Congressional Committees That Oversee 340B Policy Announced; REH Bill Reintroduced
      • Drugmaker Lawsuit Targets 340B Eligibility of In-Kind STD Clinics; STD Grantee Denies Allegations
      • AHA Urges CMS to Block Drugmaker 340B Rebate Models, Improve Medicare Transaction Facilitator
      • Indiana State Senator Renews Push for 340B Provider Reporting Bill in New Legislative Session
  • ►2024 (674)
    • ► December (52)
      • Fed. Court Rejects AstraZeneca’s Request to Halt Mississippi’s Contract Pharmacy Law, Dealing Another Blow to Drug Industry
      • After Drama Over Previous Proposals, Congress Passes Year-End Spending Bill with Pared-Down Health Center Funding, No 340B or PBM Language
      • Senate GOP Selects Republican Members for Key 340B Senate Committee in 119th Congress, Sanders Named Ranking Member
      • Continuous 340B Program Readiness: Your Two-Part To-Do List
      • Biogen to Extend 340B Contract Pharmacy Restrictions to Grantees and Add New Requirements for Hospitals, Novartis to Require Claims Submissions for Hospitals
      • Chaotic Michigan Legislative Session Ends Without House Vote on Senate-Backed 340B Contract Pharmacy Access Bill
      • Ruling Against West Virginia Contract Pharmacy Access Law May Increase Odds of Eventual SCOTUS Review as State Providers Vow to ‘Not Give Up’
      • Washington Health Officials Submit Report to State Legislature on 340B Cost Reduction Opportunities, Program Benefits to Community
      • State Action Year in Review: States Passed More 340B Contract Pharmacy Access Laws as Drugmakers Pursued Legal Challenges and Dark-Money Campaign Threatened GOP Lawmakers
      • A Year in Review: The Top 10 Most-Read 340B Report Stories of 2024
      • Rep. Buddy Carter, 340B Critic, to Chair Key Subcommittee That Oversees Program
      • After Drama from Musk and Trump Over Bipartisan Spending Bill, 340B Legislation, Health Center Funding Faces Uncertain Future
      • House GOP Names New Members to Key 340B Committee; Staffer with Drug Industry Ties To Serve in Top Post
      • The Evolving Impact of 340B on Specialty Pharmacy
      • Drugmakers Drop Lawsuits Against Kansas 340B Contract Pharmacy Law After AG Says Statute Does Not ‘Prohibit or Forbid Anything’
      • State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Mississippi, Missouri
      • COLUMN: Six Members of the U.S. House that 340B Stakeholders Should Keep an Eye on in 2025
      • Federal Judge Blocks West Virginia from Enforcing Contract Pharmacy Access Law While Challenges Play Out
      • Pallone Named Top Democrat on House Committee Overseeing 340B Program
      • IRA Rollout, Regulatory Gaps May Drive Major 340B Reforms in 2025, Says Adam Fein of Drug Channels
      • Scoping 340B Referral Capture Opportunity: It’s Bigger Than You Think
      • AbbVie’s Latest 340B Restrictions Appear to Target Hospital Alternative Distribution Models But May Not Be Enforceable, Experts Say
      • Evofem Announces NDC Code Change Effective Feb. 1 
      • Russ Barron, Director, The Alinea Group
      • Sanofi Pauses 340B Rebate Proposal, Sues HRSA to Impose Controversial Model
      • HRSA Threatens to Remove Sanofi from 340B Program Over ‘Unapproved’ 340B Rebate Proposal
      • Michigan Senate Overwhelmingly Passes Contract Pharmacy Access Bill, Sending to House for Final Push  
      • It’s Not Just Arkansas Anymore: West Virginia Becomes Second State to Start Enforcing Its Contract Pharmacy Access Law
      • Michigan 340B Contract Pharmacy Access Bill Moves to Full Senate as Legislative Session Nears End
      • Questions to Ask as you Evaluate Potential Referral Partners
      • State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Arkansas, Missouri - Dec 24
      • Despite Rep. Guthrie’s Previous Support for Legislation Opposed by Most 340B Providers, Groups Praise His Ascension to E&C Chairperson
      • NACHC, ACH Join Forces to Urge Congress for Health Center Funding, Leaving 340B Differences Aside
      • California Health System Presses Federal Appeals Court to Revive 340B Whistleblower Lawsuit Against Four Major Drugmakers
      • Rep. Guthrie to Chair Key House Committee That Oversees 340B and Medicaid Programs
      • With End of Congressional Session Fast Approaching, Time is Running Out for Long-Anticipated Senate Bipartisan 340B Bill Introduction
      • 'A Sense of Hope:' Arkansas 340B Providers and Officials Welcome SCOTUS’ Move Declining to Take Up Challenge of State’s 340B Law
      • Michigan Lawmakers, Providers Push for Contract Pharmacy Protections Before End of Session As Drug Industry Allies Step Up Opposition
      • HRSA Seeks Dismissal of Two Health Systems’ Lawsuits Over J&J 340B Audits
      • Supreme Court Declines to Hear PhRMA’s Challenge to Arkansas’ Landmark 340B Contract Pharmacy Access Law
      • Experts Predict Impact of Trump, GOP Majorities on 340B Program in Subscriber-Only Webinar
      • How the GOP’s Incredibly Slim House Majority in Next Congress Could Affect 340B Policy
      • Maximizing 340B Opportunities Through Effective Pharmacy Reconciliation
      • AbbVie Will Require Grantees to Submit Claims Data Starting Jan. 1; Grantee Representatives Criticize Move
      • Safety-Net Hospital Group Urges HRSA to Block Sanofi 340B Rebate, Calling It More Harmful than J&J Model
      • State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Missouri
      • Rachael Bowser, Lead Technician, Reedsburg Area Medical Center Community Pharmacy and 2024 Scholarship Recipient for the Apexus Advanced 340B Operations Certificate Program
      • Health Systems Temporarily Avoid HRSA 340B Termination Threats as They Fight J&J Audits in Court
      • Sanofi Escalates Legal Fight for HRSA 340B Contract Pharmacy Records Amid Controversial Rebate Push
      • Claim Capture by Provider Type: A Compliance and Maximization Guide
      • Right-leaning Outlets Publish Contrasting Op-eds on 340B Program 
      • HRSA Sends New York Times More Documents Requested in 340B FOIA Lawsuit
    • ► November (46)
      • Fourth Large Manufacturer Fights to Establish Contested 340B Rebate Model
      • It is Not Just Hospitals: Amid Increasing Drugmaker Contract Pharmacy Restrictions, Health Centers Forced to Lay Off Staff & Cut Services
      • 340B Providers Slam Sanofi’s New 340B Rebate Model for Hospitals and Health Centers
      • House Places 340B Transparency Act on Floor Calendar, But a Vote is Not Guaranteed
      • Minnesota Issues 1st State Report on 340B, Critics Say it ‘Misses Critical Context’ 
      • State Contract Pharmacy Lawsuit Weekly Roundup: Arkansas SCOTUS Appeal and Updates in West Virginia, Mississippi
      • The Demise of Chevron Deference – What Does It Mean for the 340B Program?
      • Hospital Systems Fight HRSA’s Threat to Remove Them from 340B Program Over J&J Audits
      • Wall Street Journal Reports Sanofi Will Become Third Drugmaker to Push for Controversial 340B Rebate
      • Proposition 34: Voters Narrowly Back Controversial California 340B ‘Revenge’ Ballot Measure
      • Trump Picks ‘Dr. Oz’ to Lead CMS, Key Agency that Influences 340B Program
      • More Dems Back 340B PATIENTS Act Which Would Restore 340B Discounts in Contract Pharmacy Setting
      • Struggling with Low Pharmacy Capture Rates?
      • Katheryne Richardson, a Former Senior BMS Leader and Apexus VP, Joins Berkeley Research Group as a Managing Director
      • Panelists at Healthcare Purchaser Conference Link 340B to Higher Employer Healthcare Costs, Hospital Consolidation
      • State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Mississippi, Missouri
      • Closing the Loop & Care Gaps
      • HHS Fights Sanofi’s FOIA Lawsuit Seeking Extensive 340B Contract Pharmacy Records
      • 340B Hospital Group Raises Alarm About Rebates in New Ad Blitz, Health Center Group Revamps 340B Reform Proposal
      • Onsite Pharmacies: A Win-Win-Win for Entities, Patients & Providers
      • PhRMA Dismisses Lawsuit Challenging 340B ADR Rule
      • Lilly Sues HHS, HRSA to Implement Expansive 340B Rebate for All Products and Covered Entity Types
      • J&J Lawsuit to Test Trump Administration’s Stance on 340B Rebates
      • Stakeholders Prepare for New Senate with Two Key GOP Players with Vast Differences on 340B
      • In Major Change from Previous Tenure, President-Elect Trump Selects Vaccine Skeptic RFK Jr. as HHS Secretary
      • State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Mississippi, West Virginia, Missouri
      • 340B Critic Cassidy to Chair Key Senate Committee
      • GOP Retains Control of U.S. House to Put Republicans in Charge of Congress, White House
      • Senate GOP Selects Thune, a 340B Champion, as Next Majority Leader Despite Pushback from Trump Allies
      • New CMS Rule Mulls Data Repository for 340B Claims in 2026, But Implementation Challenges Loom
      • Tammy Kinney:  A Personal Testament to 340B’s Importance in Rural America
      • AbbVie, GSK Announce Refunds for 340B Overcharges
      • Column: Post Election Analysis: Implications for the 340B Program
      • Webinar—The IRA’s Implications for 340B Stakeholders
      • J&J Sues HRSA for Blocking Controversial 340B Rebate Model
      • GOP Returns to Power: How the 2024 Election Outcomes Could Affect the 340B Program
      • Proposition 34: Results Too Close to Call in Controversial California 340B Ballot Measure Contest
      • Arkansas Officials, Providers Urge Supreme Court to Deny PhRMA’s Appeal to Overturn 340B Contract Pharmacy Access Law
      • Supreme Court Hears Arguments Over DSH Calculations That Could Result in More Hospitals Qualifying for 340B
      • State Contract Pharmacy Lawsuit Weekly Roundup: Updates in West Virginia, Missouri, Kansas
      • A New Era for Value-Based Care: Driving Better Outcomes Through Innovation and Patient-Centered Care
      • November 5 is Finally Here: How the 2024 Elections Could Affect the 340B Program
      • Major GPO Sues HRSA over Restrictions on How 340B Hospitals Purchase Initial Drug Inventory
      • Lilly Backs Sanofi Lawsuit Seeking HRSA 340B Records, Argues Contract Pharmacy Agreements Violate 340B Statute
      • BI Tightens Contract Pharmacy Restrictions for All Covered Entities
      • Eli Lilly Announces Refunds for 340B Overcharges
    • ► October (46)
      • HHS Appeals Court Ruling That Blocked DSH Calculation Changes That Impact 340B Eligibility
      • Pfizer CEO Calls 340B ‘One of the Biggest Issues’ During Earnings Call Touting $17.1B in Quarterly Revenue
      • State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Arkansas, Missouri - Oct 24
      • Ascend, Xellia Announce Refunds for 340B Overcharges
      • Column: Much-Needed Wins for 340B Providers but Challenges Could Be Lurking
      • Julie Badger, Technical Training Advisor, Verity Solutions
      • Kalderos to Resume Legal Battle Over HRSA’s Opposition to Drugmaker 340B Restrictions, Including Rebates
      • Former Presidential Candidate Howard Dean Calls for More 340B Transparency, Declines to Discuss Op-ed, Alleged Drug Industry Ties
      • AstraZeneca Announces Change to Cancer Drug Replenishment After Discontinuing Certain Dosage
      • UCB Extends Contract Pharmacy Restrictions to All Federal Grantees
      • Organon To Extend Contract Pharmacy Restrictions to CHCs on Dec. 1
      • Fifth Hospital Sues HRSA for Authorizing ‘Unlawful’ J&J 340B Audits
      • Drugmakers Urge Federal Appeals Court to Dismiss California Health System’s 340B Whistleblower Lawsuit
      • State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Minnesota, Missouri, Mississippi
      • Group That Does Not Disclose Its Funding Releases White Paper Calling for 340B Reforms, Advocates Slam Report
      • Growth in 340B Purchases Driven by Pharma Price Increases, Broader Healthcare Trends, Providers Say
      • Magic Johnson-Backed Startup Raises $31 Million to Help Build, Expand In-House Pharmacies at 340B HIV Clinics
      • 5 Key Focus Areas in a 340B Audit
      • 340B Lobbying Activity Did Not Slow Down in Q3, Federal Filings Suggest
      • Total 340B Drug Purchases Reached $66 Billion in 2023
      • Former Senior Trump Official Talks Drug Pricing Reform, Says 340B Program Is ‘Out of Control’
      • Former J&J Attorney and Current Kalderos Board Director Says Battle over Rebates Has Not Ended
      • Dark Money Poured Nearly $4M into Super PAC Opposing State 340B Contract Pharmacy Access Bills
      • LA Times Says ‘No’ to California Ballot Measure That Would Affect 340B 
      • State Contract Pharmacy Lawsuit Weekly Roundup: New Filings in Missouri, Minnesota
      • PhRMA Pans Government’s Response to J&J’s 340B Rebate Proposal in Letter to HRSA Administrator
      • 340B Health Leader Slams J&J Rebate Proposal, Urges Providers to ‘Remain Vigilant’ in Op-Ed
      • Providers Raise Caution on Claims Data Submission Requirements After 340B ESP Terms of Use Update Continues to Defer to Manufacturers
      • Health Centers Urge Federal Appeals Court to Take Their Side in Case Alleging Drug Manufacturer Collusion on Contract Pharmacy Restrictions
      • CMS Inaction on IRA-340B Conflicts May Drive ‘Manufacturer-Friendly’ Compliance Models
      • FQHCs Reinvest 340B Savings in Safety-Net Care, JAMA Study Finds
      • State Contract Pharmacy Lawsuit Weekly Roundup: Orders and Filings in Arkansas, Louisiana, Kansas, Mississippi Maryland, Missouri
      • Head of Drug Industry-Funded Think Tank Backs J&J’s Proposed Rebate Model, Slams Hospitals in Op-Ed
      • Edline Victor, Director of Pharmacy, Whole Family Health Center and 2024 Scholarship Recipient for the Apexus Advanced 340B Operations Certificate Program
      • Expert Tip from Maxor
      • CMS’ MDRP Final Rule May Impact 340B Covered Drugs, Attorneys Say
      • GSK Announces Specialty Pharmacy Senderra No Longer Eligible to Dispense Asthma Drug
      • Amgen Announces NDC Change for Osteoporosis Drug
      • Arkansas Begins Enforcement Against AstraZeneca for Allegedly Violating Contract Pharmacy Access Law
      • CMS Finalizes Next Medicare Drug Negotiation Guidance Without Resolving Key Concerns of 340B Stakeholders
      • Webinar—Neutral 340B Clearinghouse: Ready, Set, Now Go!
      • Providers Praise Federal Court’s Defense of Louisiana Contract Pharmacy Law as Drug Industry Weighs Next Steps
      • State Contract Pharmacy Lawsuit Weekly Roundup: Updates on AbbVie, AstraZeneca Cases in Missouri
      • 340B Provider Groups, Key Federal Lawmaker Praise HRSA for Pressuring J&J to Drop 340B Rebate Proposal
      • Kalderos Launches New Drug Discount Platform with 340B Rebate Capabilities as Lawsuit with HHS Remains Paused
      • Florida, North Carolina Now Eligible For Immediate 340B Enrollment Under Public Health Emergency
    • ► September (56)
      • Federal Judge Upholds Louisiana’s 340B Contract Pharmacy Law in Another Major Blow to Drug Industry
      • J&J Abandons 340B Rebate Due to HRSA's Enforcement Threats But Defends Model in Letter to Agency
      • 188 Bipartisan House Members Urge HHS Action Against J&J’s ‘Unlawful’ 340B Rebate Proposal
      • HRSA to J&J: End 340B Rebate by Monday or Lose Access to Key Government Health Insurance Markets
      • High-Ranking HRSA Official Talks Genesis Decision, Drugmaker Audits During Rare Unscripted Q&A at Industry Conference
      • Lawmakers Hit Campaign Trail Without Unveiling Highly Anticipated SUSTAIN 340B Act
      • Consolidated Service Centers and 340B: Can they Coexist?
      • Sanofi Imposes New 340B Contract Pharmacy Rule in Arkansas Following Legal Deal with State
      • State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Maryland, Minnesota
      • Norma Carrizales, Senior Account Manager, Cervey
      • Sen. Cassidy’s Letters to Drug Manufacturers Welcomed by Drug Industry Trade Group, Draw Skepticism from 340B Provider Advocates
      • CMS Publishes Final Rule on Medicaid Rebates with Significant 340B Implications
      • 7 Tips to Help Covered Entities Navigate ACA Open Enrollment
      • 340B Report Kicks Off Editorial Roundtable Podcast and YouTube Show
      • Delaware Enacts 340B-PBM Payment Law Without Contract Pharmacy Provisions from Original Version
      • PhRMA, HHS Seek Continued Pause on 340B ADR Lawsuit
      • AHA Op-Ed Takes Aim at ‘Big Pharma’s’ 340B Program Growth Rhetoric 
      • Column: CMS Should Heed the Advice of 340B Community on Medicare Negotiations
      • Senator Cassidy Extends 340B Inquiry to Two Major Pharmaceutical Manufacturers
      • House Passes Pediatric Enrollment Bill That Would Require 340B Providers to Report Medicaid Managed Care Revenue
      • HRSA’s Enforcement Threats Against J&J’s 340B Rebate Proposal Could Face Drugmaker Challenge
      • Federal Judge Upholds Four Drugmakers’ 2021 Contract Pharmacy Restrictions—Without Addressing ‘40-Mile Radius’ Rule
      • A HRSA Audit Guidebook 
      • State Contract Pharmacy Lawsuit Weekly Roundup: AbbVie Asks 5th Circuit to Reverse Ruling, New Developments in Missouri and Kansas 
      • Equiscript
      • HHS to J&J: End 340B Rebate Proposal Immediately or 'Face Potential Consequences’—Including Termination from Federal Health Insurance Programs
      • Sen. Welch Hopes His Contract Pharmacy Bill Will Move Soon, ASAP 340B and PhRMA Push for Broader Bill
      • Best Practices for 340B Program Savings Management
      • Fourth Hospital Sues HRSA for Alleged ‘Unlawful’ Authorization of J&J 340B Program Audits
      • Diabetes Drugmakers Urge Federal Appeals Court to Dismiss Health Centers’ 340B Antitrust Lawsuit
      • Eli Lilly and Amgen Announce Refunds, Amgen Issues NDC Change
      • HRSA Adds Louisiana to Eligible States for Immediate 340B Enrollment Due to Hurricane Francine 
      • 340B Covered Entities Threaten Action Against Drugmakers Over New Reporting Requirements
      • HHS Concessions in Contract Pharmacy Lawsuits Unlikely to Signal Shift in 340B Rebate Stance, Attorneys Say
      • State Contract Pharmacy Lawsuit Weekly Roundup: 5th Circuit Appeals and Updates in Arkansas, Minnesota, West Virginia
      • How to Leverage AI for Enhanced 340B Program Management: Learn More and Ask Your Questions on 9/24 at 1:00PM ET
      • AstraZeneca Tightens Contract Pharmacy Restrictions to Require Claims Data Submission
      • ACA Played Key Role in 340B Growth, Drug Industry Consulting Firm Finds
      • Expert Tip from The Craneware Group
      • Welch Introduces 340B PATIENTS Act in the Senate
      • Arkansas Plans to Challenge J&J’s Contested 340B Rebate Proposal for Violation of State Law
      • In Another Drug Industry Setback, Maryland Federal Judge Rejects Bids to Block State’s 340B Contract Pharmacy Access Law
      • AHA Calls on Congress to Defend 340B Access to Specialty, Community Pharmacies Amid Drugmaker Resistance
      • Pharma-Linked Watchdog Advocacy Group Leader Pens Op-Ed Urging Congress to Advance 340B Legislation
      • Welch Likely to Introduce Senate Version of Matsui’s 340B PATIENTS Act As Soon As Next Week
      • Experts Forecast Impact of November Elections on 340B Program, Drug Pricing and the Larger Economy
      • Webinar -- Navigating 340B Contract Pharmacy Restrictions: The Latest Developments, Field Insights, and Mitigation Efforts
      • HHS Asks D.C. Federal Court to Rule for Drugmakers in Contract Pharmacy Lawsuits, Ties Outcomes to Kalderos 340B Rebate Case
      • State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Arkansas, Maryland, Missouri, West Virginia 
      • Merck Offers Refunds to 340B Providers for Overcharges of Inhaler in Fourth Notice This Year
      • Expert Tip from PharmaForce
      • J&J’s 340B Rebate Vendor to Host In-Person Training Next Monday Despite Government’s Objection to Proposal
      • Bayer to Extend Contract Pharmacy Restrictions to Federal Grantees, Providers and Advocates Voice Concerns About Recent Trend
      • J&J Relents on Arkansas Contract Pharmacy Law; AbbVie Exempts MO, MS Covered Entities
      • UPDATED: Certain NDCs for Four of Ten Newly Announced Medicare Negotiated Drug Prices Are Below Current 340B Prices
      • EMD Serono Extends 340B Contract Pharmacy Restrictions to All Covered Entities & Adds New Restrictions
    • ► August (58)
      • Hospital Groups Urge HRSA to Take ‘Immediate Enforcement Action’ Against J&J’s Contested 340B Rebate Proposal
      • Analysis Finds Growing Private Equity, Corporate Investments in 340B; Firm Conducting Study Fails to Mention Its Own PE Funding
      • Preparing for a Neutral 340B Claims Clearinghouse
      • State Contract Pharmacy Lawsuit Weekly Roundup: Judge Calls Astra Subpoenas ‘Overly Broad,’ Mo. Officials Push to Dismiss Lawsuit 
      • Two More Drugmakers Partially Exempt Missouri Providers from 340B Contract Pharmacy Restrictions
      • Christina Breckenridge, Senior Director of Client Success, RxStrategies
      • J&J’s Contested 340B Rebate Proposal Would Further Limit Contract Pharmacies, Give Drugmaker More Control of Program, Attorneys Say
      • Missouri’s 340B Contract Pharmacy Access Law Takes Effect Tomorrow as More Drugmakers Restore Discounts, Others Sue State
      • Kedrion Posts 340B Refund Notice; Mylan Issue NDC Changes
      • Column: Unilateral Imposition of Rebate Model for the 340B Program is a Non-Starter
      • It's Not a Matter of IF but WHEN
      • HRSA Says Johnson & Johnson’s New 340B Rebate Model Did Not Receive Agency Approval, Is ‘Inconsistent’ with 340B Statute
      • J&J Announces Plans to Shift Certain 340B Discounts to Rebate Model, Prompting Fierce Backlash from Providers, Regulators
      • Federal Appeals Court Dismisses AHF’s 340B Lawsuit Against Apexus
      • Sanofi Asks 340B Hospitals for Information on Purchases of Its Top-Selling Drug
      • Unlock Your 340B Program Potential Through Data Analytics
      • Pharmacist, Hospital Groups Release Joint Model State 340B Contract Pharmacy Access Legislation
      • State Contract Pharmacy Lawsuit Weekly Roundup: New Intervenor in Arkansas; Consolidated Cases in Maryland
      • Hospital Groups ask Supreme Court to Reverse Ruling that Impacts 340B Eligibility
      • Drug Industry-funded Think Tank Raises Questions About 340B Hospitals’ Charity Care
      • Abby Kleczynski, Manager Strategic Accounts, The Craneware Group
      • Expert Tip From AuthorityRx
      • Federal Court Grants Texas Hospitals’ Request to Temporarily Block DSH Calculation Changes
      • AHA Raises ‘Serious Concerns’ with MedPAC’s Direction on 340B
      • Organon Partially Exempts Missouri, Minnesota Providers from 340B Contract Pharmacy Restrictions
      • GSK Announces Refunds for 340B Overcharges
      • 340B ESP Updates Claims Submission Policy, Stakeholders Voice Concerns About Compliance
      • SUSTAIN 340B Act On Track for Possible Early September Introduction After Last-Minute August Delay
      • Medicaid Drug Rebate Program Summit – MDRP 2024
      • State Contract Pharmacy Lawsuit Weekly Roundup: AstraZeneca Defends Subpoenas; Updates in Missouri, Mississippi, Maryland
      • Former Pfizer Exec. Slams 340B, Says IRA Will Worsen Program in New Op-Ed 
      • Expert Tip from AAFCPAs
      • After Failing To Disclose Conflict of Interest, JAMA Issues Correction to Piece Calling for Increased 340B Oversight and Transparency
      • UPDATED: AbbVie Ends Voluntary 340B Discount Pricing for Dozens of Orphan Drugs
      • Patient Turned Advocate: David Alexander Discusses 340B
      • HRSA Seeks Public Comment On ADR Process and Required Administrative Load
      • Two New Drug Industry Lawsuits Challenge 340B Contract Pharmacy Access Laws in Kansas, Missouri
      • J&J Exempts Maryland, Mississippi from Contract Pharmacy Restrictions
      • Massachusetts’ 340B Contract Pharmacy Access Bill Fails to Move in Formal Session, Stakeholders Remain Hopeful
      • HRSA Allows for Immediate 340B Enrollment in Three Southeastern States Due to Hurricane Debby
      • VP Pick Tim Walz Signed Multiple 340B Laws in Minnesota, Including Contract Pharmacy Access, But Faced Opposition from Hospitals Over Certain Policies
      • Hospital-Backed Candidate Wins Missouri GOP Governor Primary Over Two Candidates Who Vowed to Repeal 340B Contract Pharmacy Access Law
      • State Contract Pharmacy Lawsuit Weekly Roundup: AstraZeneca Subpoenas in Arkansas, Mississippi; Minnesota AG’s Defense
      • HRSA Walks Through Hospital Recertification Process Days Before Opening Date
      • Private Oncologist Group-Funded Study Highlights 340B Contract Pharmacies’ Links to PBMs
      • Two Researchers Call For More 340B Transparency, but JAMA Fails to Disclose Glaring Conflict of Interest
      • HRSA to Host Webinar Tomorrow Ahead of 340B Hospital Recertification Window Opening Aug. 12
      • Senate Committee Votes to Increase HRSA Funding, Flat Fund OPA and Chides Drug Manufacturers on 340B Restrictions
      • More Drugmakers Exempt New States from 340B Contract Pharmacy Restrictions
      • Third Drugmaker Sues Kansas Over Its 340B Contract Pharmacy Access Law
      • Highly Anticipated Bipartisan Senate 340B Overhaul Delayed Ahead of August Recess
      • U.S. Government, 340B Provider Groups Urge Appeals Court to Reverse Dismissal of Health System’s 340B Whistleblower Lawsuit
      • As GOP Primaries Near, Lawmakers in Missouri Battle Over 340B Messaging
      • State Contract Pharmacy Lawsuit Weekly Roundup: Maryland, Louisiana AGs Step Up Defense
      • PhRMA Petitions Supreme Court to Overturn Arkansas’ 340B Contract Pharmacy Access Law
      • Federal Bill Introduced to Extend 340B Eligibility to Qualifying Hospitals in U.S. Territories
      • Rep. Matsui’s 340B PATIENTS Act Picks Up New Co-Sponsors
      • Donna Tempesta, Northern Bureau Chief / VP of Finance - Pharmacy, AIDS Healthcare Foundation
    • ► July (56)
      • Bipartisan Federal Children’s Healthcare Bill with 340B Reporting Requirements Nears House Vote
      • PhRMA-Backed Conservative Think Tank Tells State Lawmakers Not to Pass 340B Contract Pharmacy Access Bills During Annual Meeting
      • AHA, RWC-340B Ramp Up Critiques of ASAP 340B-Backed Bill
      • HRSA Agrees to Send New York Times FOIA-Requested Documents 
      • Column: Three Key Observations from Efforts to Restore 340B Discounts in the States
      • Two Hospitals Sue HRSA to Block ‘Unlawfully Authorized’ Drugmaker 340B Program Audits
      • Merck, Wisconsin Health System Join 340B Working Table; 300+ Firms Lobbied on 340B in Q2
      • Missouri GOP Gubernatorial Candidate Ashcroft Calls to ‘Repeal 340B’ as State Hospitals Back Competitor in Tight Primary
      • GOP Lawmaker Grills PBM Execs on 340B Profits During House Oversight Hearing
      • State Contract Pharmacy Lawsuit Weekly Roundup: Mississippi, Maryland and Arkansas Cases Heat Up
      • Just Days After Legal Setback, Novartis Exempts Mississippi Providers From Contract Pharmacy Restrictions
      • A Closer Look at Kamala Harris’ Positions on 340B and Other Drug Pricing Issues  
      • Health System Urges Federal Appeals Court to Revive 340B Overcharge Lawsuit Against Major Drugmakers
      • First Drugmaker Sues Missouri Over its 340B Contract Pharmacy Access Law
      • Merck, Jazz Pharmaceuticals Exempt States from 340B Contract Pharmacy Restrictions — Including First for Missouri
      • 340B Coalition Summer Conference 2024: Navigating the Heat of Change and Uncertainty
      • Massachusetts 340B Measures Addressing PBM Discrimination and Medicaid Drug Coverage Fall Short in Senate, Sponsor Plans to Refile Bill Next Session
      • Trump VP Pick Vance Co-Sponsored Bill Calling for Study of 340B Use Among ‘Noncitizens’
      • State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Mississippi, Maryland
      • We Must Partner—With Pride—to Better Serve LGBTQ+ Patients
      • Massachusetts Senate to Vote on 340B PBM Nondiscrimination Measure; Status of Contract Pharmacy Bill Uncertain
      • SK Life Science Posts Refund Notice; Dr. Reddy's and Pfizer Issue NDC Changes
      • HRSA Allows for Immediate 340B Enrollment in Texas Due to Hurricane; Hawaii Remains Eligible
      • Jennifer Austin, 340B Senior Program Director, Visante
      • GOP-Led House Appropriations Committee Votes to Cut HRSA Funding, Flat Funds OPA in Party Line Vote
      • Sen. Cassidy Claims 340B Hospitals Drive Medical Debt During Key Senate Committee Hearing
      • CMS Proposes Rule to Exclude 340B Claims from Inflation Rebates; Reflects ‘Stronger Understanding’ of 340B than IRA Negotiation Guidance, Says Attorney
      • Study Finds Oncology Markups at 340B Pediatric Hospitals; AHA Slams Study and Funder 
      • Sumitomo Loosens 340B Contract Pharmacy Restrictions in Five More States
      • Missouri Become Eighth State to Enact 340B Contract Pharmacy Access Law After Governor Declines to Act on Bill
      • Upcoming Federal Elections Will Significantly Impact 340B Legislative Agenda, Say 340B Hospital Lobbyist, Drug Industry Analyst
      • Advocates March on Capitol Hill to ‘Defend 340B’ Amid D.C. Heat Wave
      • Navigating State-Level Regulations to Safeguard Your 340B Program
      • Matsui’s 340B PATIENTS Act Gains 5 Democratic Co-Sponsors Ahead of 340B Health Lobby Days
      • Pharma-Linked Conservative Nonprofit Launches Ad Campaign to ‘Stop the Feeding Frenzy’ in 340B
      • Drug Industry Takes Issue with IRA’s Drug Negotiation Guidance
      • New Hampshire Enacts Law to Bar PBMs, Payers from ‘Discriminating Against’ 340B Providers
      • Apotex to Issue Refunds to 340B Covered Entities 
      • 340B Providers Take Issue with CMS Draft Guidance on IRA Implementation Calling It “Problematic, Unworkable and Inconsistent”
      • Astellas Suspends its Contract Pharmacy Restrictions in More States; BMS and Sanofi Also Announce State Exemptions
      • TPA Fees: Before You Sign on the Dotted Line
      • West Virginia AG, Hospital Groups Fight Novartis’ Lawsuit to Block State 340B Contract Pharmacy Access Law
      • AbbVie, AstraZeneca Sue Minnesota Over Contract Pharmacy Access Law
      • Texas Hospitals Ask Judge to Block HHS’ DSH Calculation Rule That Impacts 340B Eligibility
      • Kimberly Lott, Vice President of Patient Care Coordination, AuthorityRx
      • 340B Coalition Conference Keynote: Program Faces ‘Progress Amid Challenges’
      • AbbVie, AstraZeneca Challenge Kansas’ New Contract Pharmacy Access Law
      • Federal Judge Denies Drugmakers’ Bids to Block Mississippi’s New 340B Contract Pharmacy Access Law
      • Missouri GOP Lawmaker Slams State AG’s ‘Irresponsible’ Claims Linking 340B Bill to Abortion As Governor’s Decision Looms
      • Supreme Court ‘Chevron’ Ruling Increases Pressure on Congress to Act on 340B But Unlikely to Immediately Impact Program Oversight
      • Viatris Becomes 37th Manufacturer to Place Restrictions on 340B Contract Pharmacy Use; Policy Applies to Hospitals and Health Centers
      • More Drugmakers Exempt States from Contract Pharmacy Restrictions as Four New State Laws Take Effect
      • Delaware Legislature Passes Anti-Discrimination Protections for 340B Providers from PBMs but Drug Manufacturer Restrictions Remain
      • Hospital Groups Urge Federal Court to Uphold Maryland’s 340B Contract Pharmacy Access Law
      • Hospitals in Texas and Other States Sue HHS Over DSH Calculation Changes That Impact 340B Eligibility
      • How to Leverage AI for Enhanced 340B Program Management: Learn More on 9/25 at 1PM ET
    • ► June (63)
      • New York Times Sues HRSA To Release 340B Data, Communications Between Office of Pharmacy Affairs and Apexus Leaders; Information Could Be Released Soon
      • Just Days Before New Laws Go Into Effect, GSK, Pfizer Exempt Additional States from Contract Pharmacy Restrictions
      • Navigating HRSA 340B Program Audits
      • Health Centers Fear ‘Collateral Damage’ From New Manufacturer Restrictions on Wholly-Owned Pharmacies
      • Health Centers Urge Federal Appeals Court to Reverse Dismissal of Suit Alleging Drugmaker Collusion on Contract Pharmacy Restrictions
      • California Hospital Association Pans ASAP 340B-Endorsed Bill, Encourages Congress to Support 340B PATIENTS Act
      • Nick Gnadt, Director of Pharmacy Professional Services, SpendMend
      • Expert Tip from Cervey
      • Key West Virginia Lawmaker Considering Legal Action Against Anti-340B PAC Taking Credit for his Election Loss
      • IRA Could ‘Crush the 340B Margin,’ Force Transparency into Program, Says Adam Fein of Drug Channels
      • Michigan Hospitals, Former Lawmaker Target State Contract Pharmacy Protection Bill Ahead of Summer Recess
      • PhRMA Asks Federal Judge to Block Enforcement of Maryland’s New 340B Contract Pharmacy Access Law
      • Lilly Adds Significant New Restrictions on 340B Contract Pharmacy Access; Alleges Lack of Oversight by HRSA, Pharmacies and TPAs
      • Lilly Posts 340B Refund Notice for Insulin Product Humulin
      • It’s Official: Long-Awaited Final 340B ADR Rule Takes Effect, But Findings Still Distant
      • Senate Companion Bill Introduced to Expand 340B Eligibility to Certain Rural, Outpatient Hospitals
      • CBO Analysts Say Drug Spending Through 340B Grew 19% Annually From 2010 to 2021, 340B Champion Points Finger at Drug Industry
      • GAO Reissues Recommendations to Improve 340B Compliance, Medicare Financial Stability
      • Higher Court Already Rejected AstraZeneca's Claim on Arkansas 340B Contract Pharmacy Law, State Attorney Tells Federal Judge
      • Hospital Groups Bash Novartis’ ‘Whiplash-Inducing’ Arguments in Mississippi 340B Contract Pharmacy Lawsuit
      • COLUMN: After 340B Hearing and New Bills Emerging; The Likely Path Forward
      • Mesfin Tegenu, Founder & CEO, RxParadigm
      • Expert Tip from Sectyr, LLC
      • Major Bipartisan Senate 340B Overhaul Could be Introduced by August
      • Group Representing Large Community Health Centers Slams 340B Bill Endorsed by NACHC and PhRMA  
      • Advanced 340B Education: Staying Informed and Empowered
      • Delaware House Passes 340B Contract Pharmacy Access Bill that Adds Reporting Requirements, Removes Protections for Hospitals
      • Despite Unanimously Passing Senate, Rhode Island Fails to Pass Contract Pharmacy Protection Bill 
      • In Op-Ed for Prominent Local Publication, Virginia Health Center Leader Pans Governor for Vetoing State 340B Protection Bill
      • Three Things Hospitals and Grantees Need to Know About HRSA’s 340B New Administrative Dispute Resolution Rule
      • Sanofi Sues HHS, HRSA for Contract Details Between Covered Entities, Pharmacies
      • In Stinging Op-Ed, West Virginia Senate Leader Bashes Drug Industry and Rejects Efforts to Politicize 340B Program
      • Super PAC with Dark Money Ties Launches New Anti-340B Ad
      • Range of Motives Likely Behind Surge in Drugmaker Contract Pharmacy Changes, Say Provider Advisers
      • Draft Senate Drug Shortages Bill Sparks Stakeholder Debate over 340B Provisions
      • Supreme Court to Review Case that Could Result in More Hospitals Qualifying for 340B Program
      • Jason Atlas, Senior Vice President, Pharmacy Operations, Maxor National Pharmacy Services
      • Expert Tip from RxStrategies
      • Federal Judge Presses Drug Industry on Preemption Arguments During Key Hearing on Louisiana 340B Law
      • Organon Ends or Loosens 340B Contract Pharmacy Restrictions in Four More States
      • Merck Fully Exempts West Virginia Providers From 340B Contract Pharmacy Restrictions
      • Bausch & Lomb Becomes 35th Manufacturer to Impose Contract Pharmacy Restrictions, Policy Applies to All 340B Entities
      • Alkermes Is 36th Drugmaker to Implement Contract Pharmacy Restrictions, Sanofi Tightens Policy
      • Michigan Lawmakers, Witnesses Spar Over 340B Contract Pharmacy Access Bill in Key Hearing
      • Mount Sinai Reports 340B Pharmacy Revenue Losses in Early 2024
      • 340B Reform Could Generate Federal Savings, Says Consulting Firm That Has Conducted 340B Studies for Pharma Friendly Groups
      • Five Manufacturers Announce Refunds to 340B Providers
      • Key House Hearing Intensifies Debate on 340B’s Future Amid Multiple Major Reform Efforts
      • Minnesota Is Seventh State to Enact 340B Contract Pharmacy Law, State Also Expands Covered Entity Reporting
      • New York Unlikely to Move 340B Contract Pharmacy, PBM Protections Bill in 2024, Sponsors Say
      • Novartis Follows PhRMA in Seeking to Block Mississippi 340B Contract Pharmacy Law
      • BMS Requires Re-Designation of 340B Contract Pharmacies and New Requirements Intended to Prevent Alternative Distribution Models
      • Sobi Becomes 34th Drugmaker to Implement Contract Pharmacy Restrictions, Exelixis Tightens Contract Pharmacy Policy
      • Expert Tip from The Alinea Group
      • In Key Hearing, GOP Lawmakers Raise Concerns About 340B Growth and Hospital Use While Democrats Urge Caution
      • Today’s 340B Congressional Hearing Will Include Multiple 340B Critics, Leading Hospital and Health Center Advocates
      • Vertex is First to Offer Contract Pharmacy Policy Exemptions to Several States; GSK Restores Discounts To WV Providers
      • Are You Prepared for an Office of Pharmacy Affairs (OPA) Audit?
      • Two Drug Industry Lawsuits Challenge West Virginia’s 340B Contract Pharmacy Access Law
      • UCB is 26th Drugmaker to Exempt Arkansas Providers from Contract Pharmacy Restrictions
      • Sandoz Adds Drug to 340B Contract Pharmacy Restrictions
      • OPA to Hold June 11 Webinar on Final ADR Rule
      • Column: Momentum Continues in States on Contract Pharmacy Access
    • ► May (62)
      • PhRMA Sues Mississippi Over New 340B Contract Pharmacy Law
      • RWC-340B Slams ASAP 340B Bill as ‘Dangerous to Public Health’
      • ASAP 340B-Backed Bill Would Override State Laws, Could Hurt Contract Pharmacy Agreements, Critics Warn
      • Novartis Asks Federal Court to Block New Maryland 340B Contract Pharmacy Law
      • 340B Critic, Health Center Leader Among Witnesses at Upcoming 340B Hearing
      • Expert Tip from Avita Care Solutions
      • Key House Oversight Subcommittee to Hold Hearing on 340B Next Tuesday
      • Rhode Island Senate Unanimously Passes Amended 340B Contract Pharmacy Protection Bill 
      • SUSTAIN 340B -The Imperative for a Clearinghouse to Strengthen the 340B Program
      • New Hampshire Legislature Clears Bill Barring Certain 340B-PBM Policies
      • Ohio Community Health Center CEOs, Lawmakers Urge Passage of State Contract Pharmacy Protection Bill
      • Congressional Researchers Provide Contract Pharmacy Report on 340B as Legislators Mull Bills
      • Bayer Adds Prostate Cancer Drug to Contract Pharmacy Restrictions
      • No Adverse Findings in First HRSA Drugmaker Audit of 2024
      • ASAP 340B-Backed Bill Introduced in House
      • Appeals Court Contract Pharmacy Restrictions Decision Leaves Unanswered Questions, Ups Pressure for Legislative Action
      • CMS Drops ‘Stacking’ Proposal Which Could Have Boosted 340B Savings
      • Guidance on 340B ESP Use and Management
      • 340B Hospitals Prescribe Part D Drugs to a Much Higher Share of Vulnerable Populations, Says Hospital-Backed Report
      • Teva Adds 40th Drug to Contract Pharmacy Restriction Policy
      • Curtis Frazier, Director, The Alinea Group
      • Appeals Court Approves Drugmakers’ Federal 340B Contract Pharmacy Restrictions But Leaves Open Possibility of Enforcement Against Stricter Policies
      • Minnesota Legislature Clears Contract Pharmacy Access Bill But Enforcement Measures Dropped At Last Moment
      • Ohio Senator Introduces 340B Contract Pharmacy Access Bill in State Legislature
      • PBM is not a 4-letter word: How an independent PBM and an integrated pharmacy strategy provides value for your organization
      • New Super PAC Targets GOP 340B Supporters, Takes Disputed Credit for Key West Virginia Lawmaker’s Primary Loss
      • Novo Nordisk To Provide Refunds on Ozempic and Three Other Drugs to 340B Entities
      • 340B Drugs Reach 18% of Outpatient Drug Sales, Says PhRMA-Backed Research; Providers Say It is Misleading
      • 340B Hospitals Should Consider Internal Pharmacies, Selective Contracting, Says Consulting Group
      • Virginia Governor Vetoes 340B Contract Pharmacy Access Law that Nearly Unanimously Passed State Legislature
      • On Final Day of Session, Missouri House Passes 340B Contract Pharmacy Access Bill, Sends to Governor’s Desk
      • Kansas Governor Rejects Provision to Delay New 340B Contract Pharmacy Protections
      • Maryland Is Sixth State to Enact 340B Contract Pharmacy Access Law
      • CVS Cites 340B Contract Pharmacy Restrictions in 19% Income Drop in Its Pharmacy Services
      • Federal Court Sets April 2025 Trial for AstraZeneca’s Arkansas 340B Law Challenge Amid State Enforcement Actions
      • 340B Sales Increased 17% to $124B in 2023, Drug Industry Consulting Firm Finds 
      • Four States May Act on 340B Contract Pharmacy Access Bills this Week
      • Draft Senate Bill Would Pay Hospitals to Stockpile Certain Generic Drugs if They Forgo 340B Discounts, Meet New Contracting Requirements
      • 2024 Provider Audits Begin with No Adverse Findings
      • Health System Appeal of False Claims Suit Against Drugmakers For Alleged 340B Overcharges Allowed to Move Forward
      • House Committee Clears Telehealth Medicare Extension Bill with PBM 340B Provision
      • Missouri House Committees Advance 340B Contract Pharmacy Access Bill as Legislative Session Nears End
      • Spring Cleaning of Your 340B Program
      • IRA Draft Guidance Leaves 340B Details Unclear
      • U.S. Drug Spending Increased 14 Percent in 2023; Clinic, Hospital Trends Diverge
      • NC Treasurer Report Suggests 340B Hospitals Overcharged State Health Plan, Hospitals Pan the Findings
      • 340B Hospital Groups Ask MedPAC to Oppose Part B Rate Cut
      • 340B Webinar – It’s a Risky Business: Risk Mitigation and 340B Program Compliance
      • Pfizer Exempts Arkansas Hospitals from All Contract Pharmacy Restrictions
      • Delaware Lawmakers Introduce 340B Contract Pharmacy Access, PBM Payment Bill
      • Study Finds Newer 340B Public Hospitals More Likely to Increase Unprofitable Service Lines Than Newer Non-Profit Hospitals
      • Eight More Provider Audits Closed with Corrective Action Plans in Latest HRSA Audit Findings
      • Novo to Extend Contract Pharmacy Restrictions to Grantees But Allow Them to Keep Access Under Conditions; Company Also Modifies Hospital Policy
      • Appeals Court Rejects PhRMA’s Request for a Full Panel Rehearing of Arkansas 340B Contract Pharmacy Case
      • Arkansas Enforcing 340B Contract Pharmacy Access Law Against AstraZeneca
      • Takeda Loosens Contract Pharmacy Restrictions on Arkansas Hospitals
      • Federal Bill Introduced to Expand 340B Eligibility to Outpatient-Focused Rural Emergency Hospitals
      • 340B Program Critics, Supporters Target States 
      • Group Critical of Medicare Negotiation and 340B Program Suggests 340B Providers May Avoid IRA Negotiated Lower-Cost Drugs
      • Troy Polan, Chief Information Officer, Avita Care Solutions
      • Expert Tip from Hudson Headwaters 340B
      • In Victory for Drug Industry, Kansas Legislature Pauses New 340B Contract Pharmacy Law, Sending Issue Back to the Governor
    • ► April (68)
      • Missouri Senate Overwhelmingly Passes 340B Contract Pharmacy Bill; New Kansas Law Expected to Face Setback Today
      • Louisiana AG, Health Centers Defend 340B Contract Pharmacy Law in Response to Drugmaker Suit
      • Instead of Dismissing Medicare Advantage 340B Case, Judge Allows Hospitals to Amend
      • Twenty-One Percent of 340B Hospitals Will Not Receive Lump Sum Payments: Research
      • Cosette Pharmaceuticals Offers 340B Provider Refunds on 38 Drugs
      • Kansas is Fifth State to Enact 340B Contract Pharmacy Access Law
      • Key Senator Says 340B Overhaul Bill Could Be Introduced Next Month, But Some are Skeptical of Short Turnaround
      • Bausch Health Becomes 22nd Drugmaker to End or Loosen 340B Contract Pharmacy Restrictions in Arkansas
      • CBO Recommendation: Restrict 340B Access to Get Hospitals to Join ACOs
      • Small Business Group Whose Messaging Mirrors Drug Industry Takes Aim at 340B in New Video, Social Media Posts
      • Takeda Issues Refunds to 340B Providers for 28 Drugs
      • Expert Tip from Red Chip Enterprises
      • 340B Lobbying Continues Rapid Pace Including by Big Name Firms
      • Former Sen. Pryor Dies, Remembered for Key Role Helping to Enact 340B Law
      • Attorneys Expect Many Filings under Newly Reconstituted 340B Dispute Resolution Process
      • Drug Industry Vendor, Free-Market Legal Non-Profit Echo PhRMA’s Call for Appeals Court to Rehear Arkansas 340B Contract Pharmacy Case
      • Maine Issues Draft Rule for 340B Hospital Reporting Requirements with New Data, Enforcement Provisions
      • Novartis to Refund Covered Entities After Adjusting 340B Ceiling Prices for 100-Plus Products
      • COLUMN: Despite 340B Opponents’ Unprecedented Tactics, Many States Progress on Contract Pharmacy Protection Legislation
      • Providers Generally Supportive, PhRMA Pans Final 340B Dispute Resolution Rule
      • Key Senator Says 340B Overhaul May Clear Congress in End-of-Year Package
      • Virginia Senate Democrats Narrowly Reject Governor’s Amendment to 340B Contract Pharmacy Access Bill; Bill is Back in Youngkin’s Court
      • 340B Contract Pharmacy Access Bill Clears Missouri House but Faces Tougher Path in Senate
      • AbbVie, BI Agree to Lift 340B Contract Pharmacy Restrictions in Arkansas, Making It 21 Manufacturers to End or Loosen Restrictions
      • 340B Contract Pharmacy Protection Bill Introduced in NY Senate; Lawmakers Target Other 340B Matters
      • Merck Adds Biologic to Contract Pharmacy Restrictions
      • CMS Does Not Address Lump Sum Payments for 340B Hospitals in Latest Medicare Advantage Policies But Might in 2025
      • California Initiative Targeting Nation’s Largest HIV Provider Submits Enough Signatures to Qualify for Ballot
      • HRSA Issues Final Regulations Revamping Process to Resolve Disputes Between 340B Providers and Manufacturers
      • Expert Tip from The Craneware Group
      • Virginia Legislature to Act This Week on Governor’s Amendment to 340B Contract Pharmacy Access Bill
      • Mississippi Hospitals, Health Centers Applaud Passage of 340B Contract Pharmacy Access Bill
      • Tennessee Governor Signs Bill Targeting 340B In-Kind Funding
      • Appeals Court Judges Press Both AHF, Apexus When Considering Dismissal Appeal
      • Humana Seeks Dismissal of Medicare Advantage 340B Underpayment Suit by Health System
      • MedPAC Analysis Estimates Medicare Part B Payments to 340B Hospitals are Significantly Higher than Ceiling Prices
      • Mississippi Becomes Fourth State to Enact 340B Contract Pharmacy Access Law
      • Conservative Ad Blitz Urges GOP Opposition to 340B, Praises Virginia Governor’s Drug Industry-Friendly Amendment
      • White House Completes Review of Final Rule for 340B Dispute Process, Release Expected Soon
      • 340B Webinar—340B Legislation: Navigating Changes, Championing a Better Future
      • PhRMA Asks Full Appeals Court to Rehear Arkansas 340B Contract Pharmacy Case
      • AbbVie Replies to Louisiana’s Request for Court to Expedite Decision on Contract Pharmacy Law
      • Survey Finds FQHC Prescribers May Need More Education on 340B Program
      • Brandon Patchett, Senior Director of Pharmacy-Clinical Services, AIDS Healthcare Foundation
      • Expert Tip from Maxor
      • Virginia Governor Amends 340B Contract Pharmacy Access Bill to Delay Enactment, Add Reporting Measures in Move Denounced by Health Centers
      • HRSA Names Britton As New Leader of Office Overseeing 340B Program
      • South Carolina Lawmaker Introduces 340B Contract Pharmacy Access, PBM Reimbursement Bill
      • AstraZeneca’s Lawsuit Against Arkansas’ 340B Contract Pharmacy Law Reassigned to Judge Who Previously Upheld It
      • Oregon Enacts 340B Anti-Discrimination Protections in PBM Regulations
      • Manufacturer Refunds to 340B Providers Have Steadily Increased Since 2019, Says Analysis
      • Teva Adds Blood Therapy Drug to Hospital Contract Pharmacy Restrictions
      • Hospitals Raise Concerns on Biden Drug Shortage Proposal
      • Maryland, Kansas Send 340B Contract Pharmacy Access Bills to Their Governors
      • Mississippi Legislature Sends 340B Contract Pharmacy Protection Bill to The Governor
      • Tennessee Bill Targeting 340B In-Kind Funding Heads to Governor’s Desk
      • Bridging the primary care gap: The role of in-house pharmacies in today’s healthcare marketplace
      • 340B Stakeholders Clash on Patient Definition, 340B Spending Requirements in Comments on Senate ‘Group of Six’ Draft Overhaul
      • Hospitals Say HRSA Violated Federal Rulemaking in 340B Child Site Waiver Reversal
      • Genentech Officially Issues Contract Pharmacy Restrictions
      • AbbVie Adds Cancer Drug to Contract Pharmacy Restriction Policy
      • Contract Pharmacies Have Proliferated, Conservative Group Says, Citing Data from Pharma-Funded Think Tank
      • Sectyr
      • Four More Drugmakers to End 340B Contract Pharmacy Restrictions in Arkansas Following Appeals Court Decision
      • Sumitomo Is Thirty-Second Company to Implement Contract Pharmacy Restrictions
      • Astellas Adds Second Drug to 340B Contract Pharmacy Restrictions
      • Amgen, J&J to Issue Refunds on High-Selling Drugs to 340B Providers
      • Estimated 340B Revenue Exceeded Charity Care Spending for 85% of DSH Hospitals, Says Pharma-backed Group
    • ► March (58)
      • West Virginia Providers Praise Newly Passed State 340B Contract Pharmacy Protection Law
      • Mississippi Senate Committee Approves State House’s 340B Contract Pharmacy, PBM Bill
      • Veronica Brisco: A Leading Voice for Those with HIV and AIDS
      • As Deadline Approaches, First Stakeholders Respond to Senate Group of Six Draft 340B Overhaul
      • Gaps in Hospital Financial Data Limit 340B Transparency, Analysis Says
      • Three 340B Terminations, Seven Paybacks to Manufacturers in Latest Provider Audit Findings
      • Mark Ogunsusi, Associate, Powers Law Firm
      • West Virginia Becomes Third State to Enact 340B Contract Pharmacy Protection Law
      • Kansas State Lawmakers Pass 340B Contract Pharmacy Protections in Separate Budget Bills But Face Resistance from House Speaker and Certain Advocacy Groups
      • As Arkansas Prepares to Enforce 340B Contract Pharmacy Law, Major Drugmaker Files Suit and PhRMA Plans to Seek 8th Circuit Rehearing
      • Leveraging Cash Cards to Amplify Your Patient Impact
      • Influential House GOP Group Calls for Major Medicaid Cuts and 340B Revenue to ‘Go Where Intended’
      • Judge Dismisses Health System’s Penny Pricing Coordination Lawsuit Against Drugmakers
      • CPS
      • Senate, House Appropriators Agree on Budget for Office of Pharmacy Affairs but Have Different Priorities
      • Two More Drugmakers End 340B Contract Pharmacy Restrictions in Arkansas After Appeals Court Decision
      • Key Considerations for the SUSTAIN 340B Act
      • Connecticut, Minnesota Join 20 Other States with 340B Contract Pharmacy Bills Introduced This Session
      • Hawaii Lawmakers Urge State Health Department to Protect 340B
      • California Ballot Initiative Targets Big 340B Provider Serving HIV Population
      • Jaclyn Hahn, Director of Pharmacy, Ravin Consultants
      • Two More Drug Companies Restore 340B Contract Pharmacy Access in Arkansas After Court Decision; Enforcement Action Imminent Against Others
      • Maryland House Unanimously Passes 340B Contract Pharmacy Bill
      • Two Reports Critique Financial Dynamics of 340B Program
      • 340B Hospitals’ Low-Income Prostate Cancer Patients Had Better Adherence
      • Mississippi House Passes 340B Contract Pharmacy Bill, Two Days After Senate Passes Similar Bill
      • Imminent Enforcement of Arkansas 340B Contract Pharmacy Law to Follow Court Decision Upholding It
      • Mississippi Senate Unanimously Passes 340B Contract Pharmacy Bill After Similar Legislation Dies in Florida
      • For Covered Entities, Integrated Care is No Longer an Option
      • 340B Small Share of Drugmaker Revenue, Says Hospital-Backed Report
      • U.C. Berkeley Researcher Proposes 340B Be Limited to the Indigent or that Providers Pass on their Discounts to Insurance Industry
      • HRSA Urges Federal Court to Reject Health Systems’ Challenge to 340B Child Site Registration Policy Reversal
      • Column: Key Takeaways from the SUSTAIN 340B Act and Things to Consider When Weighing In (Part 2)
      • Joel Wright, President of Pharmacy Services, Maxor National Pharmacy Services
      • Expert Tip from Cervey
      • Long-Awaited Federal Bill to Protect Contract Pharmacy Arrangements Introduced
      • In Key Decision That Could Have National Implications, Federal Appellate Court Upholds Arkansas 340B Contract Pharmacy Protection Law
      • Genentech Is Thirty-first Company to Implement Contract Pharmacy Restrictions
      • Biden Budget Request Keeps OPA Funding Flat
      • As Conservative Media Campaign Continues, Hospital Group Demands Removal of Ads Linking 340B to Illegal Immigration
      • New Hampshire 340B PBM Bill Passes Senate
      • Minnesota Lawmakers Introduce More Expansive 340B Provider Reporting Bills
      • West Virginia, Kentucky Legislative Chambers Pass 340B Contract Pharmacy Bills; Hospital Group Demands TV Stations Remove Ad
      • As Virginia Contract Pharmacy Bill Decision Nears, Conservative Media Reports GOP Voter Opposition, Ties 340B to Immigration Growth
      • Rhode Island Is Twentieth State to Introduce 340B Contract Pharmacy Legislation
      • Making the Most of Your 340B Program with a Comprehensive Pharmacy Strategy
      • South Dakota Governor Signs More Expansive 340B PBM Bill Into Law
      • Hospital Groups Slam AbbVie in Legal Battle Over Louisiana’s 340B Contract Pharmacy Law
      • Massachusetts to Bar Managed Medicaid Payments for GLP-1 Drugs for 340B Patients
      • Genentech Offers 10 Years of Refunds on High-Selling Drug, Multi-Year on Another; Merck to Give Single-Quarter Refunds
      • Chris Creamer, Chief Pharmacy Officer, Avita Care Solutions
      • Expert Tip from Apexus
      • CMS Directs Contractors to Provide Accelerated Payments as Part of Change Healthcare Cyber Attack Response
      • Dark Money Group Ominously Warns That 340B Used to ‘Launder Your Money,’ Contributes to Immigration Crisis
      • 340B Contract Pharmacy Bills Advance in Mississippi, Missouri Bill to Get Second Hearing Tomorrow
      • Minnesota Finalizes 340B Provider Reporting Rules, Data Submission to Start April 1
      • Liquidia Becomes 30th Manufacturer to Limit Access to 340B Pricing in Contract Pharmacy Setting
      • Virginia Legislature Passes 340B Contract Pharmacy Bill, Sends to Governor’s Desk
    • ► February (60)
      • 340B Contract Pharmacy Bills Die in Oregon, Utah; Oklahoma Bills Clear Committees in Both Chambers
      • 100 Days and Counting: ADR Final Rule Still Under White House Review
      • Visante Webinar: 340B Current Issues and Policy Update
      • Idaho Becomes Nineteenth State to Introduce a 340B Contract Pharmacy Bill
      • Takeda Adds Drug to 340B Contract Pharmacy Restrictions
      • HRSA Lacks Authority to Reverse 340B Child Site Registration Policy, Hospital Group Tells Court
      • Expert Tip from Sectyr, LLC
      • Amgen Extends Contract Pharmacy Restrictions to Grantees, Receives Early Pushback
      • Cybersecurity Disruption of Major Claims Processor Continues to Affect 340B Providers
      • Part 2 of 2: Understanding the Top Five Challenges Facing Health Center Pharmacies Today
      • New Hampshire Senate to Vote on 340B PBM Bill; Key Massachusetts State Committee Approves 340B Payment Bill
      • No Louisiana Move to ‘Investigate or Enforce’ Its 340B Contract Pharmacy Law, AG Tells Federal Judge
      • Oregon House to Vote Today on 340B Contract Pharmacy Bill
      • DSH Hospitals Are Using 340B in ‘Margin-Motivated Ways,’ Says Research Review
      • Column: Key Takeaways from Senate Group of Six Draft 340B Bill (Part 1)
      • Alex Homkey, Business Development Manager, Hudson Headwaters 340B
      • 340B ESP New Data Request Raises Concerns About Overreach
      • South Dakota Legislature Clears New PBM 340B Bill; Missouri Debates 340B Bills; Kentucky Contract Pharmacy Bill Advances
      • Part 1 of 2: Understanding the Top Five Challenges Facing Health Center Pharmacies Today
      • Soon After Governor Proposes 340B Provider Reporting Legislation, Connecticut Senate Introduces Similar Bill
      • Two 340B Site Terminations, One Payback to Manufacturers in Latest Provider Audit Findings
      • Expert Tip from Ravin Consultants
      • 340B Contract Pharmacy Bills Introduced in Utah, Kansas, New York; Committees Approve Bills in Oregon, Oklahoma
      • Amid Double Digit 2023 Growth in 340B, NACHC Urges Federal Over State Reform
      • Reflecting on Winter Coalition 2024
      • AIDS Group Protests Health Center-Drug Industry Alliance Outside NACHC Policy Forum
      • Health System, Drugmakers Battle Over Dismissal Request in 340B Penny Pricing Fraud Suit
      • FTC, HHS Seek Comments on Role of GPOs, Wholesalers on Generic Drug Shortages
      • PhRMA Washington Post Advertorial Highlights Data Critical of 340B Program
      • Citing U.S. Supreme Court Decision, Health System Sues Medicare Advantage Plan for Past 340B Payments
      • Republican Heavyweights Enter Race to Lead House Committee that Oversees 340B
      • PhRMA Map Highlights State-Specific Extent of Hospitals’ Contract Pharmacy Usage
      • Expert Tip From CPS Solutions
      • Bucshon Calls for 340B Hospital Transparency at NACHC Policy Forum
      • Virginia State Senate Unanimously Passes 340B Contract Pharmacy Protections
      • Connecticut Governor Proposes 340B Provider Reporting Legislation, Faces Pushback from Health Centers
      • Oregon 340B Contract Pharmacy Bill Moves Toward Vote, Illinois Introduces Its Own Bill
      • User Fees in Senate Group of Six Bill Raise Provider Concerns But Unlikely To Scuttle Bill
      • AHA Pans NEJM Study on 340B Price Mark Ups, Lead Author Fires Back
      • 340B Consulting Firm Visante Garners PE Investment, Makes Several Promotions
      • 340B Arises Briefly in Much-Anticipated Senate Hearing on High Prescription Drug Prices
      • Maryland Bills Introduced to Bar 340B Contract Pharmacy Restrictions
      • Hospital Groups Urge Supreme Court to Review DSH Payment Case with 340B Implications
      • Multiple Bills Introduced in Missouri to Protect 340B Providers from Alleged Discriminatory Practices
      • Hospital Groups Key 2024 Priorities Include Contract Pharmacy Protections Among Other 340B Goals
      • Broad Stakeholder Support for Senate Group of Six Draft 340B Overhaul
      • 340B Lobbying Reaches Record Levels in 2023
      • Essential Practices for HRSA Audit Preparedness
      • Federal Judge Rules for Diabetes Drugmakers in 340B Antitrust Case, Health Center Plans Appeal
      • Mississippi Bill Introduced to Bar 340B Contract Pharmacy Restrictions, PBM Underpayments
      • California Hospital Reaches $2.1 Million Settlement Over Alleged 340B Overbilling
      • GSK Posts 340B Refund Notice on High-Revenue Asthma Treatment
      • Highly Anticipated Draft 340B Bill Released by Bipartisan Senate Gang of Six
      • Genesis Ruling Creates Legal, Regulatory Uncertainty for 340B, Says Attorney Panel
      • Two 340B Terminations, One Payback to Manufacturers in Latest Provider Audit Findings
      • Potential Senate Flip May Increase 340B Scrutiny, But Congressional 340B Action Unlikely in 2024, Say 340B Advocate, Drug Industry Analyst
      • Tennessee Bills Introduced to Regulate 340B Funding for Certain STD Clinics
      • AIDS Group Holds Protest Against NACHC-PhRMA Partnership
      • 340B Hospital Critics Ramp Up Efforts on Capitol Hill and in Media
      • Ravin Consultants
    • ► January (49)
      • Senior HRSA Official Doubles Down on Agency’s 340B Patient Definition in Wake of Genesis Ruling
      • Former Sen. Cassidy Aide, Trump Administration Executive Criticizes Requiring More Hospital 340B Reporting
      • Genesis Decision Expected to Increase 340B Scripts, Provider-Owned Pharmacies, Says Contractor to Drug Manufacturers and Former Apexus Staffer
      • Prepping for HRSA Audits
      • Health Systems, HRSA Spar in Federal Court Over 340B Registration Policy Reversal
      • 340B Hospitals Had Largest Markups of High-Cost Infused Drugs: Study
      • GSK, Vertex Offer Refunds to 340B Providers
      • COLUMN: Action on 340B Contract Pharmacies Turns to the States
      • Genesis CEO Praises Court Decision, Blasts HRSA, NACHC, State Primary Care Association
      • Amid Possible Coming Enforcement, PhRMA Again Asks Court to Block Louisiana’s 340B Contract Pharmacy Law
      • Arkansas Looks to Amend Temporary Contract Pharmacy Agreement with Novo Nordisk
      • Arizona State Senators Introduce Latest 340B Contract Pharmacy Bill
      • HIV/AIDS Group Continues Legal Fight with Apexus Over 340B Prime Vendor Contract
      • 340B Provider-Drugmaker Lobbying Group Adds Two More Manufacturers
      • High-Ranking GOP Lawmakers Introduce Bills to Quantify 340B Use Among ‘Noncitizens’
      • 340B Health System’s Suit Against Drugmakers Seeks to Recover ‘Hundreds of Millions in Overpayments'
      • New Medicaid Policy Change Could Reduce 340B Savings, Cause Drug Discontinuations, Warn Stakeholders
      • Iowa 340B Contract Pharmacy Bill Introduced; Companion Bills Debut in West Virginia, Oklahoma
      • $7.8 Billion in Refunds from Underpayments to 340B Hospitals Begin to Roll In
      • Latest Cassidy Probe Adds to Growing Scrutiny of 340B Contract Pharmacies, TPAs
      • AbbVie Pushes to Block Louisiana 340B Contract Law, New State AG Takes Office
      • Senator Cassidy Expands 340B Inquiry to Two Major Contract Pharmacies
      • Two More States Introduce 340B Contract Pharmacy Protection Bills
      • Drug Makers Issue Record Number of 340B Refunds in 2023, Merck First to Refund in 2024
      • Unlocking the Value of 340B Consultants: Their Roles and Responsibilities
      • Takeda to Expand 340B Contract Pharmacy Restrictions
      • HRSA Announces 340B Webinar for Grantees Before Upcoming Recertification Begins
      • Rhode Island Bills Introduced to Bar PBM and Medicaid 340B Underpayments
      • Three More States Introduce 340B Contract Pharmacy Protection Bills
      • First 340B Provider Reporting Bill of the Year Introduced in Indiana
      • 340B Webinar—State of 340B in 2024: Biggest Developments Expected this Year
      • AHA Warns of ‘Adverse Impact’ from Lack of 340B Provisions in New MA Rule
      • Expert Tip from Visante
      • Key GOP House Member Active on 340B Matters to Retire
      • Nebraska Bill Introduced to Protect 340B Contract Pharmacy Arrangements
      • Visante's Top 10 Issues Facing Health System Pharmacy for 2024
      • Health System Pays $7.25 Million in Settlement of 340B-Involved Kickback Allegations, without Liability Findings
      • 2024 340B Contract Pharmacy Outlook: Expect More State Than Federal Action, Say Attorneys and Lobbyists
      • Novo Says Arkansas Agreement ‘Preserves It’s Position’; More Manufacturer Deals in the Works
      • Federal Government Passes on Appealing Key Patient Definition Ruling
      • Two 340B Terminations, Two Paybacks to Manufacturers in Latest Provider Audit Findings
      • 2024 Congressional 340B Outlook: Overhaul Unlikely Without Major Legal Developments, Senate Deal
      • Top 10 Most Read 340B Report Articles in 2023
      • Expert Tip from RxStrategies
      • Novo Nordisk, Arkansas Reach Temporary Deal Amid Contract Pharmacy Fight
      • Gilead Expands 340B Reporting to Wholly Owned Contract Pharmacies
      • Hospital Groups Urge Federal Court to Dismiss Drug Industry Suit Against Louisiana Law
      • J&J Offers Refunds on Blockbuster Drug, Other Manufacturers Update NDCs
      • 2023 Contract Pharmacy Developments: Surging Restrictions, State Law Legal Battles
  • ►2023 (582)
    • ► December (34)
      • Louisiana, Health Centers Seek Dismissal of Contract Pharmacy Law Challenge
      • Critics of 340B Urge Congressional Reforms of the Program
      • Exploring Key Aspects of the 340B Program
      • A Tribute to Our Founding Editor in Chief from the Publisher and CEO
      • Column: Hospitals Are Not the Only 340B Providers Under Scrutiny
      • Lilly to Conduct HRSA-Approved Audit That Includes First-Time Look for Medicaid MCO Duplicate Discounts
      • CMS Defers Decision on Adding 340B Modifiers for Part D Drugs
      • Implementing for Success
      • DeGette Seen as Possible Successor to Eshoo as Top Dem on House E&C Health Subcommittee
      • Takeda Becomes 29th Drugmaker to Implement 340B Contract Pharmacy Restrictions
      • HRSA Unveils Web Page with Patient Definition Compliance Resources, Guidance
      • 340B Dispute Resolution Coming This Month, White House Says
      • Minnesota Issues Draft Guidance Implementing 340B Provider Reporting Requirements
      • Michigan to Increase Medicaid Payment for 340B Hospitals, Adds Reporting Requirements
      • Novo Nordisk to Provide 340B Refunds on Hemophilia Drugs
      • House Passes Healthcare Bill with 340B Provider Reporting Requirements
      • Legislation ‘Is Coming’ to Address Contract Pharmacy Restrictions, Hospital Advocate Says
      • Missouri State Senator to Reintroduce 340B Contract Pharmacy, PBM Protection Bill
      • Wisconsin Assembly Bill Introduced to Bar PBM Practices Against 340B Providers
      • Drugmakers Highlight 340B Developments in Earnings Calls
      • Federal 340B Leader Moves On After 21 Months
      • House Committee Approves PBM Transparency Bill with 340B Provision
      • Unlocking Greater 340B Savings
      • Amid Record Drugmaker Refunds, No Adverse Audit Findings for Teva
      • Two Senior GOP Senators Suggest 340B Linked to Generic Drug Shortages
      • New Part B Drug Claims Modifier Requirement for 340B Entities Starts Jan. 1
      • Cheryl Hetland, VP of 340B Program Management, Avita Care Solutions
      • Expert Tip From 340Best
      • Four 340B Terminations, Eight Paybacks to Manufacturers in Latest Provider Audit Findings
      • Biogen Adds Drug with Narrow Approval to 340B Contract Pharmacy Restrictions
      • 340B Outlook from Capitol Hill, Federal Courts, and the States
      • Arkansas, Novo Nordisk Clash Over Court’s Role in Contract Pharmacy Law Enforcement
      • Wisconsin State Senators Introduce PBM 340B Underpayment Bill
      • 340B Reforms Needed, Says Former Presidential Candidate, Drug Industry Consultant
    • ► November (51)
      • ‘Relentless’ 340B Policy Leader Among Coming Congressional Retirements
      • Senate Drug Shortage Hearing to Include 340B-Researcher Witnesses
      • Unlocking the TRUE POTENTIAL of 340B
      • N.Y. State, Health Centers Seek Brief Pause in Medicaid Drug Benefit Lawsuit
      • Column: Why the Genesis 340B Patient Definition Court Decision Could Resolve the Contract Pharmacy Impasse
      • Expert Tip from Apexus
      • Massachusetts Senate Passes 340B Contract Pharmacy Protections for Certain 340B Grantees, Hospitals
      • 340B Provides Benefits, Needs Reform, Says Literature Review
      • 340B’s Footprint in Medicare Part D Is Growing, Study Says
      • Sen. Cassidy Mum on Next Steps for 340B Provider Probes
      • Senate Democrats Seek Drug Pricing Testimony from Three Pharma CEOs
      • Two Drugmakers Offer Refunds for 340B Overcharges
      • Michigan Bill Introduced to Protect 340B Contract Pharmacy Arrangements
      • 340B Reforms Urged by Centrist Democrat Group with Drugmaker Ties
      • Apexus Asks Appeals Court to Affirm Dismissal of Contract Breach Lawsuit
      • Jazz Pharmaceuticals Posts Refund Notice on HRSA Website
      • Harrison Garrett, Director of 340B Solutions, Cervey
      • Expert Tip from Sectyr, LLC
      • Influential Senator Extends 340B Inquiry to Community Health Centers
      • Lilly to Exempt Arkansas Providers from New Tighter 340B Contract Pharmacy Restrictions
      • Court Sets November 2024 Trial for Novo Nordisk’s Arkansas 340B Lawsuit
      • 3 Things Hospitals and Grantees Need to Know about the Genesis Decision
      • Hospitals to Meet with White House, HHS About 340B Dispute Resolution Process
      • Improved Non-Profit Hospital Outlook Helped by 340B Payout: Moody’s
      • Louisiana Provider Group to Intervene in Second 340B Contract Pharmacy Lawsuit
      • Hospitals Continue Lobbying Push to Extend Pandemic-Era 340B Eligibility Waiver
      • Novo Nordisk’s 340B Arkansas Lawsuit Reassigned to Judge Who Previously Ruled Against Drugmakers
      • Louisiana Provider Group to Intervene in 340B Contract Pharmacy Lawsuit
      • 340B Hospitals Charge Higher Commercial Insurance Prices, Says PhRMA Funded Report
      • Senate Committee Doubles Down on PBM Bill with 340B Spread Pricing Language
      • Indiana Health Care Leaders Call for 340B Transparency in Op-Ed
      • GlaxoSmithKline Posts Refund Notice on HRSA Website
      • Expert Tip from The Craneware Group
      • Genesis Ruling Could Expand 340B-Eligible Prescriptions, Say Some Attorneys
      • Hospitals Urge CMS to Reconsider Future Cuts in 340B Lump Sum Final Rule
      • Lilly Reinstates Tighter 340B Contract Pharmacy Restrictions
      • HRSA, Hospital Settle Lawsuit Over Termination from 340B
      • Senate Finance Committee Republicans Oppose CMS Plan to Redefine Medicaid Best Price
      • Drug Industry Pushes Federal Court to Block Louisiana’s 340B Contract Pharmacy Law Without Trial
      • Arkansas Urges Federal Court to Reject Novo Nordisk’s Challenge to 340B Contract Pharmacy Law
      • Federal Judge Rebukes HRSA on 340B Patient Definition
      • Medicare to Continue ASP Plus 6% for 340B Drugs in 2024
      • CMS Finalizes 340B Lump Sum Payment, Retains Offsetting Cuts Starting in 2026
      • Health Systems Sue to Reverse Elimination of Hospital Registration Waiver
      • Sixth Drugmaker Loosens 340B Contract Pharmacy Restrictions in Arkansas and Louisiana
      • Upcoming DIR Fee Changes and Their Potential Impact on 340B Programs
      • 340B Lobbying Still on Track for Record Year
      • New York State Asks Court to Dismiss Challenge to Medicaid Drug Benefit Shift
      • 340B Program May Lead to Lower Charity Care, Says Drug Industry-Backed AIDS Group
      • Expert Tip from RxStrategies
      • Sandoz Is 28th Drugmaker to Adopt 340B Contract Pharmacy Restrictions
    • ► October (57)
      • GSK Loosens 340B Contract Pharmacy Restrictions in Arkansas and Louisiana
      • 340B Hospital Registration Waiver Withdrawal Could Draw Legal Challenge
      • Arkansas Defends Enforcement of 340B Contract Pharmacy Law in Drugmaker Suit
      • 340B…or not to B…?
      • 340B Hospitals’ Community Benefit Surges in 2020, Says Hospital-Backed Report
      • HRSA To End Waiver for Some Offsite 340B Hospital Locations, Provides Grace Period
      • 340B Provider-Genentech Lobbying Group Boosts Spending, Adds Members
      • 4 Ways Hospital Pharmacies Can Unlock Financial Stability
      • New House Speaker’s 340B Stance Unclear But Supported 340B Hospitals in 2017 Bill
      • GSK Adds Drug to Contract Pharmacy Restriction List
      • Louisiana AG Election to Name Enforcer, Defender of 340B Contract Pharmacy Law
      • Biocon Announces New NDC for its Lantus Biosimilar
      • Column: Look to The Senate for 340B Action
      • Expert Tip from Cervey
      • Genentech Asks Hospitals to Check 340B Split-Billing Software Settings
      • CMS Seeks Input on Contractor to Prevent 340B, Medicare Maximum Price Duplication
      • 5 Best Practices for Running and Optimizing a Mixed-Use Program
      • Teva Adds Drug to Hospital Contract Pharmacy Restriction Policy
      • Congressional Witnesses Urge Medicare 340B Cuts
      • 340B Dispute Resolution Final Rule Enters Last Stage of Regulatory Review
      • Five More Providers Owe Drugmakers 340B Repayment: Audits
      • Rural Providers Urge Congress to Extend Pandemic-Era 340B Eligibility Exemptions
      • 10 Questions to Ask Your 340B TPA about Your Contract and Fees
      • Most 340B DSH Hospitals Provide Below-Average Charity Care, Says Analysis Backed by Critics
      • Paper Warns on Duplicate Discounts from 340B Ceiling Price, Medicare Maximum Price
      • Expert Tip From Visante
      • Eisai’s New 340B Contract Pharmacy Restrictions to Exclude Arkansas and Louisiana
      • New BMS Contract Pharmacy Policy May Target Hospital Self-Distribution, Say Attorneys
      • The 340B Program's Current State of Play
      • Following Response Deadline, Next Steps in Senator’s 340B Probe Unclear
      • CMS Says 340B Lump Sum Payments Fueled Increase in Part B Premiums, Deductibles
      • In Study, Health Center’s Patients Laud its 340B Drug Assistance Program
      • Novo Nordisk Files Suit to Block $100,000 Arkansas Fine for 340B Contract Pharmacy Violations
      • HHS and HRSA Urge Judge to Reject Health Center’s Take on 340B Patient Definition
      • Leading Senator, Provider Groups Publish Dueling Reports on Nonprofit Hospitals
      • HRSA Audit Finds Fourth Drugmaker Owes Refunds
      • Expert Tip From Verity Solutions
      • Astellas Ends 340B Contract Pharmacy Restrictions in Arkansas and Louisiana
      • Hospital Fighting 340B Expulsion Gets Temporary Reprieve
      • Hospital Advocates Meet with Regulators on Lump Sum Rule
      • Drugmaker Overcharge Fines for 340B Drugs Reach Nearly $7,000
      • Rural Organizations, New Congressional Caucus Push 340B Provider Protections
      • Two Drugmakers Post Refund Notices on HRSA Website
      • BMS Expands 340B Contract Pharmacy Conditions, Including for Grantees
      • Hospital Sues to Stop 340B Expulsion Over Alleged Failure to Recertify
      • Novartis Offering 340B Refunds on Two Diagnostic Radiopharmaceuticals
      • Understanding the Impact of the Inflation Reduction Act
      • Speaker Vacancy Paralyzes House, Stalls 340B Legislation
      • Major Drugmakers Agree to Negotiate Drug Prices with Medicare
      • Kim Barron, Vice President of Operations, Hudson Headwaters 340B
      • Expert Tip From AllianceRx Walgreens Pharmacy
      • Eisai Adopts 340B Contract Pharmacy Restrictions, Pfizer and GSK Update Their Limits
      • AbbVie Joins Legal Battle Over Louisiana’s 340B Contract Pharmacy Law
      • Hospitals Defend 340B Compliance Amid Influential Senator’s Investigation
      • As Medicare Lump Sum Payment Regulation Heads to Finish Line, Critics Weigh In
      • In Key 340B Patient Definition Case, Hospital Group Accuses Drugmakers of “Numerous Misstatements”
      • Government Averts Shutdown with 11th Hour Temporary Funding Bill, Speaker McCarthy Faces Historic Challenge
    • ► September (60)
      • Ranking GOP Senator on Key Committee Opens Investigation into 340B Hospital Revenue
      • Looming Government Shutdown Poses 340B Program Uncertainty, Potential Legal Proceeding Slowdown
      • As Shutdown Looms, Momentum Slows on Bills with Key 340B Changes
      • 3 Ways to Maximize 340B Program Savings
      • Lilly and Novo Post 340B Refund Notices, Amgen Posts 340B Replenishment Notice
      • 340B Health, Researchers Spar over Biosimilar Study
      • Transparency, Patient Assistance Requirements Needed in 340B, Say Drugmaker-Backed Groups
      • Column: Could the States Resolve the Contract Pharmacy Impasse?
      • Kirsty Gutierrez, Director of Client Success, Ravin Consultants
      • Expert Tip From CPS
      • 340B Drug Purchases Reached $53.7 Billion in 2022, HRSA Data Show
      • Hospital 340B Sites increased by 400% Over 11 Years, Analysis Finds
      • Providers Try a Range of Responses to Manufacturer 340B Contract Pharmacy Restrictions
      • Expanding 340B Eligibility Could Double Program Size, Says Report
      • Senate Committee Rejects 340B Amendment to Bipartisan Health Bill
      • Federal Appeals Court Judges Press Both Sides in Key Hearing on Arkansas 340B Contract Pharmacy Law
      • Teva Ends 340B Contract Pharmacy Restrictions in Arkansas in Response to State Law
      • Rural Reality: A Conversation with a Rural Hospital Finance Director about Adapting to 340B Challenges
      • Incyte Becomes 26th Drugmaker to Place Contract Pharmacy Restrictions
      • One Quarter of HRSA Provider Audits Closed with No Adverse Findings
      • GOP Scrutinizes Medicare Price Negotiations in House Subcommittee Hearing
      • Jason Reddish, Principal, Powers Law Firm
      • Providers Split on 340B Medicaid Provisions in Major House Healthcare Package
      • AHF Files Appeal Over Its Claim That Apexus Did Not Obtain Sub-Ceiling Discounts
      • Health Center Challenging 340B Patient Definition Responds to HRSA’s and Drug Companies’ Court Arguments
      • Uncertain Outlook for GOP Drug Shortages Bill with 340B Provisions
      • Novo Nordisk Providing 340B Refunds on Blockbuster Drug Ozempic
      • AHIP Objects to Hospital Efforts to Target Medicare Advantage 340B ‘Windfall’
      • House Subcommittee Clashes Over 340B Role in Drug Shortages
      • Louisiana AG Defends State 340B Contract Pharmacy Law Against Drug Industry Lawsuit
      • 340B Health Centers Appeal Loss in California Medicaid Lawsuit
      • Provider POV: 340B is Critical. We Must Raise Our Voices.
      • 340B Driving Anti-Competitive Health System Tactics, Says Lawsuit
      • Two More Drugmakers Owe 340B Provider Repayments, HRSA Audits Find
      • HRSA Grants 340B Enrollment Flexibility in Georgia Due to Hurricane
      • Expert Tip From Apexus Advanced 340B Operations Certificate Program
      • Jazz Pharmaceuticals Is 25th Drugmaker to Implement Contract Pharmacy Restrictions
      • Sanofi Withdraws Some Health Centers’ 340B Pricing at Contract Pharmacies
      • How to End the HIV Epidemic in One Word:  Retention
      • House Subcommittee to Examine GOP Drug Shortages Bill with 340B Provisions
      • California Legislature Passes 27th State Restriction on PBM 340B Discrimination
      • Arkansas Can Enforce 340B Contract Pharmacy Law, State Attorney Tells Appeals Court
      • Merck Offering Refunds to 340B Covered Entities
      • Steve Kuperberg, Partner, Feldesman Leifer LLP
      • Coming Major GOP Healthcare Package Includes 340B Medicaid Provisions
      • Sources Cited in Drugmakers’ Brief Question Accuracy in High-Profile 340B Patient Definition Case
      • Connect and Learn at the 340B Grantees Fall Conference 
      • Appeals Court Decision May Threaten Some State Health Plan Regulations, 340B Protections
      • Janssen Issuing Refunds for 340B Overcharges
      • HRSA Allows Immediate 340B Enrollment in Florida Due to Hurricane
      • Heather Erickson, 340B Consultant, CPS Solutions
      • Expert Tip From Maxor
      • As CMS Extends Comment Period on 340B Repayments, Hospitals Urge Changes
      • Provider Groups Oppose 340B Provisions in Committee Chair’s Drug Shortage Bill
      • Strengthening 340B Program Integrity to Improve Accountability and Confidence
      • PhRMA to Federal Appeals Court: Arkansas Enforcing 340B Contract Pharmacy Law; Seventh Drugmaker Sues Over IRA
      • Tolmar Providing Refunds for Five Years of 340B Overcharges
      • Five Value Pillars for 340B Program Compliance
      • UCB Tightens 340B Contract Pharmacy Restrictions for Hospitals
      • EMD Serono Extends Hospital 340B Contract Pharmacy Conditions to All Products
    • ► August (52)
      • Arkansas Initiates First-in-the-Nation Enforcement of 340B Contract Pharmacy Law
      • Little Chance Congress Clears 340B Overhaul in 2023—Unless Courts Act, Say Lobbyists
      • “ChatGPT, I Need 340B Help”
      • HRSA Again Selects Bizzell Group to Audit 340B Covered Entities
      • Boehringer Ingelheim Sues to Block Medicare Price Negotiations
      • Expert Tip From Hudson Headwaters 340B
      • Health Centers Fear Losing 340B Pricing From Sanofi at Multiple Contract Pharmacies
      • Lawmaker Sponsoring 340B Transparency Bill Honored by PhRMA-Provider Group
      • Covered Entities and the 340B Program: Avoid Common Pitfalls of the Medicaid Exclusion File
      • Federal Judge Accepts Drug Company Filings in 340B Patient Definition Case
      • HHS Announces First 10 Drugs Eligible for Medicare Price Negotiations
      • AstraZeneca Sues to Block Medicare Price Negotiations Over ‘Unintended Consequences’ to Orphan Drug Development
      • Health Center Leaders Urge Boards to Push State, Federal Support of 340B
      • Liz Trenkel, Senior Compliance Specialist, RPh Innovations
      • Health Center Asks Court to Reject Drug Maker Briefs in Challenge to 340B Patient Definition
      • AHA Urges Dropping Bill Language to Exclude Generic Injectables from 340B
      • Provider-PhRMA Coalition Adds Civil Rights Group
      • From the Publisher & CEO: The Big Question on the Minds of Every 340B Stakeholder
      • Federal Appeals Court Schedules Arguments in Challenge to Arkansas Contract Pharmacy Law
      • Drug Maker Owes 340B Providers Repayment, HRSA Pending Audit Finds
      • 340B Drugs Among Those at Tornado-Hit Facility Requiring Direct Purchase
      • Three Terminations, 10 Paybacks to Manufacturers in HRSA’s 2023 Pending Provider Audits
      • Share of Retail Pharmacies that Contract with ‘Core’ 340B Safety-Net Facilities Fell Over Time, Study Finds
      • HHS Asks Court to Deny Injunction Against Medicare Drug Price Negotiations
      • Pfizer Changes Costly Cardiac Drugs’ Access Rules for 340B Providers
      • Two Drug Makers Post Manufacturer Notices for 340B Overcharges
      • HRSA Allows Immediate 340B Enrollment in Hawaii Due to Wildfires
      • 340B Lobbying Activity Experiences Historic Surge
      • Major Drug Company Sues Louisiana Over 340B Contract Pharmacy Law
      • 340B Program Does Not Improve Hospital Inpatient Care for Medically Underserved Patients, HHS-Funded Study Finds
      • GSK Giving 340B Entities Refunds Again for Asthma Medicine Purchases
      • Enforceability of State Contract Pharmacy Laws Uncertain Amid Legal Challenges
      • AHA Warns of “Legal Consequences” from Proposed Cuts to Fund 340B Lump Sum Payments
      • Let For-Profit Hospitals Into 340B, Trade Association Tells Senators
      • Five Major Drug Makers Oppose Health Center’s Legal Challenge to 340B Patient Definition
      • Medicare DSH Changes Will Cut 340B Access, Draw Legal Challenge, Say Attorneys
      • Making the Case for Your 340B Program
      • Government Watchdog Reissues Controversial Finding on Adverse Incentives in 340B Program
      • Hospitals Charge Average 500% of Top 20 Drug Costs, Says PhRMA-Funded Analysis
      • Merck Loosens 340B Contract Pharmacy Restrictions in Two States as Louisiana Law Takes Effect
      • Senate Appropriators Urge HRSA to Penalize Drug Makers That Impose 340B Contract Pharmacy Conditions
      • Look to Specialty Pharmacy to Address 340B Challenges
      • Bipartisan AG Group Urges Senate to Protect 340B Contract Pharmacy Agreements, Require Provider Transparency
      • On Deadline Day for Senate Feedback, Researchers in JAMA Urge 340B Provider Reporting, Tightening Eligibility, Preventing Drug Overcharges
      • Lee Harris, Principal, Sales and Strategic Relations, SunRx
      • Louisiana’s New 340B Contract Pharmacy Law Goes Into Effect Today; PhRMA Sues and Teva Suspends its Restrictions in the State
      • Claims Clearinghouse, Strengthening HRSA Among Few Consensus Areas in Responses to Senate 340B Overhaul Effort
      • House E&C GOP Leaders' Draft Bill Would Exempt Sterile Generic Injectables from 340B Pricing Requirements
      • HRSA Tells Federal Court it Still Stands by its 340B Patient Definition in Closely Watched Case
      • Do 340B Lump Sum Payments Underscore Need for More Transparency or Are They Unrelated?
      • Amid Historic Financial Challenges, 340B Proposed Payments Will ‘Make a Difference’ for Some Hospitals’ Budgets, Says Rating Official
      • Broad Support Emerges for Adding Duplicate Discount Modifiers to Medicaid Cards
    • ► July (48)
      • Senate Panel Passes PBM Reform Bill With Medicaid Drug Payment Limits and 340B Reporting Requirements
      • 100+ Health Centers and Groups Sign Pro-340C Letter to Congress
      • Covered Entities' and Manufacturers' 340B Summit
      • HRSA Sends Previously Audited 340B Hospital a Second Follow-up Compliance Letter
      • CMS’s 340B Hospital Repayment Plan Leaves Medicare Advantage Cuts Untouched
      • 340B Recertification for Hospitals Starts Aug. 14
      • Amgen, Vertex, and AstraZeneca Post 340B Refund and Replenishment Public Notices
      • 340B Report Publisher and CEO to Providers: New 340B Reporting Requirements are Inevitable
      • Tracy Jones, Midwest Regional Director & National Director of Advocacy, AIDS Healthcare Foundation
      • Large Drug Maker, Big Health System, and Influential Health Center Jointly Lobbying for Senate Bipartisan 340B Initiative
      • Senate Panel Seems to Be on Track To Vote Tomorrow on Bill With Language that 340B Providers Oppose
      • RWC-340B Backs Senate Bill That Would Let Ryan White Clinics Cover HIV Prevention Drugs and Services
      • NACHC Names Prominent Physician with Health Center and HRSA Experience as its Leader
      • 340B May Cause Providers to Buy More Expensive HIV Prevention Drugs, Conservative Policy Group Says
      • Generic Drugmaker Amring Providing Refunds for 340B Overcharges
      • NY FQHCs Receive $135 Million to Offset State’s 340B Medicaid Shift, While Other Providers Wait
      • Johnson & Johnson, Astellas Each Sue to Stop Medicare Drug Price Negotiations
      • Expert Tip From Sectyr
      • Senate Panel Could Mark Up PBM Bill Next Week With Spread Pricing Language That 340B Providers Oppose
      • U.S. House Energy & Commerce Committee Drafting Drug Shortages Bill
      • Judge Rejects 340B Provider Challenge to California Medicaid Drug Payment Shift
      • Commentary in NEJM Backs Making Hospitals Report Gross Profits from 340B
      • 340B Is “Off the Rails,” Civil Rights Leader Chavis Says in Nationally Syndicated Op-Ed
      • Medicare Part B Keeping Default Pay Rate for 340B Drugs, Says OPPS Proposed Rule
      • U.S. Chamber of Commerce Asks Court to Pause Medicare Drug Price Negotiations
      • In What Could be a First, Drug Maker Gives Providers Deadline to Request 340B Overcharge Refunds
      • UPDATED: Contract Pharmacy Restrictions Cut $1.5 Billion in 340B Hospital Revenue, $8.4 Billion More Endangered, Report Says
      • Some 340B Hospitals Might Get Less Than Expected Under Fix for Illegal Medicare Drug Payment Cuts
      • Providers March to Capitol Hill for Second Straight Year to ‘Defend 340B’
      • Tiffany Taylor, Director of Compliance, Allies in Hope, Inc. and 2023 Scholarship Recipient for the Apexus Advanced 340B Operations Certificate Program
      • Adverse Appellate Rulings in Contract Pharmacy Cases Could Be “Truly Catastrophic,” 340B Health’s Testoni Says
      • Providers Celebrate 340B Medicare Drug Payment Fix, Object to How It’s Funded
      • Ease 340B Requirements for Generic Drugs to Ease Shortages, Trade Group Tells Congressional Committee Chairs
      • As Congress Weighs 340B Changes, Leading HIV/AIDS Group Urges it to Support the Program
      • Matthew Krah, Senior Solutions Engagement Director, Verity Solutions
      • CMS Proposes $9 Billion in Lump Sum Payments to Reimburse Hospitals for Past 340B Part B Drug Payment Cuts
      • White House Clears CMS to Issue Proposed Fix for 340B Hospital Part B Drug Payment Cuts
      • Studies Reach Different Conclusions About Whether Vulnerable Patients Benefit from 340B Savings
      • Is Your Technology a Triple Threat That Boosts Your Mission?
      • 340B Prime Vendor Apexus and AIDS Healthcare Foundation Are Trying to Settle Lawsuit Over Sub-Ceiling Price Discounts
      • 340B Issues Remain Unresolved in Latest CMS Medicare Drug Price Negotiation Guidance
      • Christopher Cooper, Health Systems Solutions Director, AllianceRx Walgreens Pharmacy
      • Top Republican on Senate HELP Committee Calls for 340B Transparency and Accountability Action
      • Group Seeking New 340C Program for Grantees and Rural Hospitals Is Ramping Up Advocacy
      • Tips for Specialty Pharmacy Success
      • NRHA Launches New 340B Policy and Advocacy Campaign
      • 340B Report Bolsters Editorial Staff with Two Key Hires
      • UPDATED: Astellas and AstraZeneca Make 340B Contract Pharmacy Moves
    • ► June (53)
      • U.S. Rep. Matsui Expected to File 340B Contract Pharmacy Bill in Connection with 340B Conference
      • Maine Enacts Nation’s Second 340B Provider Transparency Law
      • 340B Outlook from Capitol Hill and the States
      • ASAP 340B, PhRMA and NACHC’s 340B Alliance, Challenges Hospitals to “Join the Conversation”
      • Sandy Brower, Director, Quality/Risk Management and 340B Program Coordinator for Bonner General Hospital and 2023 Scholarship Recipient for the Apexus Advanced 340B Operations Certificate Program
      • Get PBMs to Squeeze 340B Drugs Harder, “Playbook” Advises Employers
      • Hospital Groups to CMS: Don’t Rob Some Hospitals to Repay 340B Hospitals for Your Illegal Drug Payment Cuts
      • Hospitals Spend More on Cancer Drugs for Insured Patients After Enrolling in 340B, JAMA Study Finds
      • California Senate Passes PBM 340B Nondiscrimination Bill
      • 340B Report Publisher and CEO: What Two State Legislative Sessions Tell Us About the State of 340B Policy
      • Boehringer Ingelheim Extends 340B Contract Pharmacy Conditions to All Covered Entities
      • Health Center Invokes 340B Contract Pharmacy Ruling in Key 340B Patient Definition Federal Lawsuit
      • Minnesota Imposes Nation’s First 340B Covered Entity Reporting Requirements
      • State Roundup: Lots of 340B Action as Many Legislatures Conclude Sessions
      • PhRMA and Bristol Myers Squibb Sue Separately To Stop Medicare Drug Price Negotiation
      • Expert Tip From Cloudmed
      • U.S. Senate “Group of Six” Elaborates on Why it Wants 340B Stakeholder Input
      • RWC-340B Slams Gilead-funded Study of 340B Grantee Entities
      • AHA Urges HRSA to Restore Policy Allowing Earlier Use of 340B Drugs in Hospital Outpatient Clinics
      • MedPAC Still Backs Cutting 340B Hospitals’ Part B Drug Payments
      • 340B Registration for Third Quarter of 2023 Will Run from July 1 to July 17
      • Six Democratic and Republican U.S. Senators Ask 340B Stakeholders for “Bipartisan Policy Solutions”
      • Congressional Republicans Want to Know if 340B Plays a Role in Drug Shortages
      • JAMA Study Says, When it Comes to Insulin, Pharma’s Gross-to-Net Problem Is Mostly its Own Doing
      • Maintaining the Patient Experience and Continuity of Care 
      • First Merck, Now Chamber of Commerce Sues to Stop Medicare Drug Price Negotiation
      • Tanya Dudley, Senior Product Manager for Sentrex contract pharmacy management application, The Craneware Group
      • Expert Tip From Signify
      • Nonprofit Hospitals’ Profits Are Up But Charity Care Is Not, Study Finds
      • Federal Court Hearing Next Week on California’s Medicaid Drug Benefit Transfer; Bill Introduced in N.J. with 340B Implications
      • Nevada Legislature Passes 340B Nondiscrimination Bill
      • Bausch Health Tightens its Conditions on 340B Pricing to All Covered Entities
      • Exelixis Extends 340B Price Conditions to Hospitals’ Wholly Owned Contract Pharmacies
      • Teva Is the 23rd Drug Maker to Impose Limits on 340B Contract Pharmacies
      • Final Connecticut Bill Excludes Both 340B Transparency and Contract Pharmacy Provisions
      • Protest Held at Indiana Congressman’s State Office Against His 340B Hospital Reporting Bill
      • New Studies on 340B and Rural Cancer Care and 340B Contract Pharmacy Demographics
      • Merck Sues to Stop Medicare Drug Price Negotiation
      • CMS Creates New Group to Lead Medicaid Managed Care Policy
      • Expert Tip From Verity Solutions
      • Connecticut Looks Like It Will Be First State to Require 340B Covered Entity Reporting
      • Louisiana Is Poised to be Second State to Enact 340B Contract Pharmacy Law
      • New York State Appeals Dismissal of 340B Antitrust Case Against CVS
      • HHS, HRSA Tell Judge They Don’t Know When They’ll Replace 340B Dispute Resolution Process
      • HRSA Posts Four Manufacturer Notices to 340B Entities
      • HRSA Allows Immediate 340B Enrollment in Guam Due to Typhoon
      • ASAP 340B and AHA Outreach Documents Are Polar Opposites on 340B DSH Hospitals
      • Merck to Pay Refunds for 340B Overcharges in Q1 and Q2 2020
      • The Potential Domino Effect of Tennessee's HIV Federal Funding Cuts
      • Massachusetts 340B Nondiscrimination Bills Would Restore Program’s Intent, Sponsor Says
      • Expert Tip From SunRx
      • Organon Is the 22nd Drug Maker to Impose Limits on 340B Contract Pharmacy
      • Novo Nordisk Tightens its 340B Contract Pharmacy Policy Today, Others Possible
    • ► May (49)
      • CMS Is a Step Closer to Saying How It Will Fix Medicare Drug Payment Cuts for 340B Hospitals
      • CMS Proposes Rules That Addresses 340B Duplicate Discounts in Medicaid Managed Care
      • How 340B Covered Entities are Disrupting the PBM and Preferred Pharmacy Landscape for Community Health Plans
      • 340B Providers Don’t Systematically Over-Prescribe Brand Drugs for Profit, JAMA Study Says
      • Arkansas 340B Contract Pharmacy Law Trespasses on Federal “Closed System,” PhRMA Tells Court
      • 340B Report Publisher and CEO: Is a Contract Pharmacy Breakthrough at Hand?
      • House GOP Rejects Democrats’ Push to Link 340B Transparency and Contract Pharmacy
      • 340B Grantees Need More Scrutiny as Drug Margins Rise, Gilead-funded Study Says
      • 3 Tips for Navigating the Current 340B Environment
      • 340B Advocacy Group CV340B Plans March on Capitol Hill July 12
      • Maria Kossilos, Associate Chief Pharmacy Officer, Cambridge Health Alliance
      • House E&C Committee Passes Two Bills That Would Create 340B Entity Reporting Requirements
      • House E&C Committee to Vote Tomorrow on Bills That Would Bring Big Changes to 340B
      • Health Centers’ Antitrust Case Over 340B Contract Pharmacy Limits Will be Argued July 20
      • Providers Added Immediately to 340B Under COVID-19 Flexibility Are Not Losing their Eligibility, HRSA Confirms
      • Bills Filed in New York to Help 340B Providers Hurt by Medicaid Drug Benefit Transfer
      • In “Nasty Surprise,” House Subcommittee Votes to Require Billing Medicaid MCOs at Cost Plus Dispensing Fee for Drugs, Including 340B
      • House E&C Full Committee May Vote on 340B Transparency Bill as Soon as Next Week
      • Amgen and GSK Announce Refunds for 340B Overcharges - May 23
      • Expert Tip From Alinea Group
      • House Subcommittee Votes on Party Lines to Impose Reporting Requirements on 340B DSH Hospitals & Potentially Other Covered Entities
      • House Subcommittee Says it Will Markup 340B Transparency Bill Tomorrow
      • New Evidence that HRSA in 2020 Declared Permanent a 340B Policy it Abruptly Ended Last Week
      • Sanofi Late Yesterday Tightened Restrictions on 340B Pricing
      • Merck Toughens Conditions on 340B Pricing for Hospitals and Health Centers Effective June 12
      • HRSA and Prime Vendor Yank FAQs About 340B Use in Hospital Child Sites, and GAO Issues a New 340B Study
      • 340B Did Not Arise in Senate Committee Today, But Might in House Subcommittee Next Week
      • Two States Move Closer to Enacting Laws Banning 340B Contract Pharmacy Restrictions
      • Janssen to Pay Refunds for 340B Overcharges in Q2 2020
      • Minh Hoang, Director of 340B Hospital Operations, Cloudmed
      • Expert Tip From RxStrategies
      • “This Is Bananas”: Hospitals Irate About HRSA’s Snap Decision to End 340B Patient Eligibility Clarification
      • U.S. House Panel Not Expected to Markup 340B Legislation at Hearing Next Week
      • Lifestar, Chartwell Announce Refunds for Q4 2022 340B Overcharges
      • Jamila ("Jam") Seibel, Director, Alinea Group
      • HRSA Says COVID Flexibility About Dispensing 340B Drugs in Unregistered Hospital Offsite Locations Will End Thursday
      • In Shift, 340B Health and AHA Now Say They Back Congressional Action on 340B Contract Pharmacy
      • 340B Sales Growth Rate Softened for Second Straight Year, Data Show
      • 340B Health Centers Urge N.Y. State Trial Court to Block Medicaid Pharmacy Transfer
      • Ex-GOP Congressman Burton Slams Current GOP Rep. Rosendale’s 340B Bill
      • Exelixis Puts 45-Day Limit on Requests to Reclassify Past Sales as 340B Purchases
      • Anthony Esgro, Director of 340B Programs, Signify Health
      • Expert Tip From Avita Care Solutions
      • 340B-Related Amendment Might Be Offered to PBM Reform Bill That Senate Panel Is Trying to Mark Up Today
      • Judge Denies Health Center’s Request for More Government Files in 340B Patient Definition Case
      • 340B Stifles Biosimilar Uptake, Study in Health Affairs Says
      • 340B COVID-19 Flexibilities Will End May 11 as Public Health Emergency Expires
      • Astellas Notifies 340B Entities for Second Time in 2023 About a Change in Drug’s NDC
      • Bayer Announces Tougher Limits on 340B Pricing for Hospitals
    • ► April (46)
      • AHA Tells House Panel It Opposes New 340B Hospital Reporting Requirements
      • 340B Abuse Claims Raised During House Hearing on Nonprofit Hospitals’ Tax Status
      • Do it Yourself: 340B Referral Prescription Capture Made Easy
      • Louisiana Takes Major Step Towards Prohibiting Drug Manufacturer 340B Contract Pharmacy Restrictions
      • A Cheat Sheet to New Groups that Use “340B” in Their Names
      • 340B Recertification for CDC Grantees Starts May 8
      • Expert Tip From The Craneware Group
      • In Surprise Move, Pennsylvania Wants 340B Modifiers on Medicaid Managed Care Drugs
      • Iowa Set to Enact Nation’s 25th 340B Nondiscrimination Law
      • Daiichi-Sankyo Offering Refunds for 340B Overcharges on Two Drugs
      • Fatimah Muhammad, Director, 340B Pharmaceutical Svcs & Drug Replacement, Saint Peter's University Hospital
      • New 340B Transparency Bill to be Discussed Next Week in House Hearing, U.S. Senate Bills Introduced
      • HRSA Administrator Open to Congress’ Help Ensuring 340B Accountability and Transparency
      • Hospitals Urge Fed. Appeals Court to Uphold Novel Ark. Law Protecting 340B Discounts in Contract Pharmacy Setting
      • Closed Pennsylvania 340B Hospital Sues CVS Health Over 340B TPA Policy
      • Dual 340B Anti-Discrimination Bills, One Protecting Discounts in Contract Pharmacy Setting, Move Forward in Missouri
      • California Senate Committee Approves Bill to Protect 340B Providers from Alleged PBM Discrimination
      • Maureen Huber, Chief Operating Officer, Avita Care Solutions
      • Expert Tip From Hudson Headwaters 340B
      • Feds Pass on Asking Full Appeals Court to Reconsider Adverse 340B Contract Pharmacy Ruling and Vacate Enforcement Letters to Three Manufacturers
      • Lilly Asks Covered Entity to Promptly Repay “Duplicate 340B/Medicaid Discounts”
      • 340B Compliance Issues Requiring Repayment to Manufacturers
      • New Group 340B Truth Seeks Provider Consensus on Federal Legislation
      • Louisiana Lawmakers to Address Drug Makers’ and PBMs’ 340B Policies in Thursday Hearing
      • Calif. Senate Committee to Hold Hearing on 340B Anti-Discrimination Bill Tomorrow
      • HHS OIG and HRSA Are Mum About 340B Manufacturer Civil Monetary Penalties and Violation Notices
      • New York State Allots $9 Million in Relief for RWCs Hurt by Medicaid Drug Benefit Transfer but No Funding So Far For Other 340B Entities
      • 340B Policies and Procedures: The Keys to Compliant Savings
      • New Mexico Governor Signs Bill Protecting 340B Providers from PBM and Payer Discrimination
      • Calif. Contract Pharmacy Overbilled Medicaid for 340B Drugs, State Appeals Court Holds
      • Expert Tip From Ravin Consultants
      • Arkansas and 340B Providers Ask Appeals Court to Back State’s Novel 340B Contract Pharmacy Law
      • AHA Again Blasts PhRMA and NACHC’s Alliance to Remake 340B
      • 340B Financial Health Check
      • Senate HELP Panel Likely Leaving 340B Out of Bipartisan Drug Policy Bill That it’s Fast-Tracking
      • Spanberger and Johnson Reintroduce PROTECT 340B Act in Congress
      • Novartis to Appeals Court: Our New 340B Contract Pharmacy Policy Doesn’t Affect Our Case Before You
      • Two GOP Senators Raise Concerns About PBM’s Infringement on 340B Savings in Recent Hearing
      • Key Takeaways From the 340B Winter Coalition Conference
      • Maine Becomes Fourth State to Introduce 340B Hospital Transparency Bill
      • Expert Tip From PharmaForce
      • Hospitals Shouldn’t Fear 340B Reporting Requirements, House E&C Republicans Say; Democrat Matsui Raises Concern About Scapegoating
      • New York Implements Medicaid Drug Benefits Transfer, 340B Entities Say Fight Isn’t Over
      • New Mexico Passes 340B Anti-Discrimination Bill, After Dropping 340B Contract Pharmacy Provisions
      • Novartis Toughens its Conditions on 340B Pricing for Hospitals
      • Expert Tip From Visante
    • ► March (48)
      • GSK Extends 340B Pricing Conditions to all Covered Entities and all Products
      • Pfizer Is the Second Drug Maker This Week to Tighten Limits on 340B Sales to Hospitals
      • ASAP 340B Hires Executive Director and Publishes FAQ in Response to Questions and Criticism
      • AIDS Healthcare Foundation Protests Against PhRMA/NACHC Alliance During 340B Coalition Conference
      • The Top 5 Marketing Tips for Building Your Patient Base
      • As April 1 Deadline Looms, NY Health Centers Urge Courts to Stop Medicaid Pharmacy Benefit Transfer
      • HRSA Allows Immediate 340B Enrollment in Mississippi Due to Tornadoes
      • HHS Secretary: 340B “Doesn’t Have the Transparency We Need”
      • AbbVie Puts Squeeze on 340B Pricing for Hospitals Akin to J&J and Amgen’s Recent Moves
      • U.S. House Panel Debates 340B in Context of Health Care Transparency and Consolidation
      • RWC-340B Opposes and Hemophilia Alliance Questions PhRMA and NACHC’s Push to Remake 340B
      • 340B Expected to Be Addressed During U.S. House Hearing Today
      • AHF: Addressing Syphilis Disparities in Franklin County, OH
      • N.Y. State Health Centers Sue to Stop April 1 Shift of Medicaid Managed Care Drug Benefits to Fee for Service
      • HRSA Posts Two Drug Manufacturer Notices to 340B Entities
      • Expert Tip From CPS
      • Confidential Document Fleshes Out ASAP 340B's Reform Objectives
      • 340B Hospitals Say Pharma’s Contract Pharmacy Policies Are Costing Them “Billions of Dollars”
      • Four Best Practices for Running Mock Audits
      • Sean Dickson, Known for 340B Research, Takes Senior Post at Health Insurance Association
      • Texas House Bill Addresses Medicaid MCO Bias Against 340B Pharmacies
      • PhRMA Discusses Joint 340B Reform Deal with Health Centers in Interview; Hospital Groups Denounce Plan
      • Connecticut Governor’s First of Its Kind Three-Pronged 340B Bill Passes Hurdle in Legislature
      • How to Make the Most Out of the 340B Coalition Conference
      • 340B Registration for Second Quarter of 2023 Begins April 1, with COVID Public Health Emergency Set to Expire in May
      • Expert Tip From Cervey
      • Amgen Expands 340B Contract Pharmacy Limits
      • U.S. House Subcommittee Could Discuss 340B on Two Consecutive Days This Month
      • MedPAC’s Call to Replace Medicare DSH Formula Could Spill Over into 340B
      • CMS Announces First Drugs Subject to Medicare Inflation Rebates, Issues Guidance Addressing 340B and Medicare Negotiated Drug Prices
      • Robin George, Director Health Systems Solutions, AllianceRx Walgreens Pharmacy
      • HRSA Wants Reporting Requirements on Use of 340B Savings and Compliance and Reporting Requirements on Use of Contract Pharmacies
      • 340B Prime Vendor Apexus Asks Court to Dismiss AIDS Healthcare Foundation’s Breach of Contract Suit
      • 340B Stakeholders Testify on Conn. Governor’s First-of-Its-Kind Multi-Pronged 340B Legislation
      • Some Provider Groups Slam NACHC and PhRMA’s 340B Plan, Others Say They’re Studying it
      • U.S. House Subcommittee Expected to Raise 340B During March 28 Hearing
      • Major Drug Industry and Health Center Groups Unite to Reform 340B for Patients and “True” Safety-Net Providers
      • N.Y. State Judge Dismisses 340B-Related Antitrust Suit Against CVS
      • U.S. House Oversight Committee Launches PBM Investigation
      • Amneal Offering 340B Refunds on Long List of Drugs for Sales Between Q3 2019 and Q3 2022
      • NACHC Hill Day Document Calls for 340B Reform and Offers Guiding Principles, Key Hill Staffer Joins Organization
      • Bottom Line, not Altruism, Could be the Main Driver of Lilly’s Insulin Price Cut, Drug Pricing Expert Says
      • Zydus Pharmaceuticals USA Announces Refunds for 340B Overcharges During 2022
      • 340B Raised Often During Senate Hearing on Community Health Centers
      • Health Centers and PhRMA Co-Developing 340B Policies, Hospital Group Says
      • Exclusive: HRSA Asking Hospitals About 340B Patient Definition, 340B Savings, and Using 340B at Child Sites
      • Verity Presents: 340B Outlook from Capitol Hill and the States
      • Feds Considering Asking Full Appeals Court to Rehear Case Over AstraZeneca, Novo Nordisk, and Sanofi’s 340B Contract Pharmacy Policies
    • ► February (36)
      • Senate Democratic Whip Durbin: 340B Hasn’t Cut Pharma Profits Dramatically
      • Arkansas 340B Contract Pharmacy Law “Trespassed on Exclusively Federal Turf,” PhRMA Tells Appeals Court
      • Judge Pauses PhRMA’s 340B Administrative Dispute Resolution Lawsuit
      • 340B Report Publisher and CEO: Is Hospital Transparency the Key to a Grand Bargain on 340B?
      • One-Third of Americans Lack a Source of Primary Care and Health Centers Can Close the Gap, Says Report
      • Key Lawmaker Introduces Bill to Protect NY Health Centers and Clinics from “Hundreds of Millions” in Lost 340B Savings
      • Calif. Medicaid Drug Benefit Transfer Will Harm Care at 340B Health Centers, National and State Groups Tell Court
      • RxStrategies' Launches "340B Insider Podcast" Series
      • 340B Hospital Transparency Bill Dies in Indiana
      • Study Raises Questions About Using 340B Claim Modifiers to Implement Medicare Drug Price Negotiation and Inflation Rebate Provisions
      • America’s Essential Hospitals Asks HHS to Swiftly Repay 340B Hospitals for Unlawful Medicare Drug Payment Cuts
      • Iowa Tries Again to End Alleged PBM Bias Against 340B Providers and Pharmacies
      • J&J Announces Major Expansion of 340B Contract Pharmacy Limits; Pushback Is Likely
      • Connecticut’s Democratic Governor Wants Hospitals to Report 340B Earnings and Manufacturers to Resume 340B Pricing
      • Contract Pharmacies: An Integral 340B Component for 30 Years
      • Baldwin, a 340B Entity Ally, Will Chair Senate Health Appropriations Subcommittee
      • Scott Carruthers, Chief Pharmacy Officer, AIDS Healthcare Foundation
      • 340B Pricing May Be Coming to Contrast Agents, Radiopharmaceuticals, and OTC Monograph Drugs
      • Ex-CMS Leader Verma: Big Health Systems Use 340B to Expand Profit and Monopoly Power
      • CMS Seeks Input on Excluding 340B Drugs from New Medicare Part D Inflation Rebates
      • Kansas Bill Targets 340B Contract Pharmacy Limits, Rhode Island Bill Targets PBM Policies
      • Sanders, Asked About Abuse in 340B, Cites His Past Effort to End a Hospital’s Tax Exemption
      • More Entities Might Share 340B Contract Pharmacy Claims Data if the Process Improves and Actually Restores 340B Pricing, Survey Shows
      • What's the Secret to 340B and Specialty Pharmacy Provider and Patient Engagement?
      • Inspector General Advises CMS to Monitor Non-Hospital 340B Entities’ Use of Modifiers on Part B Drug Claims
      • 340B Stakeholders Weigh in on HRSA’s Proposal to Replace 340B Dispute Resolution Process
      • 340B Hospital Physician Affiliated with Free-Market Think Tank Says Abolishing 340B Should be on the Table in Health Affairs Essay
      • Bernie Sanders Officially Named Chair and Bill Cassidy Ranking Republican of Senate HELP Panel
      • GSK Announces Refunds for 340B Overcharges on Respiratory Drugs
      • Andrew Crawford, Senior Vice President, Business Development, Maxor National Pharmacy Services
      • Drugmakers Urge Appeals Courts to Follow Third Circuit Ruling and Uphold 340B Contract Pharmacy Restrictions
      • Bayer: 340B “Is Enriching Middlemen Versus Benefitting Patients”
      • Upcoming End of COVID-19 Emergency Could Prompt HRSA to End or Scale Back 340B Flexibilities
      • AHA Seeks Meeting with HHS About Repaying 340B Hospitals for Illegal Medicare Drug Reimbursement Cuts
      • EMD Serono Is the Second Drug Maker Today to Impose Conditions on 340B Contract Pharmacy, and the 21st Overall
      • Bayer Is the 20th Drug Maker to Impose Conditions on 340B Contract Pharmacy
    • ► January (48)
      • The Day After: Stakeholders Take Stock of Third Circuit Court’s 340B Contract Pharmacy Opinion
      • Virginia House Subcommittee Defeats 340B Hospital Accountability Bill; Rev. Al Sharpton Says Program Direly Needs More Oversight
      • In Wake of 340B Contract Pharmacy Restrictions, Biosimilars Deserve Consideration
      • Mississippi Reintroduces Bill to Ban Drug Makers’ 340B Contract Pharmacy Restrictions
      • Eshoo and Castor Will Be Top Democrats on House E&C Subcommittees Involved in 340B
      • 340B Report Publisher and CEO Slafsky: Three 340B Observations for 2023
      • Third Circuit Court Rules for Drugmakers in 340B Contract Pharmacy Cases
      • New York Times 340B Hospital Exposé Leads to a Vote Later Today in a Virginia House Subcommittee
      • Missouri Lawmakers Try Again to Stop Drug Companies’ 340B Contract Pharmacy Restrictions
      • Staffing Success for a 340B Pharmacy
      • New York State Medicaid Drug Benefit Transfer, on Ice for Two Years, Is Back
      • Guthrie and Griffith, as Expected, Will Helm House E&C Subcommittees Involved in 340B
      • ShaiAnn Howard, Director, Health Systems Solutions & Decision Science, AllianceRx Walgreens Pharmacy
      • House GOP Bill Would Stop Additional Hospitals and Child Sites from 340B Enrollment and Make it Harder for Current Hospitals to Remain Eligible
      • U.S. House Leaders Agree on Committee Ratios: Energy & Commerce Gets to Work 
      • Astellas Notifies 340B Entities About Antifungal’s Updated NDC
      • End 340B, Commentary in New England Journal of Medicine Suggests
      • MedPAC Votes to Recommend Ditching Medicare DSH Patient Percentage for Medicare Purposes
      • The Mpox Outbreak: What a Swift Response Looks Like
      • Ryan White Clinics for 340B Access Is Dropping its 340B Dispute Resolution Lawsuit
      • Pennsylvania Rescinds Directive that Contract Pharmacies May Not Dispense 340B Drugs to Medicaid Beneficiaries
      • Oregon Bill Targets PBM Policies that Discriminate Against 340B Pharmacies
      • Federal Court Seals HRSA’s Records in Health Center’s 340B Patient Definition Lawsuit
      • 340B Recertification for HRSA and Indian Health Service Grantees Starts Jan. 30
      • Improve Quality Outcomes with ACOs and 340B
      • Pennsylvania Says Contract Pharmacies May Not Dispense 340B Drugs to Any Medicaid Beneficiaries
      • 340B Market News: Avita Acquires PrEP-by-Telehealth Provider Q Care Plus
      • Rhodie Smith, Vice President, Contract Pharmacy Sales, RxStrategies
      • First 340B-Related Bill of 118th Congress Filed
      • Nine New Republicans Named to House Committee with 340B Jurisdiction
      • Visante’s Top 10 Issues in Pharmacy in 2023 for Health Care Providers
      • Keep 340B Strong, AHA Says in Wall Street Journal Ad
      • Health System Makes Improvements at 340B Hospital in New York Times Investigation
      • CMS Announces Medicare Drug Price Negotiation Dates
      • Breaking: Judge Declines to Order HHS to Promptly Repay 340B Hospitals for Illegal Medicare Part B Drug Reimbursement Cuts
      • U.S. District Court Orders 340B Report to Destroy and Not Divulge Legally Obtained Information in 340B Patient Definition Case
      • Congressional Committee Lineups Still in Flux After McCarthy Installed as House Speaker
      • 340B “Overdue for Reform,” Industry Trade Group BIO Says in Blog
      • CMS Plans in April to Address Potential Remedies for Illegal Drug Payment Cuts for 340B Hospitals
      • 340B Provider Ally Stabenow Will Not Seek Re-Election to U.S. Senate in 2024
      • 340B Pricing: Navigating Pharmacy Discount Programs to Benefit Your Entity & Patients
      • Janssen Providing Refunds for 340B Overcharges During Q1 2020
      • William von Oehsen, Principal, Powers Law Firm
      • Lilly Says 340B Entities Can’t Designate Central Fill Pharmacies as Contract Pharmacies
      • PhRMA Takes its Fight Against Arkansas 340B Law to Federal Appeals Court
      • Alcon Providing Refunds for 340B Overcharges on 22 Products
      • House GOP Leadership Spat Stymies All Action, Including Any on 340B
      • Office of Pharmacy Affairs Get Slight Funding Bump
  • ►2022 (512)
    • ► December (38)
      • CMS Requiring All 340B Entities to Use Claims Modifiers When Billing Part B for 340B Drugs
      • Hospital Groups and Brand Drug Industry React to Wall Street Journal’s 340B Hospital Investigation
      • Top Referral Specialties And Medications Driving 340B Savings
      • Viatris Providing Credits Due to Problem that Made 340B Pricing Unavailable in August
      • Private Oncologist Group-Funded Study Models Effects of Using CMS’s Controversial 2020 340B Hospital Drug Cost Survey
      • Our Top 10 Breaking News Stories of 2022
      • Wall Street Journal Says Its Investigation of 340B Hospitals Raises Questions about Program’s Growth and Purpose
      • Breaking: Congress Wants HRSA Briefing on Action to Safeguard 340B Entities’ “Lawful Access to Discounted Drugs”
      • Amgen Sues HHS in Defense of the Company’s 340B Contract Pharmacy Restrictions
      • Merck Providing Refunds for 340B Overcharges During Q4 2019, Q3 2021, and Q2 2022
      • 340B Hospitals’ Share of Part B Drug Administration Continues Rising, PhRMA-Funded Study Finds
      • U.S. Retail Drug Spending Rose 7.8% in 2021, as COVID Eased and Patients Got Care They Postponed
      • 340B Report Analysis: Federal 340B Law Gives States Room to Regulate their Own Drug Distribution Systems, Judge Rules in Arkansas Contract Pharmacy Case
      • 117th Congress Nears End With No 340B Contract Pharmacy Fix Expected
      • The Time to Step Up Is Now: Advocating for 340B
      • 340B Registration for First Quarter of 2023 Will Run from Jan. 1 to Jan. 17
      • Breaking: Biogen Announces 340B Contract Pharmacy Restrictions
      • Breaking: Federal Law Doesn’t Preempt Arkansas’s Novel 340B Contract Pharmacy Law, Judge Rules
      • Michigan Senate Rejects Attempt to Weaken Recent 340B Anti-Discrimination Law
      • 340B’s Critics Often Misunderstand its Intent, Ex-House E&C Chair Waxman Says in Health Affairs Commentary
      • 340B Report Publisher and CEO Slafsky: Expect More Attention to 340B in New Congress
      • Novo Nordisk Announces Third Round of 340B Refunds This Year
      • Provider of HIV/AIDS Care Refiles Suit Against 340B Prime Vendor
      • Senior U.S. House Democrat and Republican Say They’re Hopeful Congress Will Act on 340B; Hearings Expected in New Congress
      • Lilly for the Fifth Time This Year Announces Refunds for 340B Overcharges
      • Extent of 340B’s Impact on Overall Drug Prices Unclear Due to Lack of Data, Study Finds
      • Novo Nordisk Updates 340B Contract Pharmacy Policy, Will Allow Claims Submission to 340B ESP
      • Hospital and Pharmacy Groups Launch Second Pro-340B Ad Campaign This Year
      • Webinar: 340B Judicial, Legislative and Regulatory Developments
      • RWC-340B Assessing Dispute Resolution Proposed Rule’s Impact on Its Lawsuit and Current Dispute Resolution Petition
      • Mike Braun, Key U.S. Senator on 340B Matters, Won’t See Re-Election in 2024
      • 340B Dispute Resolution Proposed Rule Would Eject CMS Staff and HHS Lawyers from Process and Put OPA in Charge
      • Provider Groups Cite Inaction on 340B Pricing Denials in Their Reactions to Dispute Resolution Proposal
      • The Importance of Strong Partnerships to Enhance Patient Care, Reduce Costs and Maximize Compliance
      • AIDS Healthcare Foundation Criticizes Idea of Creating a 340C Program for Non-Hospital Providers
      • Local Community Group Continues Late Congressman’s Push for 340B Hospital Oversight
      • HHS Enlists Health Centers in Six-Week COVID Vaccine Drive, GOP Leaders Question Funding and Priorities
      • Anula Courtis, CEO and Founder, 340Best
    • ► November (36)
      • BREAKING: HRSA Proposes Streamlined, Less Trial-like 340B Dispute Resolution Process
      • CSL Behring Confirms that First Gene Therapy for Hemophilia B Will Be Available at a 340B Price
      • Health Care as a Human Right? Why Not?
      • 340B Hospitals Use Biosimilars Less Than Others, PhRMA-Commissioned Study Finds
      • 340B Prime Vendor Sued for Allegedly Not Negotiating Sub-Ceiling Pricing on HIV/AIDS Drugs
      • Arkansas Health System Asks State to Enforce its 340B Contract Pharmacy Law Against Novo Nordisk
      • Important Operational Insights for Covered Entities Choosing to Access 340B ESP
      • CMS Defends Delayed Fix for Illegal Medicare Drug Payment Cuts for 340B Hospitals
      • HRSA Sanctions Manufacturer for Not Issuing Refund for 340B Overcharges
      • White House Gives HRSA Green Light to Publish Proposed New 340B Dispute Resolution Regulations
      • A Closer Look at Tuesday’s Arguments in Federal Appeals Court Over the Legality of the 340B Contract Pharmacy Program
      • Optimize Specialty Pharmacy Outcomes at ASHP Midyear in Las Vegas
      • With GOP Control of U.S. House, Expect Increased Oversight of 340B Providers
      • How One Pharmacy Successfully Pivoted to an Entity-Owned Pharmacy to Overcome Mounting 340B Restrictions
      • Two of Three Appeals Court Judges Question Government’s Stance That Drug Companies May Not Impose Conditions on 340B Sales
      • Appeals Court To Hear Arguments Today in AstraZeneca, Novo Nordisk, and Sanofi’s 340B Contract Pharmacy Suits
      • Hospital Group Says Survey Shows Drug Companies’ 340B Contract Pharmacy Limits Are Harmful
      • With Democrats Retaining Control of U.S. Senate, Expect New Leadership in Key Committee
      • 340B Law Should Be Amended to Include Emergency-Use COVID-19 Drugs, Health Affairs Opinion Article Says
      • Fake Lilly Twitter Account Tweets “Insulin Is Free Now,” Temporarily Wiping Billions From Company’s Stock Value
      • Miles Truesdell, 340Best Board Member
      • With Party Control of Congress Still Undecided, 340B Providers Lose Some Key Champions but Retain Some Heavy Hitters
      • MedPAC Is Expected to Make a Policy Recommendation That Could Prompt a Look at 340B Hospital Program Eligibility Criteria
      • Law Firm Releases Survey of State Action on 340B Amid Mounting Calls for Congressional Action
      • Arkansas and Providers File Briefs Defending State’s Novel 340B Contract Pharmacy Law in Important Fed. Court Case
      • Hospital Groups Ask Court Again to Make CMS Promptly Repay 340B Hospitals for Illegally Withheld Medicare Drug Reimbursement
      • 340B TACTICS: Reduce Manufacturer Exclusion Impact + Capture More Claims
      • GSK and Purdue Pharma Announce New Rounds of Refunds for 340B Overcharges
      • Hospital Group Blasts CMS for Delaying Redress for Illegal 340B Drug Payments Cuts
      • Is There a Loophole That Might Let CMS Keep Paying Some Hospital Departments ASP Minus 22.5% for 340B Drugs?
      • Top 20 Moments in 340B’s History
      • Alex Hennum, Vice President/General Manager, Macro Helix
      • CMS Says It Will Announce Sometime Next Year How it Will Repay 340B Hospitals for Five Years of Illegal Drug Reimbursement Cuts
      • HRSA for Now Will Not Seek More Info from 340B Providers About Ownership of Onsite Pharmacies
      • Feds and S.C. Health Center Spar Over Center’s Access to Government Info in its 340B Patient Definition Case
      • HHS Official Under Trump Calls for “Honest Conversation” About 340B at it Reaches Age 30
    • ► October (36)
      • Appeals Court Questions Yet Again if it Has Jurisdiction Over Lilly’s 340B Contract Pharmacy Case
      • Second of Three U.S. Appeals Court Hearings on 340B Contract Pharmacy Is Set for Monday
      • AIDS Advocates Holding Weeklong Protest Over Gilead’s 340B Contract Pharmacy Restrictions and Changes In Patient Assistance Program
      • HRSA Cites Almaject for 340B Price Data Lapse, No Sanctions Imposed 
      • Federal Appellate Judges Ask Lawyers, What is a Bona Fide Offer of 340B Pricing?
      • As Interest in Legislation Grows, Congressional Research Service Issues Back-to-Back Reports on 340B Program
      • New York State Stands by its 340B-Related Antitrust Claims Against CVS
      • Your Guide to Navigating 340B ESP
      • Feds in Mediation with Tenn. Health System that Allegedly Paid for Referrals to Boost 340B Profits
      • In Key Hearing, Appeals Court Panel Seems to Lean in Favor of Some Drug Manufacturer Conditions on 340B Pricing
      • HRSA Refers Merck to HHS Inspector General Over its 340B Contract Pharmacy Policy
      • CMS Says Steps to End Medicare Drug Payment Cut for 340B Hospitals Are in Progress
      • 340B COVID-19 Flexibilities Will Continue Through Mid-January
      • Kalderos Announces New 340B Drug Claims Verification Tool
      • NACHC Seeks Meeting with Becerra About 340B Contract Pharmacy Restrictions After “Inexplicable” ADR Decision
      • HRSA Tells AbbVie and Amgen Their 340B Contract Pharmacy Restrictions Are Illegal
      • Twice as Many Providers as in May Are Submitting 340B Drug Claims Data to 340B ESP, Pharma Contractor Says
      • Effort Launched to Create 340C—a Separate Drug Discount Program for Health Centers and Possibly Other Entities
      • Congressman Who Represents Virginia 340B Hospital Profiled by New York Times Is Exploring Oversight and Legislation
      • With Elections Nearing, Biden Is Ordering HHS to do More to Drive Drug Costs Down
      • BIO CEO McMurry-Heath Steps Down Amid Reported Conflict with Board
      • Hospital Group Urges MedPAC to Drop Part B Pay-Cut Proposal, Cites 340B Impact
      • Anthony Velasquez, Chief Product Officer, PharmaForce
      • PhRMA Makes its Case for Invalidating Arkansas’s First-of-its-Kind 340B Contract Pharmacy Law
      • Amgen Announces Second Round of Refunds this Year for 340B Overcharges
      • 340B Pharmacy Services Company Avita Expands into Clinician and Support Staff Services
      • Federal Court Clears Way for Medicare to Boost 340B Hospitals’ Part B Drug Payments
      • 340B Report Holding Oct. 28 Webinar on What the Midterm Elections Mean for 340B
      • CBO Raises Changing 340B Patient Definition to Ease Pressure on Commercial Insurers
      • Genentech CEO Cites New York Times’ Front Page Story in Appeal for 340B Reforms
      • Jillian Lichner, Senior Manager of Implementations, 340B Solutions, Maxor National Pharmacy Services
      • UCB Files 340B Contract Pharmacy Suit Against HHS, the Ninth Company to Do So
      • U.S. Appeals Court Tentatively Set to Hear Three 340B Contract Pharmacy Cases on Nov. 15
      • An Innovative Approach to Addressing a Key Social Determinant of Health
      • New York Times Investigative Story Aftermath: Leading Local Paper Dives into 340B, Emphasizing its Importance for Community Health Centers
      • HRSA Allows Immediate 340B Enrollment in Florida, South Carolina Due to Hurricane
    • ► September (46)
      • Exclusive: HHS OIG Declines to Penalize Drug Manufacturers at This Time Over 340B Contract Pharmacy Restrictions
      • Groups Representing 340B Hospitals Praise Federal Court Decision Halting Deep Medicare Part B Cuts
      • Fallout from New York Times’s 340B Investigative Piece Continues as Local Media, Policymakers, and Community Weighs In
      • Manchin and Braun Call on HHS To Take Immediate Action Against Drug Manufacturers in Contract Pharmacy Battle
      • CVS Moves to Dismiss New York AG’s Antitrust Suit That Alleges Monopolistic Behavior Related to Wellpartner
      • Generic/OTC Drug Maker Owes Refunds to 340B Providers, HRSA Audit Shows
      • National Association of Community Health Centers Calls On Congress “To Move Urgently” To Tackle 340B Contract Pharmacy Impasse “Before It’s Too Late”
      • New York Times Front Page Story on 340B Program Causes Shockwaves
      • 340B HIV Providers Warn of "Drug Industry Disinformation Campaign"
      • PhRMA, BIO, and Others Unleash a Torrent of 340B Hospital Criticism
      • Walgreens Takes Full Ownership of 340B Specialty Pharmacy Company Shields Health Solutions
      • Amber Mitchell, Senior Solution Engagement Executive, Sentry Data Systems, now The Craneware Group
      • Feds Tell Court They Oppose Health Center’s Effort to Sink 340B Patient Definition
      • 340B Report Exclusive: GAO Is Asking Hospitals if They Share 340B Savings with Low-Income Uninsured Patients at Contract Pharmacies
      • New Rule Gives Force to Ground-Breaking State 340B Contract Pharmacy Law
      • Merck Announces Third Round of 340B Refunds for 2019 Drug Purchases
      • Court Upholds $23 Million Judgement Against CVS Caremark for Unfair Pharmacy Reimbursement
      • HRSA Grants 340B Enrollment Flexibility in Puerto Rico Due to Hurricane
      • Feds Tell Judge They Accept that Part B Drug Payment Cuts in 2020-22 Were Unlawful
      • Arkansas’ Novel 340B Contract Pharmacy Law Doesn’t Conflict with Federal Law, State Officials Tell Court
      • Are You Ready to See Pharmacy in a Whole New Light?
      • Judge Issues Stay in Merck’s 340B Contract Pharmacy Lawsuit
      • 340B Provider Groups Decry Federal Judge’s PrEP Coverage Decision
      • Navigating the 340B Program for Maximum Benefits and Guaranteed Compliance
      • Federal Appeals Court Will Hear Arguments in Lilly’s 340B Contract Pharmacy Suit on Oct. 31
      • CMS Gets Conflicting Advice About Unwinding Drug Payment Cuts for 340B Hospitals
      • Unichem Says 340B Audit Found it Overcharged Just Two Entities and Must Repay Them Just $110.20
      • U.S. Uninsured Rate Dipped Last Year, Census Bureau Says
      • Jason Mills, Senior Consultant, 340B Solutions, CPS
      • Judge Dismisses 340B Contract Pharmacy-Related Antitrust Claims Against Insulin Manufacturers
      • Comments Due Today on How Feds Should Rectify Drug Payment Cuts for 340B Hospitals
      • Health Policy Think Tank Commonwealth Fund Issues 340B Primer
      • In Violation of ‘Spirit’ of Anti-Kickback Law, Drug Manufacturer Donations to Patient Assistance Charities Result in Bigger Profits, Study Finds
      • Restoring 340B Hospitals’ Part B Drug Payments Would Cut Net Outpatient Payments for 80% of Hospitals, Private Cancer Doctor-Funded Study Finds
      • Senior HRSA Official Pedley to Deliver ASHP’s Prestigious William A. Zellmer Lecture Next Week
      • Maximizing 340B Program Value with Specialty Medication Access
      • Judge Continues Stay in 340B Dispute Resolution Lawsuit
      • White House Seeks $27 Billion for COVID-19 and Monkeypox Response
      • Federal Judge Asks About Overdue Status Report in 340B Dispute Resolution Case
      • MedPAC May Back a Cut in Part B Drug Payments, This Time Not for 340B Hospitals Only
      • Federal Health Officials with Significant 340B History Play Major Roles in CDC Revamp
      • Becerra Says Legislation Is Needed to Strengthen HHS Authority to Address 340B Contract Pharmacy Pricing Denials
      • 340B Report Exclusive: CMS May Owe 340B Hospitals More Money Than Anticipated
      • 340B Stakeholders Seek Clarity on HRSA Flexibilities as COVID-19 Public Health Emergency Winds Down
      • GOP House Leaders Want Answers from Becerra on Implementation and Impact of Medicare Drug Price Negotiation
      • Kristin Fox-Smith, SVP, Visante
    • ► August (44)
      • With Just a Month to Go, HRSA Releases First FY 2022 Manufacturer 340B Audit Result
      • Advocates Urge Feds to Allow Distressed Rural Hospitals to Remain 340B Eligible
      • Financial Outlook Deteriorating for Nonprofit Hospitals in 2022 and Beyond, Credit Rating Agency Says
      • Key Takeaways from New Medicare Law and 340B Implications
      • Ivy Espendez, Director, 340B Compliance & Audit, Sentry Data Systems, now the Craneware Group
      • Exclusive: HRSA Hasn’t Posted a Limited Distribution Plan Notice to 340B Entities in Almost a Year. No One Outside of the Agency Knows Why.
      • Judge Orders HHS to Respond to Ruling Letting Health Center Challenge 340B Patient Definition
      • House GOP Lawmaker Reintroduces Bill to Collect and Report 340B Hospital Data
      • Sixth Group of 340B Hospitals Sues HHS Over Medicare Drug Payment Cuts
      • Colleen DiClaudio, President and Founder, Nuvem
      • GSK Announces Third Round of Refunds This Year for 340B Overcharges
      • In Show of Support, House GOP Conference Chair Stefanik Visits 340B Contract Pharmacy
      • 340B Webinar: Optimize Your 340B Program and Cut Costs in 30 Minutes
      • HHS Has ‘No Real Plan to Stop Underpaying’ 340B Hospitals’ Part B Claims, Groups Tell Court
      • Apexus Solutions to Support 340B Program Compliance
      • Development May Expedite Ruling on Widely Watched State Law Intended to Require Rx Manufacturers to Provide 340B Discounts
      • Appeals Court Will Hear Oral Arguments in October in Novartis and United Therapeutics’ 340B Contract Pharmacy Suit
      • Melissa Palchak Opraseuth, SVP Operations, Cloudmed, an R1 company
      • Feds File Briefs in Response to AstraZeneca and Lilly Arguments in Key 340B Cases
      • Medicare and Hep C Patients Would Save Over $100 Million if Plan Sponsors Adopted Generic Use, OIG Finds
      • Federal Data Show 340B Sales Hit $43.9 Billion in 2021, Drug Industry Consultant Reports
      • At Request of Senior GOP Lawmakers, GAO Studying Law That Gave Relief to Hospitals Forced Out of 340B Due to COVID-19
      • Health Centers Criticize Kaiser Health News Story About Profit Margins
      • Bill Giving Medicare Drug-Price Negotiating Power Set to Become Law
      • Let Us Decide How to Remedy Illegal Drug Payment Cut for 340B Hospitals, HHS Asks Judge
      • Senate Panel Wants HRSA to Tell How It Has Responded to Drug Makers’ 340B Pricing Denials
      • 340B Providers Won’t Share in $183 Million Damages Award Against Lilly for Misstating AMP
      • HHS Tells Judge Unwinding Medicare Payment Cuts for 340B Drugs Needs Caution, Not Haste
      • HRSA Grants 340B Enrollment Flexibility in Kentucky Due to Floods
      • Senate Rejects 340B-Related Amendment to Major Drug Pricing and Climate Change Bill
      • Senate Passes Historic Bill that Would Let Medicare Negotiate Some Drugs’ Prices
      • Vermont Passes Bill Enhancing 340B Anti-Discriminatory Protections but Measure Aimed at Drug Manufacturers Fails
      • Civica Rx Subsidiary Offers First Low-Cost Generic Drug in Outpatient Pharmacy Space, with More to Come
      • Boehringer Ingelheim Expands its 340B Drug Pricing Restrictions
      • Providers March on U.S. Capitol Grounds to “Defend 340B”
      • Ex-Surgeon General Adams Urges 340B Entities to Publicize Program’s Benefits
      • 340B Hospitals Ask Judge to Stop Part B Drug Payment Cuts Immediately
      • New PhRMA-Funded Study Questions 340B Hospital Eligibility Yardstick
      • William A. Riley, Senior Director, Health Systems Solutions & Decision Science, AllianceRx Walgreens Pharmacy
      • Purdue Pharma Is Providing 340B Refunds Spanning 16 Years of Overcharges
      • 340B Coalition Conference Speakers to Providers: Give Us Your Success Stories
      • 340B Hospitals Treat Bigger Shares of Underserved Patients than Non-340B Hospitals and Clinics, Study Finds
      • Senate Democrats Say They Are on Track to Pass Drug Pricing Bill Before Aug. 8
      • Scott LaChute, Vice President of Operations, Verity Solutions
    • ► July (49)
      • HRSA Unveils New 340B Contract Pharmacy Services Webpage That Is Silent on Manufacturer Obligations
      • New York State Sues CVS for Allegedly Forcing 340B Entities to Use Third Party Administrator Wellpartner
      • A Blizzard in July (of Briefs in 340B Contract Pharmacy Lawsuits)
      • Hospitals Want Expedited Order Stopping Medicare Payment Cuts for 340B Drugs 
      • Essential 340B Reporting
      • AIDS Healthcare Foundation Calls PhRMA’s Washington Post 340B Ad “Hypocritical Slander”
      • First-Ever Conference Just for 340B Grantee Entities Set for October in Denver
      • Part 2: “There Have Been Challenges Up and Down the Supply Chain”: The View from the Field and Responses from Stakeholders
      • Part 1: “I Don’t Want to Go Through This Nightmare”: Frustrations Grow Over Significant Delays in Restoration of 340B Pricing for Contract Pharmacy Purchases
      • Biden Administration Kills Trump-era Rules Casting Doubt on HHS Guidance and Enforcement Actions
      • Hospital Pharmacy Leaders Call Staff Shortages, Vendor Management Their Biggest Operational Challenges
      • 340B Report Publisher and CEO: What to Expect Following Midterm Elections
      • The Frustrating Realities of 340B ESP Data Submission
      • War Over Hearts and Minds in 340B Battle Heats Up as Hospitals Launch Their Own Campaign
      • U.S. Supreme Court Formally Notifies Lower Court and Parties About its Decision Striking Down Medicare Part B Drug Payment Cuts for 340B Hospitals
      • 340B Advocacy – Preserving Underserved Health Care in America
      • 340B DSH Hospitals Upped Services to the Poor During Pandemic’s Brutal First Year, 340B Health Says
      • Senate Democrats Optimistic About Passing Drug Pricing Bill Before August Recess
      • As Part of New Ad Campaign, PhRMA Buys Full-Page Ad in Washington Post Blasting 340B Hospitals and Pharmacy Chains
      • Hospital Groups Cheer, Private Cancer Docs Deplore CMS’s Decision to End Deep Cut in 340B Hospitals’ Drug Payments
      • HRSA's 340B Program Website Gets a New Look
      • AHF Sues Express Scripts Over Medicare Part D Reimbursement Claw Backs
      • How One Leading 340B Services Company Has Taken Action to Stay Ahead of the Contract Pharmacy Restrictions Game
      • 181 House Members Prod HHS to Start Fining Drug Makers for “Unlawful” 340B Overcharges Involving Contract Pharmacies
      • In Big Win For 340B Hospitals, CMS Will Reverse Massive Drug Reimbursement Cut for 2023 and Seeks Input on Potential Remedies for Prior Years
      • House GOP Task Force Apparently Takes a Pass on Making 340B Recommendations
      • Feds Ask Appeals Court to Uphold HRSA’s 340B Program Violation Letters to Novo Nordisk and Sanofi
      • In Effort to Rein in High Prices, Another Big Player Jumps into the Insulin Market
      • HHS Warns Pharmacies Not to Turn Away Women Requesting Abortion Medication
      • Shrujal Patel, Managing Partner, The Alinea Group
      • The Need for a 340B Uninsured Prescription Discount Card Program
      • Merck Becomes Eighth Drug Maker to Sue HRSA in Defense of 340B Contract Pharmacy Restrictions
      • PhRMA and J&J File Amicus Briefs in Support of Novartis and United Therapeutics
      • Senate Democratic Drug Pricing Bill Buoyed by Large Savings Estimate
      • 340B Hospital Annual Recertification Begins Aug. 27
      • 3 Most Common Ways 340B Referral Savings Are Missed
      • Analysts Still Digesting Senate Democratic Drug Pricing Bill’s 340B Changes
      • Appropriations Committee Passes Spending Bill with Increase in OPA Funding and Call to Action on Manufacturer Restrictions
      • View from Capitol Hill Luncheon: Get the Latest Developments in the Ever-Changing 340B Program
      • 100 Congressional Democrats Urge HHS to Use Existing Power to Lower Drug Prices
      • Hospital Groups Cite Supreme Court Decision in Latest Briefs Backing Feds in Lilly and AstraZeneca 340B Cases
      • Castle Family Health Centers Supports Excellence in Its 340B Program
      • Drug Makers’ 340B Overcharging Must Be Addressed, House E&C Democrat Dingell Says During Hearing
      • Lilly Announces Fourth Round of Refunds for 340B Overcharges in 2019
      • Novo Nordisk, Sanofi, and Feds Trade Arguments in 340B Contract Pharmacy Litigation
      • 340B Sales Were $38.8 Billion in 2020, PhRMA-Funded Study Finds
      • Meet AIDS Healthcare Foundation Pharmacist, and Artist, Alsean Bryant
      • In Important Ruling, Federal Appeals Court Says Health Center May Challenge 340B Patient Definition’s Legality
      • Bausch Health Announces 340B Contract Pharmacy Restrictions on All Covered Entities
    • ► June (48)
      • House Appropriators Ask Feds to Use “Any Available Measures” to Curb Pharma’s 340B Pricing Denials
      • As UCB Reviews HRSA’s 340B Enforcement Letter, Grassley Presses OIG for Answers
      • Sponsor Halts California Bill to Shield 340B Providers from Manufacturers and PBMs’ Actions
      • AHA Tells HHS It Wants Prompt Repayment for All Years Hospitals’ Medicare Drug Payments Have Been Cut
      • Q3 340B Entity Registration Starts Tomorrow
      • Jessica Rivas, Chief Pharmacy Officer for Big Bend Cares and Scholarship Recipient for the Apexus Advanced 340B Operations Certificate Program
      • HRSA Tells UCB its 340B Contract Pharmacy Policy Is Illegal
      • Feds Ask Appeals Court to Partially Reverse Ruling on Lilly’s 340B Contract Pharmacy Policy
      • Clinics Pay Gilead $33 Million to Settle Fraud Claims Involving 340B-Related PrEP Transactions
      • Supreme Court DSH Calculation Ruling Leaves 340B Status Quo in Place, Experts Say
      • Schumer Pledges to Hold Senate Vote Soon on New Bill to Make Insulin More Affordable
      • 340B Report Publisher and CEO: Takeaways from Supreme Court’s Part B Cuts Decision
      • White House Now Says This Is Target Month for New 340B ADR Rule, but Publication Date Remains a Mystery
      • Bill Would Give HIV/AIDS Clinics More Leeway to Use 340B Savings and Other Program Income
      • Gilead Adds 45-Day Lookback Clause to its 340B Contract Pharmacy Policy
      • Top 5 Considerations for Community Health Centers Seeking a Pharmacy Management Partner
      • Exclusive: 340B Entities Report Unannounced and Unexplained Claims Reversals Involving CVS and Blue Cross Blue Shield
      • Feds Urge Appeals Court to Overrule Lower Court in AstraZeneca’s 340B Contract Pharmacy Lawsuit
      • West Virginia Hardens its 340B Anti-discrimination Law to Explicitly Bar 340B Claims Modifiers
      • PhRMA and Private Oncology Practices Slam PBMs’ Role in 340B in Comments to FTC
      • NACHC Asks HHS to Swiftly Punish Drug Makers for 340B Pricing Denials Involving Contract Pharmacies
      • New Study Finds 340B Contract Pharmacy Growth in Affluent and White Neighborhoods, Hospitals Criticize Research
      • The Supreme Court Aftermath: What Comes Next in Fight Over Medicare Part B Drug Payments to 340B Hospitals?
      • Bipartisan U.S. House Group Renewing Pressure on HHS to Punish Drug Makers Over 340B Pricing Denials
      • NACHC Tells Merck its 340B Contract Pharmacy Policy for Health Centers Can Be Explained by “Only Greed”
      • U.S. Supreme Court Strikes Down Medicare Part B Drug Payment Cuts for 340B Hospitals in 2018 and 2019
      • NACHC Hopes Congress Will Pass Laws Protecting 340B Providers This Year
      • Drug Manufacturer 340B Overcharge Notices Reach New Record, Novo Nordisk Is the Latest
      • Arizona Lawmakers Pass and Send 340B Anti-discrimination Bill to Governor
      • HRSA Seeks Comments on Proposed Changes to 340B Program Forms
      • Health Centers Ask Congress and Biden to Intervene to Protect 340B Savings from Pharma and PBM “Greed”
      • Community Voices For 340B Holding Aug. 3 March in Washington
      • Novartis and United Therapeutics File Briefs in Appeals Court in 340B Contract Pharmacy Lawsuits
      • Congress Turns House Floor to 340B For an Hour
      • FTC To Investigate PBMs’ Impact on Drug Access and Affordability
      • Exelixis, Maker of Expensive Cancer Drugs, Is Latest Manufacturer to Impose 340B Contract Pharmacy Conditions
      • AstraZeneca and Sanofi Ask 340B ADR Panel to Dismiss Health Centers’ Overcharging Claims
      • GlaxoSmithKline Ending Voluntary 340B Pricing on Two Orphan Drugs
      • In a Move to Expand its Specialty Pharmacy Services, CPS Acquires Trellis Rx
      • Generic-drug Maker e5 Pharma Offering Refunds for 340B Overcharges
      • OptumRx Says Providers Can’t Share 340B Claims Data Without its Consent
      • Judge’s 340B Statutory Interpretation Was “Exactly Backward,” Lilly Tells Appeals Court
      • Groups Blast PBMs’ Discrimination Against 340B Hospitals in Letters to FTC
      • 340B Report Publisher and CEO: Momentum for 340B Protections Is Growing
      • PhRMA-funded Study Faults 340B Hospitals’ Financial Aid and Debt Collection Policies
      • NEJM Article Says HIV Prevention Should Rely Less on 340B Revenue
      • BMS Updates its Conditions on 340B Pricing Involving Contract Pharmacy
      • BMS and Merck Announce Refunds for 340B Overcharges
    • ► May (39)
      • With Talk of Legislation Heating Up, PhRMA Seeks a New 340B Policy Director
      • 340B ADR Proposed Rule Remains at White House 5 Months Past Expected Publication Date
      • CMS Asks Court Again to Dismiss 340B Health Centers’ Suit Over Medicaid Drug Benefits Transfer
      • Maryland Governor Signs 340B Anti-discrimination Bill into Law
      • Glen Pietrandoni, SVP, Patient and Community Advocacy, Avita Pharmacy
      • The New Rules of 340B Contract Pharmacy—a Recap of 340B Report’s First-Ever Webinar
      • In What Would Be the Only Second State to Enact Such Legislation, Calif. Senate Votes to Shield 340B Providers from Manufacturers and PBMs’ Actions
      • Tennessee Health System Strikes Back Against DOJ Claims It Paid for Referrals to Boost 340B Revenue
      • Provider Groups File Appellate Briefs in Key 340B Contract Pharmacy Cases
      • With Screws Tightening on 340B Contract Pharmacy, More Health Centers Plan to Open their Own
      • State Bill That Would Have Stopped Drug Industry from Imposing 340B Contract Pharmacy Restrictions Dies
      • Colorado Lawmakers Pass 340B Anti-discrimination Bill
      • U.S. Uninsured Rate Dipped Slightly in 2021 to 9.2% but Rates for Hispanics and Blacks Remain High
      • 25 States Say Drug Companies’ 340B Contract Pharmacy Actions Are Illegal and Harm Public Health
      • GOP-aligned Think Tank Alleges that 340B Expansions Contributed to Drug Spending Spurts
      • HRSA Audits: Scared or Prepared?
      • HRSA Announces 340B Enrollment Flexibilities in Fire-Ravished New Mexico
      • Danielle Boehm, Customer Services Manager, Sectyr
      • 25 States File Joint Briefs Backing HHS and HRSA in 340B Contract Pharmacy Cases
      • Mallinckrodt Is the Third Drug Company This Month to Announce Refunds for 340B Overcharges
      • 340B Providers Lose their Biggest GOP Ally in U.S. House
      • Drug Makers Ask Michigan Lawmakers to Erase Section from New 340B State Law
      • Mike Loftus, 340B Director Pharmacy Services, Mercy Health
      • Letting Pharma Put Strings on 340B is Letting Fox Guard Henhouse, Feds Tell Appeals Courts
      • Amgen and GSK Announce Refunds for 340B Overcharges - May 22
      • Drug Industry-Funded Consumer Group Slams 340B on Conservative News Site
      • 340B Publisher & CEO: 340B Ceiling Price Website Is Welcome Step but Needs Improvement
      • HRSA Sends Merck 340B Contract Pharmacy Cease and Desist Letter, Agency’s First in Seven Months
      • Survey: Hospitals’ Losses from 340B Contract Pharmacy Restrictions Ballooned During Q1 2022
      • Fed. Judge Lets 340B Providers Intervene in Closely Watched Contract Pharmacy Lawsuit
      • Putting a Human Face on 340B
      • AstraZeneca Stops Voluntary 340B Pricing on Orphan Drugs to Rural and Cancer Hospitals
      • California 340B Health Centers Blast CMS in Court Over its Role in State Medicaid Drug Benefit Transfer
      • Non-Hospital Infusion Centers See a Path to 340B Reform that Runs Through the States
      • Patti Schnieder, Vice President, Caravan Health
      • Sen. Grassley Presses HHS OIG to Punish Drug Makers Over Denials of 340B Pricing
      • Merck Adds 45-Day Time Limit on Replenishment Orders to its 340B Contract Pharmacy Policy
      • Appeals Court Consolidates AstraZeneca, Sanofi, and Novo Nordisk’s 340B Contract Pharmacy Cases
      • Sen. Manchin Endorses 340B Ally McKinley in Tight GOP Primary Race
    • ► April (46)
      • Merck Extends its Conditions on 340B Pricing Involving Contract Pharmacies to Health Centers
      • 340B Report Holding May 18 Webinar on Implementing Drug Makers’ New 340B Contract Pharmacy Rules
      • Providers Alarmed About 45-Day Lookback Clauses in Drug Makers’ 340B Contract Pharmacy Policies
      • How 340B Works for People Living with HIV
      • HIV/AIDS Clinics Tell FTC that PBMs Usurp 340B Discounts for Themselves
      • With Retired Sen. Hatch’s Passing, a Legendary 340B Tale is Told
      • Federal Circuit Court Begins Lilly’s 340B Contract Pharmacy Lawsuit Appeal in Earnest
      • Influential HIV/AIDS Group Asks Gilead to Exempt Ryan White Clinics from Company’s 340B Contract Pharmacy Restrictions
      • 73 Groups Want Congress to Enact Major Drug Pricing Reforms by Memorial Day
      • Six Groups Slam Drug Makers’ 340B Pricing Conditions on Hepatitis C Medicines
      • 48 Hospitals Seek Readmission to 340B After Losing Eligibility Due to COVID-19 Pandemic
      • 340B Hospitals’ Pharmacies and Child Sites Often Located in Richer, Less Diverse Areas, Study Finds
      • JAMA Study Finds Prominent Cancer Centers With 340B Connections Mark Up Infused Drugs Significantly
      • Apexus Releases Its Annual 340B Trends and Hot Topics Learning Module
      • Harvard Drug Policy Experts Write in JAMA About How Congress Could Fix 340B Contract Pharmacy Mess
      • At Direction of U.S. Appeals Court, Judge Issues Amended Judgement in Lilly’s 340B Contract Pharmacy Case
      • AHF Provides Stigma-Free Care with Thrift Store Chain
      • Sanofi Makes Two Big Changes to its 340B Contract Pharmacy Policy
      • BMS Fleshes Out How It Will Use Claims Data for 340B Myeloma Drug Purchases
      • How Sentry Is Helping Covered Entities Contend With Contract Pharmacy Exclusions
      • 340B Providers Say Express Scripts’ New 340B Claims Validation Requests Raise Red Flags
      • Feds Tell Court Tennessee Health System Paid for Referrals to Recoup “Staggering” 340B Discounts
      • The Right Prescription: How a Pharmacy Management Partner Can Alleviate Your Workforce Woes
      • Feds Appeal Court Ruling in AstraZeneca’s 340B Contract Pharmacy Lawsuit
      • Today Is Last Day for Some Hospitals to File Paperwork for 340B Reinstatement
      • COVID-19 Public Health Emergency Extended Through July 15
      • Astellas Providing Refunds for 340B Overcharges from Q3 2020 Through Q2 2021
      • Don’t Miss Out on 340B Savings from In-Office Injectables
      • Multiple Developments in 340B Contract Pharmacy Lawsuit Appeals
      • Lilly Providing Refunds for 340B Overcharges During Q3 2019
      • Drug Makers’ 340B Pricing Restrictions Hit Small Rural Hospitals Especially Hard, Survey Shows
      • 340B Sales Growth Rate Slowed in 2021, the First Year of 340B Contract Pharmacy Restrictions
      • Virginia Governor Signs 340B Anti-Discrimination Bill for Grantees
      • 340B Report Publisher and CEO Slafsky: 340B Contract Pharmacy Program Has Fractured Into 17 Pieces
      • While All Eyes are on 340B Contract Pharmacy Battle, Federal Appeals Court Hears Arguments in Key Case Challenging HRSA’s Patient Definition
      • 340B Patient Definition Is at the Heart of Case Debated Before Federal Appeals Court
      • 340B ESP Makes Changes to Its Terms of Use that Entities Must Accept
      • 340B and Value-Based Payment Keep Safety Net Doors Open
      • Influential 340B Lawmaker Upton Announces Retirement
      • Influential Drug Cost-Effectiveness Organization Endorses Partially Lifting 340B Orphan Drug Exclusion
      • Illinois Legislature Passes 340B Anti-Discrimination Bill
      • Nick Rebmann, CEO, Hudson Headwaters 340B
      • Exclusive: Gilead Responds to Health Center Group’s Criticism of its 340B Contract Pharmacy Policy
      • Roundtable Discussion: 340B Drug Pricing Program: Recent Legislative Updates and Key Trends Impacting Hospitals, FQHCs and Other Designated Entities
      • House Passes Bill to Limit Insulin Co-Pays, but the Way Forward in Senate Is Unclear
      • Security Matters for 340B
    • ► March (47)
      • 340B Advocacy Group Expresses Concern About Apparent Unique Feature in J&J’s Contract Pharmacy Policy
      • CMS Projects that Drug Spending and Drug Prices Will Keep Rising Through 2030
      • Next Month’s 340B Registration Period Overlaps with Deadline for Hospitals Seeking Reinstatement
      • Conservative Massachusetts Think Tank Slams State’s 340B Hospitals over Charity Care and Calls for Reform
      • HRSA Refers Boehringer Ingelheim to HHS Inspector General over its 340B Contract Pharmacy Policy
      • HRSA Invokes Contract Pharmacy Fight in Pitch for Comprehensive 340B Regulatory Power
      • Arkansas Health Centers and Community Hospital Want Role in Challenging PhRMA’s Lawsuit Over State’s Novel 340B Contract Pharmacy Law
      • BioComp Providing Refunds for 340B Overcharges Spanning a Whopping 8 Years
      • Ryan White 340B Clinic Association Names New Managing Director
      • Feds Take Over Prosecution of Whistleblower Suit Against Tenn. Health System Alleged to Have Paid Cancer Docs Illegally for Referrals that Boosted 340B Profits
      • HIV/AIDS Advocates Protest in Front of Gilead HQ Against Company’s New 340B Contract Pharmacy Policy
      • Becker’s Hospital Review Webinar: How Health Systems Are Driving Growth Through Specialty Pharmacy Services
      • BMS Providing 340B Refunds on Cancer Drug Opdivo
      • California 340B Health Centers Say State “Essentially Admits” Flaws in Medicaid Drug Reimbursement Change
      • Could J&J’s Decision to Limit 340B Contract Pharmacy Spur Congress to Act?
      • Influential Group that Offers Conservative Model Bills to State Lawmakers Wades into 340B Debate
      • Nebraska Governor Signs 340B Anti-Discrimination Bill
      • Johnson & Johnson Becomes the 16th Drug Manufacturer to Restrict 340B Contract Pharmacy
      • Exclusive: Leading Health Center Organization Calls Gilead’s New 340B Contract Pharmacy Restrictions “Unconscionable”
      • HRSA Starts Contacting Hospitals Forced Out of 340B During Pandemic About Possible Reinstatement
      • Virginia Legislature Passes 340B Bill, One of at Least 14 States With 340B Legislation This Year
      • Health Care Provider Groups Slam Gilead’s Conditions on 340B Contract Pharmacy
      • For 2-3 Years, CMS Could Pay 340B Hospitals More for Pricey New Alzheimer’s Drug Than Current Norm
      • CMS Asks Judge to Dismiss 340B Health Centers’ Claims in Suit Over Medicaid Drug Benefits Transfer
      • Gilead Announces 340B Contract Pharmacy Restrictions that Apply to Hospital and Grantee Entities
      • Judge Clears Way for Feds to Appeal His Ruling in AstraZeneca’s 340B Contract Pharmacy Lawsuit
      • Biden to Sign Bill Today Giving Some Relief to Hospitals Forced Out of 340B Due to COVID-19
      • Economists Say 340B Hospital and Grantee Entities Use Contract Pharmacy for Different Reasons
      • Drugmakers Janssen and Kala Providing Refunds for 340B Overcharges
      • U.S. Senate OK’s Limited Relief for Hospitals Forced Out of 340B Due to COVID-19
      • U.S. House Approves Partial Relief for Hospitals Forced Out of 340B Due to COVID-19
      • Novo Nordisk and Sanofi Make Their Cases to Federal Appeals Court in 340B Contract Pharmacy Lawsuit
      • Learn How to Sustainably Scale Your 340B Program
      • AbbVie Adds its Top-Selling Cancer Drug Imbruvica to its 340B Contract Pharmacy Restrictions
      • Congress Is Close to Passing a Spending Bill that Likely Will Address Hospitals’ Loss of 340B Eligibility During Pandemic
      • Non-Hospital 340B Entities Form Group to Fight on Their Own Behalf at National and State Levels
      • 340B Report Publisher and CEO: Time for Congress to Pass 340B Contract Pharmacy Legislation
      • AHA Asks Becerra Again to Waive DSH Percentage Eligibility Requirement for 340B Hospitals During Pandemic
      • 340B ADR Panel Wants to Know if Court Decision Affects HIV Advocacy Group’s Claims Against AstraZeneca and Sanofi
      • As 340B Providers Grapple with High Cost Diabetes Medicine, Civica Plans to Make and Distribute Generic Insulins Priced as Low as $30
      • Akorn Providing Refunds for 340B Overcharges
      • Biden Renews Call for Lowering Insulin Costs and Letting Medicare Negotiate Drug Prices
      • Congressional Democrats Confront PhRMA About Brand Drug Price Hikes
      • AstraZeneca and Feds Disagree Over Next Steps in 340B Contract Pharmacy Case
      • 340B Stakeholders Congratulate Egwim on Being Named OPA Director
      • Biden to Address Drug Pricing in Speech Tonight Amid Signs of Shift in Congressional Dems’ Strategy
      • Bruce Eddins, Administrator, Horizon Ridge Wellness Clinic, Inc.
    • ► February (43)
      • HRSA Picks Federal HIV/AIDS Policy Specialist Emeka Egwim To Be its Next 340B Program Director
      • Despite Expected Jan. Publication Date, White House Review of New 340B ADR Proposed Rule Is Approaching 100-Day Mark
      • Hospitals Say the Three Confirmed to Have Left 340B Due to Fallout from COVID Are the Tip of the Iceberg
      • Rural Providers Ask Becerra for Action on 340B Contract Pharmacy and on Hospitals at Risk of Losing 340B Eligibility
      • New JAMA Study Casts Doubt on CMS Reason for Cutting Hospitals’ Medicare Part B Payments for 340B Drugs
      • Michigan Governor Signs Three Bills Addressing PBM and Insurer Discrimination Against 340B Entities and Contract Pharmacies
      • Federal Judge Denies Fla. Healthcare Providers’ Bid to Throw Out Gilead’s Suit Alleging 340B Fraud
      • Pharma Consultant Sounds Alarm About Potential Sub-Zero 340B Prices on Some Brand Drugs Starting in 2024
      • Mary Van Hoozer, Vice President of Sales & Account Management, SunRx
      • AstraZeneca Court Ruling Means All Six of HRSA’s 340B Original Contract Pharmacy Violation Letters are Dead
      • Drug Makers Ask Judge Again to Dismiss 340B-Related Antitrust Charges
      • Merck Offering Refunds for 340B Overcharges
      • California Asks Judge to Dismiss 340B Health Centers’ Suit Challenging Medicaid Drug Payment Change
      • Signify Health Acquires Caravan Health For $250 Million
      • Robert Ferraro, Chief Pharmacy Officer, Ravin Consultants
      • Federal Judge Vacates HRSA’s Finding that AstraZeneca’s 340B Contract Pharmacy Policy Is Illegal
      • HHS Secretary Becerra Pledges to Keep Fighting Against 340B Contract Pharmacy Restrictions “Because it’s the Law”
      • In a Win for Health Centers, 340B ADR Panel Says Proceedings Against AstraZeneca & Sanofi Must Go On
      • In a Move that May Get Significant Pushback, Lilly Signals that it Can Recoup 340B Underpayments from Entities at its Discretion
      • Hospital Groups Pan GSK’s New 340B Contract Pharmacy Policy, PhRMA Says It Will Continue to Push for Reform
      • News Alert: GlaxoSmithKline Becomes the 14th Drug Maker to Limit 340B Contract Pharmacies
      • News Alert: Biden Praises Congresswoman’s “Relentless” Work on 340B During Major Speech on Drug Pricing Reform
      • Exclusive: AIDS Healthcare Foundation Says Re-Opening 340B Law Over Contract Pharmacy Fight Will Backfire
      • With Planned Series of House Speeches Delayed, GOP Lawmaker Speaks Out in Support of 340B
      • Biden and Becerra Slated to Speak at NACHC Event Next Week
      • GSK Providing Refunds for 340B Overcharges During Q1 2020
      • HRSA Says at Least Three Hospitals Have Lost 340B Eligibility So Far Due to COVID-19 Patient Mix Changes
      • Democratic Senator’s Illness Stalls Action on Drug Pricing Indefinitely
      • Second Major 340B Stakeholder Says Congress May Need to Stop Drug Makers’ Contract Pharmacy Actions
      • Apexus Picks Ohio Health System Pharmacy Exec Michelle Wiest For Influential 340B Position
      • ICER Says Four Drugs Are Cost-Effective in Keeping COVID-19 Patients Out of Hospitals
      • Ross Halsne, VP, 340B Solutions, Maxor National Pharmacy Services
      • Despite Initial Optimism, Rural Hospitals Won’t Benefit from 340B Pricing on BMS’s Myeloma Drugs
      • Spanberger and Johnson Lining up an Hour of Pro-340B Accolades on U.S. House Floor Next Tuesday
      • Ready to Future Proof Your Business? The Time to Act Is Now.
      • 11 out of 15 Top-Selling Drugs in U.S. Are Subject to 340B Pricing Restrictions, Analysis Shows
      • Kalderos Hires Veteran Health Care Tech Company Leader Brent Dover to be its New CEO
      • News Alert: At 340B Conference, Feds Laud 340B Providers, Criticize Drug Makers Embroiled in Contract Pharmacy Fight
      • Hospital Group Leader Says “We’re Prepared to Go” in Direction of Federal 340B Contract Pharmacy Legislation
      • Federal Judge Approves Government’s Request to Pause Kalderos’ 340B Contract Pharmacy Lawsuit
      • Scholarship Created in Memory of Long-Time 340B Leader Carl Taylor
      • Vertex Providing Refunds for 340B Overcharges on Cystic Fibrosis Drug Trikafta
      • 340B Report Publisher and CEO Forecasts What to Expect After November Congressional Elections
    • ► January (40)
      • News Alert: Pfizer Becomes the 13th Drug Maker to Limit 340B Contract Pharmacies
      • Exclusive: Nearly Five Years Before BMS Voluntarily Opened Up Myeloma Drug Network, HRSA Told Celgene it “Must Ensure” Entities Could Buy at 340B Price
      • Novo Nordisk Will Let Hospitals Designate Two 340B Contract Pharmacies—one Retail and one Specialty
      • In a Relief to Rural Providers, Gilead Is Waiving 340B Orphan Drug Exclusion for its COVID-19 Drug Veklury
      • Hospitals Taking Heavy Losses Due to Drug Company Limits on 340B Pricing, Survey Says
      • Vizient Asks Congress to Pass Senate Version of Bill to Protect Hospitals from Losing 340B Eligibility During Pandemic
      • Julie Valdes, Clinical Pharmacist & 340B Program Coordinator, Zufall Health Centers Inc.
      • Bipartisan U.S. House Group Wants HHS to Start Punishing Drug Makers Over 340B Pricing Denials
      • Health Center Opposes AstraZeneca’s Motion to Pause 340B Dispute Resolution Proceedings Over Company’s Contract Pharmacy Policy
      • FDA OKs COVID-19 Drug Veklury (remdesivir) for Outpatients, Opening the Way for 340B Pricing
      • PhRMA and Arkansas Seek Faster Court Ruling on State’s Novel 340B Contract Pharmacy Law
      • AHA Asks Congress to Attach 340B Hospital Protections to Must-Pass Spending Bill
      • Three Drug Makers, Including Two with Contract Pharmacy Restrictions, Post 340B Refund Notices
      • Democrats Weigh Passing Build Back Better Act—Possibly Including Drug Pricing Reforms—in “Chunks”
      • View from Capitol Hill Breakfast: Get the Latest Developments in the Ever-Changing 340B Program
      • Groups and Individual Health Care Providers Grapple with BMS’s New 340B Contract Pharmacy Policy
      • With Judge in Astra 340B Case About to Get Promotion, What Will Happen to the Highly Anticipated Case?
      • “Pharma Bro” Who Drew Ire of 340B Providers and Drug Industry Alike Barred from Pharmaceutical Industry for Life
      • With Public Health Emergency Extended, 340B Flexibilities to Continue
      • BMS Clamps Down on 340B Contract Pharmacy for Most of its Drugs but Expands 340B Access to its Controversial Myeloma Meds Program
      • News Alert: NACHC Long-Time Leader Van Coverden Takes Leave, Could Augur Generational Change
      • 340B-Related Conference Organizers Readjust as COVID-19 Persists
      • 340B “Anti-Pickpocketing” Bills Filed in Five States
      • In Big Win for Pharmacy Groups, CMS Proposes Significant Changes to Medicare Part D Clawbacks
      • Visante’s Top 10 Issues Facing Hospital & Health System Pharmacy in 2022
      • PhRMA Says More than Half of Pharmacy and Provider Profits on Brand Drug Sales Come Through 340B
      • In a Big Relief for 340B Providers, Sen. Thune Will Run Again
      • N.Y. State and Va. Health Centers Ask Fed. Judge to Let their 340B-Related Antitrust Suit Against Drug Makers Go on
      • Judge Denies Calif. 340B Health Centers’ Motion to Halt State Medicaid Drug Payment Change
      • Marcus Cox, Chief Pharmacy Officer, Klamath Health Partnership, Inc
      • A Personal Look at Some of the Nation's Top 340B Lawyers
      • Appeals Court Signals it Might Send Lilly’s 340B Lawsuit Back to Lower Court
      • Judge in AstraZeneca’s 340B Case, on Verge of Big Promotion, Gives Parties Just Two Days for a Status Report
      • Carole Johnson Takes Charge of HRSA and the 340B Program
      • California Asks Judge to Reject 340B Community Health Centers’ Request to Stop Medicaid Drug Payment Change
      • Larry Crowder, Vice President, 340B Solutions, Cervey
      • Drug Makers Want to Halt 340B Dispute Resolution Proceedings, Citing Lawsuits and Forthcoming Rule
      • Feds Back and Kalderos Resists Pausing Company’s 340B Lawsuit
      • Biden Axing Trump’s “Most Favored Nation” Drug Pricing Rule that 340B Entities and Pharma Both Disliked
      • Three Big Predictions for the 340B Program in 2022
  • ►2021 (550)
    • ► December (44)
      • News Alert: Calif. 340B Health Centers Ask Judge to Stop Tomorrow’s “Devastating” State Medicaid Drug Payment Changes
      • Breaking News: AbbVie Becomes 11th Drug Maker to Restrict 340B Contract Pharmacy. Feds Appeal Rulings in Lilly, Novo Nordisk, and Sanofi Cases.
      • Breaking News: Feds Appeal Rulings in Novartis and United Therapeutics 340B Contract Pharmacy Cases
      • John Thune, Senate’s No. 2 Republican and Strong 340B Provider Ally, Weighs Retirement
      • Manchin’s Idea that VA Negotiate Medicare Drug Prices Could Adversely Impact 340B Program, Expert Suggests
      • Key Considerations to Reduce Impact of Contract Pharmacy Restrictions
      • Citing Omicron Wave, 340B Coalition Weighs Making Winter Conference a Hybrid Live/Virtual Event
      • N.Y. and Va. Health Centers Say Discovery Should Continue in their Novel 340B-Related Federal Lawsuit
      • Novo Nordisk and Sanofi Have Jan. 26 Deadline to File Opening Briefs in 340B Contract Pharmacy Appeal
      • Boehringer Ingelheim Extends 340B Contract Pharmacy Restrictions to Previously Exempt Specialty Drug Ofev
      • HRSA Adds Three Days to 1Q 340B Registration Period
      • Referral Prescription Capture Drives Significant 340B Savings Enhancing 340B’s Mission
      • More Than 850 Hospitals Ask Feds to Appeal Judge’s 340B Contract Pharmacy Ruling
      • Provider Groups Pan Lilly’s 340B Contract Pharmacy Policy Change
      • Is There a New 340B Stakeholder Group for Pharma Companies?
      • Democratic Defection on Build Back Better Act Sets Back Drive to Lower Drug Prices
      • Cloudmed Acquires 340B Technology Company par8o
      • News Alert: Carole Johnson Will Take Over as HRSA Administrator in January
      • Breaking News: Lilly Will Honor Unlimited 340B Contract Pharmacy Arrangements in Exchange for Entities’ Claims Data
      • U.S. Retail Drug Spending Hit $348.4 Billion in 2020 but Overall Prices Fell 0.1%
      • House Committee Releases Report With 340B Implications
      • A Q&A with Two 340B Industry Experts About the Importance of Innovation and a Competitive Edge
      • Calif. Health Centers Will Ask Court to Stop State Medicaid Change That Could Reduce 340B Savings Significantly
      • In What Is Believed to Be the First State Action, W.Va. Says Express Scripts’ 340B Claims ID Policy Violates State Law
      • Senate Finance Committee’s New Drug Pricing Text Includes a New 340B Provision
      • Judge Grants Stay in Boehringer Ingelheim’s 340B Contract Pharmacy Lawsuit
      • Update: Lilly Comments on Forthcoming New 340B Dispute Resolution Rule
      • 340B Covered Entities: Are You Ready for the Changes to Gilead’s Advancing Access Program?
      • News Alert: Biden Administration Plans to Scrap Existing 340B Dispute Resolution Rule and Publish New One Shortly
      • Drug Makers May Be Getting Orphan Drug Designations to Exploit 340B Orphan Drug Exclusion, HHS OIG Tells Congress
      • “Pharma Bro’s” ex-Company and ex-Partner Settling Claims Arising from Daraprim “Scheme,” FTC Says
      • 340B Teaching Hospital Sues Over Medicare Part B Drug Payment Cut
      • Influential House Lawmaker and Rural Hospitals Upset About J&J’s 340B Orphan Drug Policy Change
      • GlaxoSmithKline, Exelan, and BioMarin Issue 340B Refunds
      • House Panel Holding What Might be Last Hearing of its Drug Pricing Investigation
      • Omnicell Is Acquiring ReCept, a Specialty Pharmacy Management Company with 340B Expertise
      • News Alert: Johnson & Johnson Ending Voluntary 340B Pricing on Orphan Drugs to Rural and Free-standing Cancer Hospitals
      • Feds Say They Need Time to Decide Whether to Appeal Ruling in Novartis and United Therapeutics 340B Cases
      • HRSA Audit Finds Drug Maker and Subsidiary Overcharged 340B Providers
      • Maker of Plan B One-Step Contraceptive Exiting 340B Program
      • Five Strategies to Optimize Your Specialty Pharmacy Program
      • Lilly and Feds Disagree Over Whether 340B Case Is Ripe for Appeal
      • Supreme Court May Upend Medicare DSH Calculation Formula, Which Would Impact 340B Stakeholders
      • Breaking News: Amgen Announces 340B Contract Pharmacy Limits for Hospitals
    • ► November (48)
      • News Alert: U.S. Supreme Court Justices Question CMS’s Legal Basis for Slashing 340B Hospitals’ Drug Reimbursement
      • 340B Providers Take Center Stage Before U.S. Supreme Court Today
      • Clovis Oncology Reverses Decision to Use Kalderos’ 340B Pricing-as-Rebate System
      • U.S. House GOP Conference Chair Stefanik Backs Protecting 340B Hospitals from Losing Eligibility During Pandemic
      • Peter Welch, Long-Time 340B Advocate in the U.S. House, Announces Run for Senate
      • UCB Becomes Ninth Drug Manufacturer to Announce 340B Contract Pharmacy Limits
      • HRSA Weighs in on Recent 340B Contract Pharmacy Court Decisions
      • Carole Johnson Appears to be Leading Candidate to Run HRSA
      • AIR340B Releases Study Criticizing DSH Hospital Commitment to the Underserved
      • 340B Report Publisher and CEO: Expect Congress to Act on 340B Contract Pharmacy Before Midterm Elections
      • Drug Pricing Watchdog Identifies Most Significant Price Hikes
      • After Successful House Vote, Attention Turns to Senate on Major Drug Pricing Bill
      • Michael Yount, CEO, Avita
      • News Alert: Novo Nordisk Joins Sanofi in Appealing Court’s 340B Contract Pharmacy Decision
      • News Alert: Sanofi Is the Second Manufacturer to Appeal a 340B Contract Pharmacy Court Ruling
      • News Alert: HRSA Sets Wheels in Motion for a New 340B Administrative Dispute Resolution Proposed Rule
      • Appeals Court Raises Procedural Questions About Lilly’s 340B Contract Pharmacy Case
      • GOP Congressman Slams PBMs for Taking Away Safety Net Providers' 340B Savings
      • HIV Care Providers Sound Alarm About Threats to 340B Savings
      • For the First Time Since Pandemic, Some 340B Providers Are Being Audited in Person
      • CMS Delays Implementing Rule Allowing Multiple Best Prices for Drugs Until Next July
      • As Contract Pharmacy Losses Climb into the Billions, Fine for Overcharging 340B Providers Gets Closer to $6,000 Per Instance Mark
      • AstraZeneca and Feds Keep Sparring over 340B While Waiting for Judge to Rule
      • Insulin and Diabetes Drug Makers Ask Judge to Dismiss 340B-Related Antitrust Charges
      • AHA Criticizes JAMA Study of What Hospitals Charge for Clinician-Administered Drugs
      • Kaiser Health News Story on 340B Likely to be Read and Seen Widely
      • Key Questions 340B Providers Should Ask When Choosing a TPA
      • In What Could be the First of Many Challenges, Lilly Appealing U.S. District Court’s 340B Contract Pharmacy Ruling
      • In Pursuit of New 340B Leader, HRSA Expands Its Search Beyond Pharmacists
      • 340B Providers Appear to Escape Bullet as Negotiations Continue on Build Back Better Bill’s Drug Pricing Provisions
      • Attention Turns to Merck and AstraZeneca After Courts’ 340B Contract Pharmacy Rulings
      • Hospitals, Drug Manufacturers, and Lawyers Give their Takes on 340B Contract Pharmacy Rulings
      • Two New Studies on Hospital and Health Center Participation in 340B
      • Breaking: Another Federal Judge Issues a Mixed Opinion in 340B Contract Pharmacy Litigation, this Time in Novartis and United Therapeutics’ Cases
      • Breaking: Federal Judge Hands Down Mixed Opinion in Sanofi and Novo Nordisk’s 340B Contract Pharmacy Lawsuits
      • Feds Ask Judges to Follow Judge in Lilly Case and Validate HRSA’s Take on 340B Contract Pharmacy
      • Biden Taps Judge in AstraZeneca’s 340B Lawsuit for Appeals Court Seat
      • Kalderos Tells Hospitals its Service to Turn 340B Discounts into Rebates is Operational
      • Limited Medicare Drug Price Negotiation Placed into Reconciliation Bill; 340B Impact Unclear
      • 3 Requirements for Exceptional Specialty Pharmacy Patient Satisfaction
      • News Alert: CMS Will Continue Deep Cut in 340B Hospitals’ Medicare Part B Drug Reimbursement
      • 340B Stakeholders Size Up Friday’s Mixed Decision in Lilly’s 340B Contract Pharmacy Lawsuit
      • CMS Decision on Whether to Keep Part B Drug Payment Cuts for 340B Hospitals Could Come as Soon as Today
      • Grassley Asks HHS General Counsel Nominee About Drug Companies “Harming Access” to 340B
      • Sectyr Acquires LicenseTrak, Will Merge Capabilities into Single Platform
      • Democrats Still Trying to Make a Deal on Federal Drug Pricing Legislation
      • Biden Administration Wants to Scuttle Azar’s Rule to Automatically Snuff Out HHS Regulations
      • Kelly Kolker, President, 340B Solutions, CPS
    • ► October (49)
      • Breaking: Federal Judge Vacates HRSA’s May 17 Letter to Lilly on 340B Contract Pharmacies, Sends Matter Back to Agency
      • 340B Lobbying Intensifies on Capitol Hill and in Federal Agencies
      • Both Sides in AstraZeneca’s 340B Contract Pharmacy Case Want a Quick Ruling, but It’s Unclear if They Will Get One
      • D.C. Federal Judge Picks Up a Fourth 340B Contract Pharmacy Lawsuit
      • Federal Court Decision on Novel Arkansas 340B Contract Pharmacy Law Might Not Come Until 2023
      • HRSA Orders Two Drug Makers to Repay 340B Entities After Audits Show Overcharges
      • Updates on 340B Administrative Dispute Resolution Lawsuits and ADR Panel Hearings
      • Virginia Health Center Joins 340B-Related Antitrust Suit Against Insulin and Diabetes Drug Makers
      • California Still Plans to Move Medicaid Pharmacy Benefits to Fee-for-Service in January
      • News Alert: Boehringer Ingelheim Sues HRSA in Defense of its 340B Contract Pharmacy Policy
      • Senate Panel Backs Penalizing Drugmakers for their 340B Contract Pharmacy Actions
      • Biden Moves to End Trump’s Limits on HHS Guidance Including for 340B
      • Appeals Court Affirms Dismissal of Privacy Lawsuit Involving 340B Contract Pharmacy
      • BMS Tells 340B Entities It Has Lifted Purchasing Limits on Leukemia Drug
      • During Crucial Oral Arguments in AstraZeneca 340B Suit, Feds Urge Judge to Take a Fresh Look at Their Case
      • Arkansas Ending PhRMA Proceeding Against State 340B Contract Pharmacy Law as Focus Turns to Federal Lawsuit
      • 340B ADR Rule Is Fundamentally Defective, PhRMA Tells Federal Court
      • University White Paper on 340B Says Pharma and Hospitals Will Keep Testing 340B’s Bounds Until Congress Acts
      • Becerra Extends COVID-19 Public Health Emergency Through Mid-January
      • 340B Report Publisher and CEO: If Congress Flips Next Year, Expect 340B To Get A Very Close Look
      • Patient Centered Care: It’s All About the Partnerships
      • Ben Kelly, RPh, MBA, VP of Pharmacy Operations, Maxor Pharmacy Management
      • News Alert: Judge Denies Sanofi Stay Against 340B ADR Proceedings, as Stakeholders Brace for Coming Whirlwind of Crucial Decisions in 340B Cases
      • In Important Development, HHS Close to Rescinding Trump-era Rule that Undercuts its Sub-Regulatory Power
      • A Closer Look at Critical Court Hearing on 340B Contract Pharmacy Legality
      • Feds Oppose Sanofi’s Request for Emergency Protection Against 340B ADR Proceedings
      • Drug Manufacturers May Seek Orphan Designations to Avoid Paying 340B Discounts, HHS OIG Concludes
      • 340B Coalition Says It Will Hold 2022 Winter Conference in-Person
      • Why Contracting with Specialty Pharmacies Could Seriously Grow Your 340B Referral Script Savings
      • Judge Expresses Doubt About Government’s Position During Arguments in Novartis and United Therapeutics’ 340B Contract Pharmacy Lawsuits
      • Lifting of Title X Gag Rule Could Spur Hundreds of Clinics to Rejoin 340B
      • Feds Have Until Tomorrow to Oppose Sanofi’s Request for Stay Against 340B ADR Proceedings
      • CMS Rule that Will Set 340B Hospitals’ Part B Drug Reimbursement for 2022 Moves Closer to Release
      • Managed Care Journal Article Gives 340B Hospitals Low Marks on Uncompensated Care
      • The 340B ACE Advantage: A Credential that Sets the Standard for 340B Expertise
      • Kalderos Sues HHS and HRSA, Says Ban on Drug Company Conditions on 340B Sales is Illegal
      • Sanofi Seeks Emergency Stay Blocking 340B Dispute Resolution Proceedings
      • In Significant Development, HRSA Assigns Panels to Review 340B Dispute Resolution Claims Against Drug Companies
      • Boehringer Ingelheim Defends its 340B Contract Pharmacy Policy After HRSA Finds it Is Unlawful
      • Judge Sets Deadlines for Briefs in 340B Contract Pharmacy Antitrust Suit
      • New Judge Assigned to PhRMA’s Lawsuit Challenging Arkansas’s First-of-Its-Kind 340B Nondiscrimination Law
      • Montana GOP Congressman Proposes a Host of New Conditions on 340B Hospitals
      • 340B Providers Might Insure HIV-at-Risk Patients in Response to Gilead’s PrEP Reimbursement Cuts
      • Half of Congressional Black Caucus Asks CMS to End Medicare Drug Payment Cuts for 340B Hospitals
      • Federal Appeals Court Hears Arguments in Case Involving Walgreens's 340B Program
      • Final 340B Registration Period of 2021 Ends on Oct. 15
      • Claims Manager Plus: Helping 340B Pharmacies Smooth Out the Bumps
      • Keith Chop, Managing Partner, The Alinea Group
      • Breaking: HRSA Tells Boehringer Ingelheim its 340B Contract Pharmacy Restrictions Are Illegal
    • ► September (53)
      • It’s Official: Biden Administration Rescinds Trump’s 340B Insulin/EpiPen Final Rule
      • PhRMA Asks Federal Court to Strike Down Arkansas’ Novel 340B Nondiscrimination Law
      • 340B Dispute Resolution Process is Constitutional, Feds Tell Court
      • Hospital Groups and Drug Industry Vendor File Briefs in Sanofi’s 340B Contract Pharmacy Suit
      • Rough Sailing for Drug Pricing Reform in Congress
      • GOP Senator Files Bill to Preserve Trump’s 340B Insulin/EpiPen Mandate
      • Hospitals Ask Hill Leaders to Shield 340B, as Vote Nears on Drug Pricing Reform
      • Janssen Providing Refunds for 340B Overcharges Including Diabetes Drug
      • Seven-Term Senator Grassley, Often Attuned to 340B, Will Run Again in 2022
      • Cancer Drug Reimbursement Study Could Ramp Up Pressure on 340B Hospitals
      • Daniel Palestrant, MD, CEO, par8o
      • Judge Rejects Novartis’ Request to Speed Up Hearing in 340B Contract Pharmacy Lawsuit
      • News Alert: New Senate Bill Would Let HRSA Audit 340B Providers to See How They Use 340B Net Income
      • Parties at Center of Contract Pharmacy Standoff React to HHS OIG Referral
      • With Delta Variant Persisting, Health Care Groups Struggle with Conference Planning
      • Starting Next Month, HRSA Plans to Audit Some 340B Entities Onsite for First Time Since Pandemic
      • Hospitals Urge CMS To Abandon Medicare Part B Cuts While PhRMA Presses For More Action
      • Breaking: HRSA Refers Six Drug Companies to HHS OIG For Refusing to Offer Discounts
      • U.S. Supreme Court Schedules Oral Arguments on 340B Reimbursement Case
      • House GOP Conference Chair Stefanik Signs on to 340B Anti-Pickpocketing Bill
      • Capture Cares Foundation Awards $300,000 in Grants to 340B Providers for 2021
      • HHS Is Vetting OPA Director Applications and Apexus Is Seeking a New Senior VP For High-Profile Position
      • "The Biggest Crisis Since 340B’s Inception:" 340B Report Leader Provides Input in New Podcast
      • Biden Picks Academic with Hospital Connections to Run HHS Policy Shop
      • North Carolina Enacts PBM Oversight Law Protecting Most 340B Covered Entities
      • House GOP Effort to Amend 340B Falls Short in Key Committee
      • In His First Public Comments, Ex-HHS Top Lawyer Stands by 340B Contract Pharmacy Advisory Opinion
      • Divisions Among 340B Provider, Manufacturer, and Oncology Stakeholders on Stark Display During Webinar
      • 340B Hospitals and Independent Oncologists Issue Dueling Reports on Drug Discount Program
      • Judge Schedules Joint Hearing in Novartis and United Therapeutics’ 340B Contract Pharmacy Cases
      • Sanofi Reaches Out to 340B Entities that Complained to HRSA About its Contract Pharmacy Restrictions
      • Biden Administration Moves a Step Closer to Trashing Trump’s 340B Health Center Insulin/EpiPen Rule
      • Keys to Ensuring Adherence in HIV Treatment and Care
      • Arkansas Insurance Dept. to Rule Next Month on PhRMA’s Petition to Block Novel 340B Contract Pharmacy Law
      • U.S. Supreme Court Gets Several Briefs Urging Rejection of CMS’s Drug Payment Cuts for 340B Hospitals
      • Napo Pharmaceuticals Tells Entities How They Can Keep Getting 340B Price on Limited-Distribution Drug
      • Jeff Spencer, Senior Director, Sales and Account Management, Omnicell 340B
      • News Alert: Key House Committee Excludes “Spread Pricing” Language that 340B Entities Feared from Drug Pricing Legislation
      • In Largely Symbolic Move, Becerra Expresses “Strong Support” for 340B in Drug Pricing Plan
      • N.C. Lawmakers Leave 340B DSH, Children’s, and Cancer Hospitals and HTCs Unprotected from PBM Pickpocketing
      • As Hospital Recertification Deadline Nears, 340B Eligibility Challenges Appear Not to Be Widespread for Now
      • 340B Report Publisher and CEO: Congress Needs to Intervene to Resolve Contract Pharmacy Impasse
      • 340B Hospitals Provide Almost $68 Billion Annually in Community Benefits, AHA Says
      • HRSA Grants 340B Flexibilities to N.J. and N.Y. Due to Hurricane
      • Providers Concerned About Drug Pricing Reform’s Potential to Undermine 340B
      • 340B Hospitals Make Their Case to Supreme Court for Ending Deep Medicare Drug Payment Cuts
      • Hearing Friday on PhRMA’s Push to Quash First State Law to Protect 340B Contract Pharmacy Program
      • A Level Best Compliance Approach to 340B Optimization
      • After HRSA Notification, NACHC Refiles 340B Dispute Complaints Against Drug Manufacturers
      • Feds Are “Trying to Muscle” Pharma on 340B Contract Pharmacy, Manufacturer Says in Legal Brief
      • Genentech Notifies 340B Entities of Limited Distribution of Key COVID-19 Drug
      • Medicare Trustees Say Part B Drug Payments Will More than Double by 2030
      • In Hurricane Ida’s Wake, HRSA Announces 340B Registration Flexibility in Louisiana and Mississippi
    • ► August (37)
      • Merck Due to Impose 340B Pricing Policy Changes Tomorrow
      • HRSA Veteran Herzog to Oversee 340B Program as Agency Begins Search for New OPA Director
      • Congress Tweaks its Projection of Drug Pricing Bills’ Impact on Rx Drug Pipeline
      • News Alert: Becerra Signs off on HRSA Reorganization that Elevates 340B Program’s Status
      • Health Centers Plan to Resubmit 340B Dispute Resolution Petitions
      • As Frustration Mounts Over 340B Contract Pharmacy Impasse, Arguments in Highly Anticipated AstraZeneca Lawsuit Postponed to Mid-October
      • Hospital Groups Back Feds in United Therapeutics 340B Contract Pharmacy Case
      • House Passes Framework for $3.5T Budget Bill That Will Include Key Drug Pricing Measures
      • As Biden and House Dems Prepare to Unveil Drug Pricing Plans, 340B Providers Fret Over About Lost Savings
      • Key House Democrats Keep Up Pressure on Insulin Manufacturers
      • BioMarin Paying Refunds for Two Years of 340B Overcharges on Pricey Drugs
      • N.C. Lawmakers Debate Over the Reach of 340B “Pickpocketing” Protections
      • Jim Donnelly, President, Hudson Headwaters 340B
      • 340B Entities Left Out of BMS’s $75 Million Settlement; Whistleblower Pursues Case Against Lilly
      • PhRMA Challenges First State Law Protecting 340B Contract Pharmacy Program
      • Merck Defends and Hospitals Slam the Company’s Tougher 340B Contract Pharmacy Policy
      • Recent Supreme Court Ruling Could Affect 340B Dispute Resolution Lawsuits
      • Breaking: Merck Will End 340B Contract Pharmacy Pricing for Hospitals That Don’t Share their Claims Data
      • In Strongly Worded Brief in United Therapeutics Case, Feds Defend 340B Contract Pharmacy Actions
      • Feds and AstraZeneca Trade Punches in Drug Maker’s 340B Lawsuit
      • 340B to Be Key Agenda Item for Biden’s New HHS General Counsel Pick
      • Biden Lays Down Markers for Action to Lower Drug Prices
      • U.S. Senate Sets Stage for Action on Lowering Drug Prices
      • PhRMA Urges Court Again to Strike Down 340B Dispute Resolution Process
      • Biden Wants to Rescind Trump’s Most Favored Nation Proposal That Received Widespread Criticism from Drug Industry and 340B Providers
      • In Fight with National Implications, Calif. 340B Providers Try to Stop Move That Could Result in Millions of Lost Savings
      • Wisconsin Lawmakers Introduce 340B Anti-Discrimination Measure but Leave Out Most 340B Hospitals
      • Contrary to Reports, Judge in AstraZeneca Lawsuit Did Not Strike Down 340B Unlimited Contract Pharmacy, Court Clerk Says
      • Insulin Manufacturers Colluded on 340B Contract Pharmacy After Joint Lobbying Push Failed, Lawsuit Alleges
      • 340B Report Publisher and CEO Says New Bipartisan 340B Bill is Win for Providers and Drug Industry
      • Biopharma Company Apellis Posts 340B Limited Distribution Notice
      • Jennifer Lockwood, CEO/Founder, Ravin Consultants
      • Health Center Files 340B Contract Pharmacy Antitrust Suit Against Insulin Makers, Seeks Nationwide Class Action Certification
      • Boehringer Ingelheim Halts 340B Pricing on Contract Pharmacy Drugs
      • Infrastructure Bill Excludes Spread-Pricing Language That 340B Entities Oppose
      • Young Firebrand Lawmaker Gets into Shouting Match with 340B Champion
      • Distressed Critical Access Hospitals that Devolve to Stay Open Would Lose 340B Eligibility
    • ► July (48)
      • Feds and Lilly Make Their Case to Federal Judge in Key Hearing Today
      • Key GOP Congressman Opposed 340B Amendment to Spending Bill During Committee Hearing
      • In AstraZeneca’s 340B Lawsuit, Focus Shifts to HRSA’s May 17 Violation Letter
      • 340B Won’t be Overlooked if There’s a Grand Bargain on Drug Pricing, Analyst Predicts
      • Novo Nordisk Providing Refunds for 340B Overcharges on Insulin
      • Kalderos Urges Feds to Protect Hospitals from Losing 340B Eligibility During Pandemic
      • Retired Senator Enzi, Who Backed 340B Inquiries, Dies Following Accident
      • Building the Case for Dedicated 340B Program Management
      • News Alert: U.S. House Votes to Highlight Need to Halt Pharma’s “Unlawful” 340B Actions
      • HRSA Posts Novartis Notice About 340B Refunds on a Top-Selling Drug—With Contract Pharmacy Strings Attached (Updated)
      • With COVID-19 Surging Again, Hospital and Pharmacist Groups Back Employee Vaccine Mandates
      • For 340B Hospitals, Some Consolation in Otherwise Disappointing CMS Drug Reimbursement Rule
      • 340B Contract Pharmacy Litigation Could Drag on for Years, Hospital Group Leader Says
      • Pedley Provides 340B Update but Avoids Contract Pharmacy Controversy
      • House GOP Starts Crafting Health Care Bills in Anticipation of Retaking Majority
      • 340B Program Flexibilities to Continue As COVID-19 Emergency Extended
      • With 340B Hospital Recertification Set to Begin Soon, HRSA To Host Webinar Aug. 11
      • Thriving with HIV: How a Compassionate Pharmacy Technician Made All the Difference
      • Biden Administration's Proposal to Retain 340B Hospital Drug Payment Cuts Draws More Fire
      • One-Fourth of 340B DSH Hospitals at Risk of Losing Eligibility Due to Pandemic, Analysis Finds
      • Help Wanted Ads Suggest HRSA Reorganization Is in Gear
      • Judge Consolidates Arguments in Two 340B Contract Pharmacy Lawsuits
      • United Therapeutics Fleshes Out its 340B Contract Pharmacy Legal Arguments
      • Providers Support, Eli Lilly Opposes, Rescinding Trump’s 340B Health Center Insulin Rule
      • Evolving Payor Strategies to Control Spending on Specialty Medications
      • In Surprise Move, Biden Administration Proposes Keeping Trump’s Nearly 30% Cut in 340B Hospitals’ Drug Reimbursement
      • Key Congressional Committee Urges HRSA to Fine Drug Makers Over 340B Contract Pharmacy Denials
      • House Appropriators Want an Update from HRSA on its Plans to Clarify 340B Patient Definition and Provider Eligibility Criteria, Calls for New GAO Report
      • Law Firm Sues HRSA Over FOIA Request for 340B Contract Pharmacy Documents
      • Feds, Novartis, and UT Weigh in on Consolidating 340B Contract Pharmacy Lawsuits
      • Lilly Updates its Arguments in 340B Contract Pharmacy Lawsuit
      • FQHCs Say Patients Will Suffer if Telehealth Flexibilities Aren’t Extended
      • Sixth Drug Manufacturer Sues HHS and HRSA Over 340B Contract Pharmacy
      • Multiple Developments in 340B Contract Pharmacy Lawsuits
      • Biden Gives Becerra 45 Days to Deliver a Plan to Fight Excessive Drug Prices
      • Rosen Introduces Bill to Boost Nonprofit Drug Makers’ Competitiveness
      • News Alert: Bipartisan Bill Introduced to Protect 340B Providers From Reimbursement Cuts and Address Duplicate Discount Challenge
      • Hospital Groups Outraged at Boehringer Ingelheim, Company Defends Its Plans and Calls for 340B Overhaul
      • Two High Profile Opioid Makers Among Companies Announcing Refunds to 340B Providers But Refunds for Mallinckrodt’s Top-Selling Drug Remain Elusive
      • In Taking Up 340B Case, Supreme Court Could Reverse Longstanding Legal Doctrine
      • Medicare Part B Payment Challenge Not Only Supreme Court Case That Will Impact 340B Program
      • BREAKING: Supreme Court Will Take Up Case Involving Medicare Part B Cuts to 340B Hospitals
      • Boehringer Ingelheim Will Stop Shipping 340B Drugs to Hospitals’ Contract Pharmacies on Aug. 1
      • Judge Rejects Government’s Contention that AstraZeneca’s 340B Lawsuit Is Moot
      • Hospitals File New Suit To Reverse Steep Part B Payment Cuts for 340B Drugs
      • Pfizer Invokes 340B Contract Pharmacy Ruling in its Lawsuit Over Copay Assistance
      • 16 States Have Passed Laws Since 2019 Targeting PBMs’ 340B Payment Cuts
      • HRSA Makes Tweaks to 340B Program Database
    • ► June (51)
      • Three Drug Makers Answer HRSA’s 340B Contract Pharmacy Letters Defiantly
      • DOJ Says Lilly and Novo Nordisk’s 340B Actions Cost Providers Over $125 Million a Month and Hurt Patients
      • CMS Taps Massachusetts Medicaid Director to Run Key Post Impacting 340B Program
      • NEWS ANALYSIS: Top Job at HRSA Remains Unfilled as Biden Presidency Enters its Sixth Month
      • Recent Supreme Court Ruling Frees States to Stop PBMs’ 340B Two-Tier Pricing, Health Care Lawyers Say
      • 340B Report Publisher and CEO Examines Four Burning Questions in Contract Pharmacy Standoff
      • HRSA’s Order for 340B is a Win for Rural Accountable Care
      • News Alert: Becerra Puts His Imprint On Long-Awaited 340B Dispute Resolution Board
      • Pharma’s 340B Contract Pharmacy Limits Are Costing Providers $3.2 Billion a Year, DOJ Tells Court
      • DOJ and AstraZeneca Far Apart on How Company’s Lawsuit Should Proceed
      • DOJ Asks Judge to Toss PhRMA Suit Against 340B Dispute Resolution System and Audit Guidelines
      • Government Notifies Drug Companies About 340B Contract Pharmacy Advisory Opinion’s Withdrawal
      • 340B Sales Totaled $38 Billion Last Year, Industry Friendly Blog Reports
      • Biden Nominates Acting HHS Inspector General for the Job Full Time
      • BREAKING: HHS Withdraws 340B Contract Pharmacy Advisory Opinion, and Becerra Appoints 340B Dispute Resolution Board Members
      • 340B Entity Groups Accentuate Positives in 340B Contract Pharmacy Court Opinion
      • Supreme Court Preserves ACA and, with it, the Health Care Reform Law’s 340B Provisions
      • Congressman Asks Becerra to Commit to Pause 340B Hospitals’ DSH Percentage Requirement
      • AHA Wants Express Scripts to End 340B Claims ID Policy Immediately
      • 340B Hospitals Concerned About New UnitedHealthcare Claims Reimbursement Policy
      • “Need to Know” – Visante’s Series of Key Takeaways for HRSA Grantees
      • BREAKING: Judge Hands HHS Major Setback in AstraZeneca’s 340B Contract Pharmacy Lawsuit
      • Biden Administration Proposes to Rescind Trump’s 340B Health Center Insulin Rule
      • MedPAC Recommends Part B Drug Payment Changes That Could Exacerbate Financial Strain for 340B Hospitals
      • Health Centers and 340B Play Integral Role In Filling Gaps After Rural Hospital Closures, MedPAC Finds
      • Two Closely Watched 340B Lawsuits Will Soon Get a New Judge
      • Rep. Porter Files Bill to Require Medicare Part B inflation-Based Rebates
      • Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 6
      • Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 5
      • Sentry Data Systems Is the Latest 340B TPA to Change Hands
      • CMS Seeks Medicare DSH Calculation Change That Could Disqualify Some Hospitals From 340B
      • In First of Its Kind Legislation, Louisiana Cracks Down on White-Bagging Requirements
      • More Than a Third of State Lawmakers Accept Pharma Campaign Contributions, Analysis Shows
      • Becerra’s Message to Pharma on 340B: “You Violate the Law, You Pay the Consequences”
      • Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 4
      • Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 3
      • Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 2
      • Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 1
      • Novartis Says Its Reputation Has Been Injured By HRSA’s 340B Demand Letter
      • White House Clears Path for HRSA to Rescind Trump’s Health Center 340B Insulin Rule
      • Health Centers Launch a New National Advocacy Group
      • Lynn Barr, a Value-Based Payment and 340B Champion, is Appointed to MedPAC
      • Judge Declines to Issue Stays Against HRSA Stemming from its May 17 Demand Letters
      • 340B DSH Hospitals More Likely To Treat Black, Disabled, and Low-Income Patients With Chronic Conditions, Study Indicates
      • CMS Moves to Delay Multiple-Best-Price Rule For Value-Based Drug Purchases
      • Sanofi and Novartis Fight HRSA’s 340B Contract Pharmacy Demand Letters
      • 340B Hospitals Ask Supreme Court Again to End Steep Medicare Drug Payment Cut
      • Two Drug Makers Providing Refunds for 340B Overcharges
      • Brooks-LaSure Sworn in as CMS Administrator
      • Grassroots Group Launches Regional Events to Promote 340B’s Importance
      • BREAKING: Novartis Sues HRSA in Defense of its 340B Contract Pharmacy Policy
    • ► May (42)
      • HHS Wants to Audit 340B Providers to See How They Use 340B Net Income
      • Late Breaking Developments in Lilly and AstraZeneca’s 340B Contract Pharmacy Lawsuits
      • As June 1 Deadline Looms, Drug Manufacturers and Feds Make Their Case in New Jersey Federal Court
      • Key Hearings Today in AstraZeneca and Lilly’s 340B Contract Pharmacy Lawsuits
      • Vermont Places 340B-Related Strictures on PBMs and Adds Protections to Contract Pharmacies
      • HHS Contract Pharmacy Advisory Opinion Author Returns to Private Sector
      • Ex-HRSA Administrator Wakefield Back at HHS, Hospital Association Exec Joins Too
      • PhRMA Sues to Block Medicaid Best Price Change
      • New Developments in 340B Contract Pharmacy Lawsuits
      • Much Cheaper PrEP Drugs Could Mean Financial Upheaval for 340B Covered Entities
      • Brooks-LaSure Poised to be Confirmed as CMS Administrator
      • BREAKING: Developments in Multiple 340B Contract Pharmacy Lawsuits
      • BREAKING: Developments in AstraZeneca’s 340B Lawsuit
      • Drugmakers Show No Sign So Far of Giving in to HRSA on 340B Contract Pharmacy
      • Health Centers, HIV/AIDS Clinics, and Feds Agree on Keeping Stays in Place in 340B Lawsuits
      • AbbVie Abused Humira’s Orphan Drug Designation, House Panel Says
      • Year 2 of 340B Contract Pharmacy Fight Starts With a Bang
      • Drug Makers Defensive, Providers Thrilled About HRSA’s 340B Contract Pharmacy Letters
      • Montana Enacts Expansive Bill Intended to Protect 340B Providers
      • BREAKING: HRSA to Six Drug Makers—Your 340B Contract Pharmacy Policies Are Illegal, Resume Offering 340B Pricing Immediately
      • HHS Asks U.S. Supreme Court to Reject 340B Hospital Request to Hear Medicare Part B Case
      • Bipartisan Lawmakers Re-Introduce Bill Shielding Hospitals From Lost 340B Eligibility Due to COVID-19
      • Will New Administration Reverse Deep Medicare Part B Cuts to 340B Hospitals?
      • DOJ Cites 1996 HRSA Letter to PhRMA in Request to Dismiss Novo Nordisk’s 340B Contract Pharmacy Suit
      • OTC Drug Manufacturer Owes 340B Entities Refunds, HRSA Audit Finds
      • United Therapeutics Delays its 340B Claims Data Upload Requirement
      • Andrea Palm Confirmed as HHS Deputy Secretary
      • Breaking: Becerra, on 340B Pricing Denials, Tells House Panel, “Everyone Has to Follow the Law”
      • Takeda Pharmacy Partner Forcing 340B Pricing Opt-in/Opt-out Choice on Entities
      • HRSA Signals It Will Rescind Trump’s 340B Insulin Rule
      • House GOP Leadership Shake Up Could Benefit 340B Providers
      • Lilly Wants Judge To Schedule June Arguments in 340B Suit Against HHS
      • North Dakota Is the Latest State to Pass a 340B Non-Discrimination Law
      • What Covered Entities Should Know About Contracting with Specialty Pharmacies
      • 340B Non-Discrimination Bills Signed in Arkansas and Indiana and Passed in Tennessee
      • Multiple Developments in AstraZeneca’s 340B Contract Pharmacy Lawsuit
      • Bristol-Myers Squibb Hires Apexus VP Richardson to Be its 340B Strategist
      • Study: Better Use of 340B Can Help Shrink Urban “Pharmacy Deserts”
      • Expect to Hear a Lot About Drug Pricing During Next Week’s House Hearing With Becerra
      • State Attorney General Is Investigating Lilly and AstraZeneca’s 340B Pricing
      • Hospital Groups Want FDA to Curtail Specialty Drug White Bagging
      • Study: Patients with Deductibles and Coinsurance Pay More When a Drug’s List Price Rises
    • ► April (42)
      • Arkansas Passes First-of-its-Kind Bill to Counter Pharma’s 340B Contract Pharmacy Moves
      • Vermont AG Issues Subpoena to Novartis for 340B Documents and Information
      • Tech Firm Convening Working Group to Address 340B Duplicate Discounts
      • Biden Wants to Let Medicare Negotiate Drug Prices, but Not Via His American Families Plan
      • Key Factors To Consider To Ensure Effective Management of a 340B Pharmacy Program
      • Hospitals Could Get Another Shot to Intervene in AstraZeneca’s 340B Lawsuit
      • Nonprofit Generic Drugmaker Civica Is Providing Refunds for 340B Overcharges
      • Will Biden’s American Families Plan Include an Rx Drug Pricing Measure?
      • BREAKING: Judge Nixes Hospital Groups’ Participation in AstraZeneca’s 340B Contract Pharmacy Case
      • 340B Providers Escape Bullet in House Dem Rx Bill, but Not in GOP Version
      • Feds Asks Courts to Reject Lilly and Sanofi’s 340B “Self-Help”
      • Hospital Groups Ask HHS to Start Fining Pharma Over 340B Pricing Denials
      • Kalderos: 3-5% of 340B Discounts and Medicaid Rebates Are Duplicates
      • Congress Passes Bills Aimed at Boosting Generics and Biosimilars
      • CBO Report: R&D Costs Do Not Influence Pharma Pricing
      • HHS Tells Judge 340B Dispute Resolution Is Back on Track and It Is Weighing Other Pharma Enforcement Steps
      • AstraZeneca Tells Court: Congress Didn’t Make 340B to Generate Profits for Providers
      • Public Relations War Over 340B’s Intent Intensifies
      • 24 Health Systems List 8 Ways HHS Can Stabilize 340B Without Involving Congress
      • BREAKING: Key GOP U.S. Senator Presses HHS Deputy Secretary Nominee to Take Action on 340B
      • Pharma’s Plans to Rebuild Health Care Include Overhauling 340B
      • Could Concern About Hospital Price Transparency Boost Push for More Hospital 340B Transparency?
      • Historic U.S. Rise in STDs Boosts 340B’s Importance, STD Program Directors Say
      • 340B Report Publisher and CEO Slafsky: Providers Need Swift Action on Contract Pharmacy
      • News Alert: United Therapeutics Unveils 340B Contract Pharmacy Claims Submission Requirement
      • Gilead’s HIV Drug Reimbursement Cut Will be Devastating, 340B Covered Entities Say
      • 340B Could Come Up During Congressional Hearings Thursday
      • MACPAC Backs Medicaid Change That Could Lower Some 340B Prices
      • Express Scripts Defends 340B Claims ID Requirement
      • 340B Entities Won’t Share in BMS’s $75 Million Medicaid Drug Pricing Settlement
      • Optimizing 340B Savings Through Referral Capture
      • 340B Sales Grew 18% from 2019 to 2020, Drug Industry Consulting Firm Says
      • NY State 340B Providers Get More Time to Challenge Reimbursement Change
      • Panel Lauds Women’s Role in Creating and Leading 340B
      • 340B Groups Ask Express Scripts to Drop Claims Submission and ID Requirement
      • 340B Hospitals More Likely to Make Medicine More Accessible, Study Finds
      • Study in Health Affairs Could Reignite Debate Over Some 340B Hospitals Charity Care
      • AHA Warns MedPAC its Recommendations Would Harm 340B Hospitals
      • Panelists Share Insights on Using 340B in Prisons and Jails
      • HHS’s Latest Regulatory Agenda Is Silent on 340B, but Program Rulemaking Is Possible
      • AHA Asks Becerra to Waive a 340B Hospital Eligibility Requirement During COVID-19 Emergency
      • For-Profit Hospitals Back Medicare’s 340B Hospital Cuts in Legal Brief, Study, and Blog
    • ► March (45)
      • For-Profit Hospitals Make Major Pitch for Keeping Medicare’s 340B Hospital Cuts
      • Feds Oppose Hospitals’ Intervention in Three More Pharma 340B Lawsuits
      • 340B Entities Keeping Watch on Bills to Create State Drug Affordability Boards
      • Q2 340B Registration Period Starts April 1
      • Origin Biosciences Posts Limited Distribution Notice on 340B Program Site
      • HRSA Takes Step Forward on 340B Dispute Resolution Petitions
      • Merck Pitches Its Voluntary 340B Integrity Initiative to Providers as a Better Option than Audits
      • Feds Oppose Hospitals’ Motion to Intervene in Novo Nordisk’s 340B Lawsuit
      • 340B Gets Cameo Role in Senate Hearing on Government Drug Price Negotiation
      • 340B Dispute Resolution Injunction Is Having Ripple Effects
      • Federal Judge To Get Status Report Today from Ryan White Clinics and Government
      • Drug Pricing Is Heating Up in Congress Again
      • Survey: Pharma’s 340B Contract Pharmacy Actions are Putting the Squeeze on Hospitals
      • Health Centers Get Reprieve as 340B Insulin Pricing Rule Delayed Again
      • Becerra Expected To Usher in Sea Change to 340B Governance
      • Six Senators Reintroduce Bipartisan Bill to Protect 340B Hospitals From COVID Fallout
      • The Patient Journey: Are You Missing Something?
      • Sanders Holding Senate Hearing on Drug Prices Next Week
      • Amazon Is Opening its Employees-only Primary and Urgent Care Service to Companies Nationwide
      • Injunction in Lilly Case Could Cause HHS to Re-Issue 340B Dispute Resolution Rule
      • Breaking: Federal Judge Grants Lilly’s Motion to Halt 340B Dispute Resolution System
      • Opposition to Express Scripts’ 340B Claims ID Requirement Grows
      • FQHCs Fiercely Oppose Trump’s 340B Insulin Pricing Rule in New Round of Comments
      • Medicare’s 340B Drug Reimbursement Cuts in 2019 Were Exacerbated by Change in Drugs’ Payment Status
      • Biden Nominates Veteran Capitol Hill Aide to be HHS Assistant Secretary
      • Utah Might Soon Outflank Express Scripts’ New 340B Requirement
      • State Activity to Rein in PBM Discrimination Against 340B Entities Heats Up
      • Biden Wants to Delay 340B Health Center Insulin Rule Again, to July 20
      • Sanofi Calls 340B ADR System “a Faux Judicial Process”
      • COVID Relief Bill With Implications for 340B Set to Become Law Tomorrow
      • PhRMA: Providers Use 340B as “Slush Fund”
      • Biden Names Health Care Advisers with Strong Ties to Hill Democrats
      • News Flash: State Attorney General Orders Sanofi to Hand Over 340B Information
      • Providers Worried About Humana’s 340B Claims ID and Data-Reporting Conditions
      • COVID-19 Relief Bill Includes Many Provisions Affecting 340B Providers
      • Hospitals Want Role in Three More Pharma Lawsuits Over 340B Contract Pharmacy
      • Senator Cassidy Again Cites 340B in Opposing Becerra for HHS Secretary
      • A Recap of the Acentrus Specialty Conference
      • Orphan Drug Study’s Authors Say Findings May Warrant Lifting 340B Exemption
      • Senate Democrats Soften, But Don’t Yank, COVID Relief Bill’s Medicaid Rebate Language
      • 340B Report Publisher/CEO: Look for a Return to an Era of 340B Guidance
      • DOJ Opposes Sanofi’s Move to Head Off 340B Dispute Resolution in Contract Pharmacy Battle
      • 340B Providers Cheer Bipartisan House Letter to HHS on Manufacturer Actions
      • N.Y. and Calif. 340B Pharmacies Get Reprieve From Medicaid Cuts
      • Huge COVID Relief Bill That Would Lift Medicaid Rebate Caps Moves to Senate
    • ► February (54)
      • 226 Bipartisan U.S. House Members Ask HHS to Stop Pharma From Unilaterally Changing 340B
      • Express Scripts’ New 340B Rules Will Have Big Impact on Contract Pharmacy and Drug Reimbursement, Providers and Consultants Say
      • Bipartisan U.S. House Members Corralling Last-Minute Signatures on 340B Letter to HHS
      • Becerra Reconfirms Strong Support for 340B During Finance Committee Hearing
      • Express Scripts' New 340B Claims ID Requirement Has Covered Entities Worried
      • Hospitals, Health Centers, and HIV/AIDS Clinics Want Roles in Lilly’s 340B Contract Pharmacy Lawsuit
      • Health Care Reporter Foresees Federal Action on Drug Pricing, But Not Immediately
      • 36 State Hospital Groups Ask U.S. Supreme Court to End Part B Drug Payment Cuts for 340B Hospitals
      • BREAKING: HHS Secretary-Designate Becerra Pledges to “Build On” 340B Contract Pharmacy Advisory Opinion
      • HHS-Designate Becerra May Face 340B Questions Today During First Nomination Hearing
      • Biden Staffs Up with 340B Policy Experts in Key Positions
      • Ex-Energy & Commerce GOP Chair Walden Launches Lobbying Firm
      • HRSA Allows 340B Enrollment Flexibility in Storm-Battered Texas
      • AEH Asks Biden to Prioritize Three 340B-Related Issues
      • Biden Will Turn to Drug Pricing Once COVID-19 Ebbs, Shalala Predicts
      • Federal Judge Dismisses Hospitals’ 340B Contract Pharmacy Lawsuit Against HHS
      • DOJ Slams Lilly’s Arguments for Derailing 340B Dispute Resolution
      • CBO Says Lifting Medicaid Drug Rebate Cap Would Save $16 Billion
      • Senate Hearings Next Week on Becerra’s Nomination to Head HHS
      • Biden Reportedly Has Settled on His Choice to Run CMS
      • Generic Drug Manufacturer Posts 340B Refund Notice
      • Muted by Litigation, Pedley Avoids Hottest 340B Topics But Provides Some Nuggets
      • AstraZeneca Tells Court HHS’s 340B Enforcement Poses “Imminent Irreparable Harm”
      • Legislation Lifting Maximum Cap on Medicaid Rebates Advances
      • PolitiFact Calls Senate Candidate’s 340B Insulin Claim “Mostly False”
      • Bausch Health Confirms 340B Rapprochement with AmeriSourceBergen
      • PhRMA Slams 340B Hospitals in Report, AHA Returns Fire
      • Indiana House to Vote on Stopping PBMs From Squeezing 340B Entities
      • In Key Hearing, Federal Judge Expresses Doubt About Court’s Ability To Take Action on Contract Pharmacy Matter
      • House Set To Act on Bill that Could Result in Higher Medicaid Rebates and 340B Discounts
      • Hospitals Ask U.S. Supreme Court to End “Crushing” Medicare Payments Cuts for 340B Drugs
      • AHA Asks CMS to Rein In UHC’s Specialty Pharmacy Policies
      • Biden Administration Position in Supreme Court ACA Case Has 340B Implications
      • Drug Manufacturers GSK and Esperion Offering Refunds for 340B Overcharges
      • Health Centers to Begin Receiving COVID-19 Vaccines Directly
      • Burr Named Ranking Republican On Committee with 340B Oversight
      • Court Hearing Today on Hospitals’ 340B Contract Pharmacy Suit Against HHS
      • Welch and McKinley Will Try Again to Get Rural and Cancer Hospitals 340B Pricing on Orphan Drugs
      • Failed Amendment to Federal Budget Bill Could Have Required All Providers to Pass 340B Savings on Insulin to Patients
      • Calif. Health Centers Ask Newsom to Delay Medi-Cal Drug Benefit Shift Until 2022
      • Generic Drug Manufacturer Hikma Providing Credits for 340B Overcharges
      • Surprise Amendment to Senate Budget Bill Could Portend Busy 340B Legislative Session
      • EXCLUSIVE: Bipartisan U.S. House Group Circulating 340B Sign-on Letter to Becerra
      • Drug Companies Are Looking at Multiple Ways to Reduce their 340B Exposure
      • Democrats Shake Up Lineup on Key Health Committees Impacting 340B
      • Two New Manufacturer Notices to 340B Entities on HRSA Website
      • Court Freezes Trump’s Rule Banning Pharma Rebates to PBMs
      • Sanofi Lifts 340B Contract Pharmacy Requirements for Some Providers But Many Are Still Affected
      • AmeriSourceBergen Has Resumed Distributing 340B-Priced Bausch Health Drugs
      • Half of Health Care Execs Surveyed Expect Biden to Act on Pharma’s 340B Pricing Denials
      • USA Today Fact-Checks Claim that Biden Raised Insulin Prices by Freezing 340B Rule
      • 44 New York State Lawmakers Urge Cuomo to Reverse Medicaid Drug Benefit Transfer
      • TV Humorist Bestows “Baldy” Award on Co-Author of 340B Law
      • Proven Strategies 340B Covered Entities Can Use to Enhance the Specialty Pharmacy Experience for Patients
    • ► January (37)
      • 340B Guidance Documents Removed from HHS Public Database
      • 340B Report Publisher/CEO: It Will Take Time for Contract Pharmacy Battle to Play Out
      • AHA Asks CMS to Withdraw Trump’s Most Favored Nation Drug Pricing Rule
      • Generic Liquid Drug Manufacturer Providing Refunds for 340B Overcharges
      • Drug Company Eton Posts 340B Limited Distribution Notice
      • New Walgreens Leader Will Be Fortune 500’s Sole Black Female CEO
      • 340B COVID-19 Flexibilities Expected to Run Through the End of 2021
      • Portman’s Retirement in 2023 Will Deprive 340B Entities of a Key GOP Ally
      • Conservative News Sites Cast Shade on Biden’s Freeze on 340B Insulin Rule
      • BREAKING: PhRMA Asks Court to Strike Down 340B Dispute Resolution Rule and Manufacturer Audit Guidelines
      • Biden Administration Withdraws Azar’s Notice of Appointments to 340B Dispute Resolution Board
      • Biden Team Freezes 340B Insulin Rule, to Health Centers’ Relief
      • In Surprise Move, 340B Dispute Resolution Board Members Appointed
      • Pedley’s Promotion May Presage Hiring of a New 340B Program Director
      • Biden Appoints Acting Leaders at HRSA, CMS, and HHS
      • Health Centers Scramble to Secure a Freeze on 340B Insulin Rule
      • House E&C Leaders Announce Leadership Team and New Committee Members
      • Our First Issue Behind Our Paywall
      • Gilead Adjusts Planned Change in its Patient Assistance After HIV Community Pushes Back
      • HHS Asks Court to Toss Out Hospitals’ 340B Contract Pharmacy Lawsuit
      • Senate Finance Report Might Shed Light on Insulin Manufacturers’ 340B Contract Pharmacy Actions
      • Azar and Verma Touch on 340B in Valedictory Remarks
      • 340B Stakeholders Reconsider Campaign Contributions in Wake of Capitol Riot
      • Top 10 Issues to Consider in 2021 - Sponsored Content
      • Important Information About Accessing 340B Report
      • Health Centers File 340B Dispute Resolution Petitions Against Drug Manufacturers
      • Lilly Asks Court to Shield it From “Crippling” 340B Sanctions
      • Nevada ADAP Postpones Controversial 340B Policy Change
      • Top 10 Issues to Consider in 2021
      • AstraZeneca, Lilly, and Sanofi Sue HHS to Block Requirement To Give 340B Discounts To Contract Pharmacies
      • Welcome to The New 340B Report
      • HRSA Releases Details and FAQs About New 340B Dispute Resolution System
      • 340B Providers Blindsided by Bausch Health’s Decision to Drop AmerisourceBergen as Distributor
      • Senate Democratic Chairs-in-Waiting Waste No Time Going to Bat for 340B Providers
      • Nevada Ryan White Clinics Furious About State ADAP’s 340B Policy Change
      • 340B Providers Welcome Democratic Control of Congress and White House
      • Chicago Tribune’s 340B Article Grabs Senior U.S. Senator’s and Governor’s Attention (Updated)
  • ►2020 (152)
    • ► December (18)
      • BREAKING: HHS’s Top Lawyer Says Pharma’s 340B Contract Pharmacy Actions Are at Odds with the Law
      • BREAKING: HHS Says 340B Discounts Apply to Contract Pharmacies
      • Trump Pardons Disgraced 340B Critic
      • HRSA Releases 340B Insulin Final Rule Over Health Centers’ Strong Objections
      • White House Clears 340B Insulin Final Rule for Publication
      • Kalderos Expects its 340B Rebate Model Will Finally Lift Off During Q1 2021
      • The New York Times, Often a Public Policy Shaper, Runs Article on 340B Pricing Denials
      • Providers Are Pleased, PhRMA Isn’t, With Becerra and State AGs’ 340B Letter to Azar
      • BREAKING: 28 State AGs—Including HHS Nominee Becerra—Want Action on Pharma 340B Pricing Denials. Also, New GAO Report on HRSA 340B Oversight. (Updated)
      • BREAKING: Hospitals Sue HHS Over Drug Companies’ Denials of 340B Pricing
      • After a 10-Year Odyssey, HRSA Finally Releases 340B Dispute Resolution Rule (Updated)
      • BREAKING: 340B Dispute Resolution Final Rule Released
      • BREAKING: Amgen Ending 340B-Like Price Reductions on Orphan Drugs on Jan. 1 (Updated)
      • White House Clears 340B Dispute Resolution Final Rule for Publication
      • BREAKING: Florida Medicaid Asks Rx Manufacturer to Suspend “Broad Brush” 340B Pricing Restrictions, Will Other States Follow?
      • 340B Hospitals Face Another Year of Deeply Reduced Medicare Drug Reimbursement
      • BREAKING: Novo Nordisk Will Cease 340B Pricing for Hospital Contract Pharmacies on Jan. 1
      • Coming Proposed Rule Could Shed Light on HRSA’s 340B Enforcement Power
    • ► November (12)
      • News Digest: 340B Insulin Rule, Hospital Eligibility Protection, Purdue Pharma Credits
      • RWC-340B Seeks Quick Judicial Relief from 340B Contract Pharmacy Rollbacks
      • United Therapeutics Imposes Limits on 340B Contract Pharmacy Pricing
      • BREAKING: Trump Issues Drug Pricing Rules That Impact 340B; Says 340B Health Center Final Rule Is Coming
      • Stakeholders Weigh in on Forthcoming 340B Dispute Resolution Rule
      • BREAKING: A Decade Overdue, HRSA Puts 340B Dispute Resolution Final Rule in Motion
      • Lilly’s 340B Policy Tweak Pushes Contract Pharmacy Farther Out of Reach
      • BREAKING: Bipartisan Group of 217 U.S. Representatives Ask HHS to Stop 340B Rebate Model and Look Into Third Party Vendors
      • Biden Names Ex-HRSA Leader Wakefield to His HHS Transition Team
      • Gilead Accuses Florida 340B STD Clinics of “at Least $43 Million” in Fraudulent PrEP Transactions
      • U.S. Sen. Braun Introduces Bill to Collect and Report 340B Hospital Data
      • GOP Committee Leaders Asked for and Got 340B Reform Ideas. What Happens Now?
    • ► October (15)
      • BREAKING: Novartis Retreats, But Not Entirely, on 340B Contract Pharmacy (Update 2)
      • EXCLUSIVE: Lilly’s Letter to HRSA on Why it Thinks 340B Contract Pharmacy is Unlawful
      • Health Centers to White House: Don’t Implement “Misguided” 340B Executive Order
      • Iowa’s U.S. Senators Meet With HHS Top Brass About Pharma’s 340B Moves
      • U.S. House Democrats and Republicans “Deeply Concerned” About 340B Rebate Model
      • BREAKING: Health Centers Sue HHS Over Drug Company Denials of 340B Pricing
      • 340B Hospitals Ponder Next Moves After U.S. Appeals Court Setback
      • BREAKING: Major Developments in 340B Hospital Lawsuit and in 340B Contract Pharmacy Dispute
      • HIV/AIDS Activists March To Protest AstraZeneca’s 340B Contract Pharmacy Cutbacks
      • Sanofi Reportedly Is Not Providing Some Promised 340B Pricing
      • BREAKING: HIV/AIDS Clinics Sue HHS Over Drug Manufacturers’ Denials of 340B Pricing
      • BREAKING: Congressional GOP Committee Leaders Seek 340B Reform Ideas by Oct. 30
      • More than Half of Health Care Industry Execs Expect 340B Reporting Requirements Within Five Years
      • BREAKING: Connecticut Attorney General Demands Five Manufacturers Cease 340B Actions
      • AstraZeneca and Sanofi Block Access to 340B Contract Pharmacy Pricing, Novartis Does Not (UPDATED)
    • ► September (18)
      • The Calm Before the 340B Storm?
      • Only 30 Providers Are Supplying Merck with Requested 340B Claims Data
      • BREAKING: Novartis Says It’s Weighing Whether to Start Cutting Off 340B Contract Pharmacy Discounts on Oct. 1. Sanofi Says it Will. (Update 1)
      • Is Novartis Backing Off its Oct. 1 Deadline for 340B Covered Entities? (Update 2)
      • BREAKING: HHS Top Lawyer Tells Lilly, Don’t Assume We Endorse Your 340B Policy
      • Supreme Court ACA Overturn Could Cut Rural Hospitals from 340B, Gut HRSA Enforcement
      • BREAKING: Rule Implementing 340B Executive Order on Insulin Might be Imminent
      • HHS Inundated with Concerns About Pharma’s and Administration’s 340B Actions
      • BREAKING: 22 U.S. Senate Democrats Want Answers from PhRMA About its Members’ 340B Actions
      • In Partisan U.S. House, Consensus Emerges Over Manufacturer 340B Actions
      • BREAKING: More than Half of the U.S. House Asks Azar to Address Drug Makers’ 340B Actions Immediately
      • Lilly’s 340B Contract Pharmacy Ban Has Crept Into In-House Pharmacies
      • Health Centers Are Preparing to Sue Over Drug Makers' 340B Actions
      • BREAKING: House Democratic Committee Chairs Say Drug Companies’ Actions Could Put 340B on “Treacherous Path”
      • White House Fast-Tracking 340B Executive Order on Insulin, Epinephrine
      • BREAKING: HRSA is Investigating Whether Manufacturer Policies to Restrict 340B Pricing at Contract Pharmacies Violates Statute
      • BREAKING: Eli Lilly Comment on Today's Actions
      • Eli Lilly Dramatically Escalates Efforts to Restrict Access to 340B Pricing
    • ► August (11)
      • Drug Store Chains Want HHS to Block Pharma’s Moves Against 340B Contract Pharmacy
      • BREAKING: Kalderos Wants to Give Drug Manufacturers a Way to Pay 340B Rebates in Lieu of Discounts
      • 340B Supply Chain Partners Push Back Against Manufacturer Contract Pharmacy Requests
      • BREAKING: Novartis the Latest to Seek 340B Contract Pharmacy Claims Data
      • BREAKING: AstraZeneca Raises the Ante in Drug Industry Push Against 340B Contract Pharmacy
      • A Closer Look at Democratic VP Choice Harris’s Positions on the 340B Program
      • BREAKING: Omnicell Buys PSG’s 340B Line of Business, the Latest in a Trend of 340B TPA Acquisitions
      • Health Centers Seek Meeting With Merck About its 340B Contract Pharmacy Data Request
      • Hospitals Slam Proposal to Deepen Medicare Payment Cuts for 340B Drugs
      • After Big Win in Court, CMS Proposes Cutting 340B Drug Payments Even More
      • Could CMS Follow Up 340B Court Victory with Deeper Cuts for Hospitals?
    • ► July (15)
      • BREAKING: U.S. Appeals Court Upholds Deep Cuts in 340B Hospitals’ Medicare Part B Drug Reimbursement
      • 340B Bill Introduced in House; Senate 340B Bill Gets Two More Sponsors
      • Sanofi Joins Growing List of Drug Companies Challenging 340B Contract Pharmacy
      • BREAKING: Health Centers Challenge Administration Suggestions They Put 340B Profits Over Patients
      • BREAKING: Presidential Executive Order Targets 340B Health Centers’ Savings on Insulin and EpiPen
      • A Bipartisan Bill Will Be Introduced in the U.S. House Soon to Protect 340B Hospitals During the Pandemic
      • Pedley: HRSA’s Power to Enforce 340B Guidance is Limited.Testoni: Some in Pharma Want to Make 340B a Rebate Program.
      • HRSA Updates 340B Covered Entity Registration and Recertification Requirements
      • BREAKING: Hospitals and Other Providers Ask HHS to Halt Lilly and Merck’s Clampdowns on 340B; Companies Defend Their Positions
      • 340B ESP Wants to Be Pharma’s Go-to on 340B Duplicate Discounts. Kalderos Says Not So Fast.
      • Key House Committee Rejects HRSA Request for More Regulatory Authority
      • HRSA Says its 340B Contract Pharmacy Guidance Is Not Legally Enforceable
      • Eli Lilly Says It Doesn’t Have to Provide 340B-Priced Drugs to Contract Pharmacies
      • BREAKING: New U.S. Senate Bipartisan Bill Would Preserve Hospitals’ 340B Eligibility During Pandemic
      • More Evidence That 340B Program Guidance Is Unenforceable
    • ► June (11)
      • Brace Yourselves: A Major 340B Hospital Court Ruling and CMS Proposed Rule Are Coming
      • Hospitals Might Not Get 340B Discounts on Drugs Being Investigated as COVID-19 Treatments
      • House Bipartisan Bills Address Worries About COVID-19 Drug Price Gouging
      • MedPAC Report Endnote Sheds Light on Hospital Losses Due to CMS 340B Drug Payment Cuts
      • 340B Drug Manufacturer Audits: A Q&A with HRSA
      • HRSA Takes Step to Improve 340B Pricing Consistency
      • 340B Experts Welcome HRSA’s Policy Clarifications on Hospital Child Sites and Telemedicine
      • EXCLUSIVE: HRSA Confirms 340B Hospital Offsite Location and Telehealth Flexibilities Are Permanent
      • BREAKING: HRSA Moves Forward on Plan To Allow for Expedited 340B Hospital Clinic Enrollment
      • HRSA Lifts Major Barrier to Using 340B Drugs at Hospital Offsite Locations
      • Possibly Hundreds of Millions of Dollars Annually in Lost 340B Savings Draw Closer in California
    • ► May (7)
      • Largest Hospital Group Asks Congress to Reject Administration's "Harmful" 340B Policy Requests
      • The CMS 340B Drug Cost Survey Is a Wrap. So, What Happens Now?
      • Sasse Reintroduces Bill in U.S. Senate to Keep Hospitals from Losing 340B Eligibility During Pandemic
      • 340B Hospital Provisions Left Out of Latest COVID-19 Bill
      • Over 100 U.S. House Members Want More Help for 340B Hospitals During Pandemic
      • Two More National Hospitals Groups Urge CMS to Stop 340B Drug Cost Survey
      • Largest Hospital Group to CMS: 340B Drug Survey Is Burdensome, Ill-Timed, Illegal
    • ► April (11)
      • Bipartisan Duo in Congress Wants to Protect 340B Hospitals During Pandemic
      • The COVID-19 Pandemic Is No Time for a 340B Drug Cost Survey, Hospitals Say
      • BREAKING: CMS Begins Controversial 340B Hospital Drug Cost Survey
      • Nation’s Biggest Hospital Group Asks HHS to Waive 340B Requirements and Suspend Audits During Pandemic
      • COVID-19 Casts a Shadow Over 340B-Related Meetings, Including the Year’s Main Event
      • Hospitals Concerned About Limits of HRSA’s 340B Enrollment Flexibility During Pandemic
      • 340B Protections and Clarifications Sought in Next COVID-19 Relief Bill
      • BREAKING: HRSA Now Says it Will Let Some Providers Enroll in 340B Immediately During COVID-19 Pandemic
      • Congress Is Starting to Ask About Drug Shortages Due to COVID-19
      • Telehealth Is Becoming the New Normal. What Does it Mean for 340B?
      • New York State Poised to Cut 340B Providers’ Medicaid Drug Reimbursement, Could Other States Follow?
    • ► March (13)
      • NY Lawmakers to Decide by Midnight on Medicaid Cuts to 340B Providers
      • HRSA Relaxes Policy on GPO Prohibition During COVID-19 Pandemic
      • Kentucky Health Centers Sue State To Block 340B Claims Requirement
      • HRSA Answers More Questions About 340B Compliance During Pandemic
      • Senate Stimulus Bill Would Put Space Between Health Centers and Funding Cliff
      • All Indications Are CMS Plans to Launch its 340B Drug Acquisition Survey on Monday
      • For Now, HRSA Doesn’t Plan to Change Its April 340B Registration Period
      • HRSA Tells COVID-19 Responders Concerned About 340B Compliance to Contact it Directly
      • Congressional Medicare Advisers Say 340B Has Minor Effect on Cancer Drug Spending and Patient Cost-Sharing
      • HRSA: 340B Dispute Resolution Will Stay on Hold Until We Get Broader Regulatory Authority
      • Hospital Groups to OMB: Quash 340B Hospital Drug Acquisition Cost Survey
      • DOJ Says Mallinckrodt Owes Medicaid Hundreds of Millions in Rebates, but Is Silent About 340B Overcharges
      • 340B Providers Could Face Drug Access Challenges Due to Coronavirus
    • ► February (21)
      • Update: 340B-Related Action in the States
      • Welcome To 340B Report From Publisher & CEO Ted Slafsky
      • Distressed Rural Hospitals that Downgrade into Emergency Centers Could Gain 340B Eligibility
      • Think Tank to States: Use 340B to Reduce Drug Prices
      • Drugmakers Are Doing a Better Job of Supplying 340B Ceiling Price Data, 340B Program Head Pedley Says
      • In Budget, Trump Seeks 340B Changes Congress Has Taken a Pass on Before
      • A Message to Our Inaugural Subscribers
      • CMS Takes Another Step Toward Collecting Hospitals’ 340B Acquisition Costs
      • President Expected to Address Drug Prices in State of the Union Message
      • CMS Unveils Medicaid Block Grant Option, Ramifications for 340B Unclear
      • Hospital Group: GAO’s 340B Duplicate Discount Recommendations “Contrary to Federal Law”
      • BREAKING: GAO Criticizes Policing of 340B Duplicate Discounts
      • Vermont Bills Would Require 340B Hospitals to Report Drug Discount Savings and Spending
      • Another New Study of Differences in Cancer Drug Spending Could Have 340B Implications
      • Breaking: MedPAC Staff Unable to Link Higher Drug Spending at 340B Hospitals to Incentives Created by 340B Discounts
      • Massachusetts Medicaid Wants to Stop Covering “High Cost” Drugs Bought Through 340B
      • MedPAC Will Weigh in on Whether 340B Causes Hospitals to Use More Expensive Drugs
      • BREAKING: GAO Says HRSA Should Strengthen Oversight Over Private-Nonprofit Hospitals’ 340B Eligibility
      • BREAKING: States Can Limit Providers’ Use of 340B Drugs for Medicaid Patients, CMS Says
      • BREAKING: HRSA Awards 340B Prime Vendor Agreement to Apexus
      • BREAKING: Drugmaker Xspire Owes 340B Refunds